7-Alkyl and cycloalkyl-substituted imidazotriazinones

ABSTRACT

The present invention relates to 7-alkyl- and cycloalkyl-substituted imidazotriazinones, to processes for their preparation and to their use as medicaments, in particular as inhibitors of cGMP-metabolizing phosphodiesterases.

This application is a continuing application of U.S. Ser. No. 10/251,939, filed Sep. 20, 2002, now U.S. Pat. No. 6,838,459 which is a continuation of U.S. Ser. No. 09/720,051, filed Mar, 23, 2001, now U.S. Pat. No. 6,476,029.

The present invention relates to 7-alkyl- and cycloalkyl-substituted imidazotriazinones, to processes for their preparation and to their use as medicaments, in particular as inhibitors of cGMP-metabolizing phosphodiesterases.

The published specification DE-28 11 780 describes imidazotriazines as bronchodilators having spasmolytic activity and inhibitory activity against phosphodiesterases which metabolize cyclic adenosine monophosphate (cAMP-PDEs, nomenclature according to Beavo: PDE-III and PDE-IV). An inhibitory action against phosphodiesterases which metabolize cyclic guanosine monophosphate (cGMP-PDEs, nomenclature according to Beavo and Reifsnyder (Trends in Pharmacol. Sci. 11, 150-155, 1990) PDE-I, PDE-II and PDE-V) has not been described. Compounds having a sulphonamide group in the aryl radical in the 2 position are not claimed. Furthermore, FR 22 13 058, CH-59 46 71, DE-22 55 172, DE-23 64 076 and EP-000 9384 describe imidazotriazinones which do not have a substituted aryl radical in the 2 position and are likewise said to be bronchodilators having cAMP-PDE-inhibitory action.

The compounds according to the invention are potent inhibitors either of one or of more of the phosphodiesterases which metabolize cyclic guanosine 3′,5′-monophosphate (cGMP-PDEs). According to the nomenclature of Beavo and Reifsnyder (Trends in Pharmacol. Sci. 11, 150-155, 1990) these are the phosphodiesterase isoenzymes PDE-I, PDE-II and PDE-V.

An increase in the cGMP concentration can lead to beneficial antiaggregatory, antithrombotic, antiprolific, antivasospastic, vasodilative, natriuretic and diuretic effects. It can influence the short- or long-term modulation of muscular and cardiac inotropy, of the pulse and of cardiac conduction (J. C. Stoclet, T. Keravis, N. Komas and C. Lugnier, Exp. Opin. Invest. Drugs (1995), 4 (11), 1081-1100).

The present invention, accordingly, provides 7-alkyl- and cycloalkyl-substituted imidazotriazinones of the general formula (I)

in which

-   R¹ represents straight-chain or branched alkyl having up to 4 carbon     atoms, -   R² represent straight-chain [lacuna] having at least 5 carbon atoms     or branched alkyl having at least 3 carbon atoms, or represents     cycloalkyl having 3 to 10 carbon atoms, -   R³ and R⁴ are identical or different and represent hydrogen, or     represent straight-chain or branched alkenyl having up to 8 carbon     atoms, or represent a straight-chain or branched alkyl chain having     up to 10 carbon atoms which is optionally interrupted by an oxygen     atom and which is optionally mono- to trisubstituted by identical or     different substituents from the group consisting of trifluoromethyl,     trifluoromethoxy, hydroxyl, halogen carboxyl, benzyloxycarbonyl,     straight-chain or branched alkoxy, alkoxycarbonyl and alkylthio     having in each case up to 6 carbon atoms and/or by radicals of the     formulae —SO₃H, -(A)_(a)-NR⁷R⁸, —O—CO—NR^(7′)R^(8′), —S(O)_(b)—R⁹,     HN═SO—R^(9′), —P(O)(OR¹⁰)(OR¹¹), -    in which     -   a and b are identical or different and represent a number 0 or         1,     -   A represents a radical CO or SO₂,     -   R⁷, R^(7′), R⁸ and R^(8′) are identical or different and         represent hydrogen, or represent cycloalkyl having 3 to 8 carbon         atoms, aryl having 6 to 10 carbon atoms, a 5- to 6-membered         unsaturated, partially unsaturated or saturated, optionally         benzo-fused heterocycle having up to 3 heteroatoms from the         group consisting of S, N and/or O, where the ring systems listed         above are optionally mono- to trisubstituted by identical or         different substituents from the group consisting of hydroxyl,         nitro, trifluoromethyl, trifluoromethoxy, carboxyl, halogen,         straight-chain or branched alkoxy and alkoxycarbonyl having in         each case up to 6 carbon atoms or by a group of the formula         —(SO₂)_(c—)NR¹²R¹³,         -   in which         -   c represents a number 0 or 1,         -   R¹² and R¹³ are identical or different and represent             hydrogen or straight-chain or branched alkyl having up to 5             carbon atoms, or     -   R⁷, R^(7′), R⁸ and R^(8′) represent straight-chain or branched         alkoxy having up to 6 carbon atoms, or represent straight-chain         or branched alkyl having up to 8 carbon atoms which is         optionally mono- or polysubstituted by identical or different         substituents from the group consisting of hydroxyl, halogen,         aryl having from 6 to 10 carbon atoms, straight-chain or         branched alkoxy and alkoxycarbonyl having in each case up to 6         carbon atoms or by a group of the formula —(CO)_(d)—NR¹⁴R¹⁵,         -   in which         -   R¹⁴ and R¹⁵ are identical or different and represent             hydrogen or straight-chain or branched alkyl having up to 4             carbon atoms, and         -   d represents a number 0 or 1, or     -   R⁷ and R⁸ and/or R^(7′) and R^(8′) together with the nitrogen         atom form a 5- to 7-membered saturated heterocycle which may         optionally contain a further heteroatom from the group         consisting of S and O or a radical of the formula —NR¹⁶,         -   in which         -   R¹⁶ represents hydrogen, aryl having 6 to 10 carbon atoms,             or straight-chain or branched alkyl having up to 6 carbon             atoms, which is optionally substituted by hydroxyl,     -   R⁹ and R^(9′) are identical or different and represent aryl         having 6 to 10 carbon atoms or benzyl, or represent         straight-chain or branched alkyl having up to 4 carbon atoms,     -   R¹⁰ and R¹¹ are identical or different and represent hydrogen or         straight-chain or branched alkyl having up to 4 carbon atoms,     -   and/or the alkyl chain listed above under R³/R⁴ is optionally         substituted by cycloalkyl having 3 to 8 carbon atoms, aryl         having 6 to 10 carbon atoms or by a 5- to 7-membered partially         unsaturated, saturated or unsaturated, optionally benzo-fused         heterocycle which may contain up to 4 ring heteroatoms from the         group consisting of S, N, O or a radical of the formula —NR⁷,         where the alkyl chain may optionally also be attached via a ring         nitrogen atom,         -   in which         -   R¹⁷ represents hydrogen, hydroxyl, formyl, trifluoromethyl,             straight-chain or branched acyl or alkoxy having in each             case up to 4 carbon atoms, or represents straight-chain or             branched alkyl having up to 6 carbon atoms which is             optionally mono- to polysubstituted by identical or             different substituents from the group consisting of hydroxyl             and straight-chain or branched alkoxy having up to 6 carbon             atoms, -   and where aryl and the heterocycle are optionally mono- to     trisubstituted by identical or different substituents from the group     consisting of nitro, halogen, —SO₃H, straight-chain or branched     monohydroxy-substituted alkyl, alkylthio or alkoxy having in each     case up to 6 carbon atoms, hydroxyl, trifluoromethyl,     trifluoromethoxy and/or by a radical of the formula     —(SO₂)_(e)—R¹⁸R¹⁹,     -   in which     -   e represents a number 0 or 1,     -   R¹⁸ and R¹⁹ are identical or different and represent hydrogen,         phenyl, benzyl or straight-chain or branched alkyl or acyl         having in each case up to 6 carbon atoms, and/or -   R³ or R⁴ represent radicals of the formulae —NR²⁰R²¹ or     —(O)-E-NR²²R²³,     -   in which     -   R²⁰ and R²¹ have the meaning of R¹⁸ and R¹⁹ given above and are         identical to or different from this meaning, or together with         the nitrogen atom form a 5- or 6-membered saturated heterocycle         having a further ring heterocycle from the group consisting of S         and O or a radical —NR²⁴,         -   in which         -   R²⁴ has the meaning of R¹⁶ given above and is identical to             or different from this meaning,     -   E is a straight-chain alkylene group having up to 5 carbon         atoms,     -   R²² and R²³ have the meaning of R¹⁸ and R¹⁹ given above and are         identical to or different from this meaning, and/or -   R³ or R⁴ represent radicals of the formulae -    or represent cycloalkyl having 3 to 8 carbon atoms, aryl having 6     to 10 carbon atoms or represent a 5- to 7-membered partially     unsaturated, saturated and unsaturated, optionally benzo-fused     heterocycle which may contain up to 4 heteroatoms from the group     consisting of S, N, O or a radical of the formula —NR²⁵ which may     optionally also be attached via a ring nitrogen atom,     -    in which     -   R²⁵ has the meaning of R¹⁶ given above and is identical to or         different from this meaning, or represents carboxyl, formyl or         straight-chain or branched acyl having up to 5 carbon atoms, and         where cycloalkyl, aryl and/or the heterocycle are optionally         mono- to trisubstituted by identical or different substituents         from the group consisting of halogen, trifluoromethyl,         trifluoromethoxy, carboxyl, straight-chain or branched acyl or         alkoxycarbonyl having in each case up to 6 carbon atoms, nitro         and/or by groups of the formulae —SO₃H, —OR²⁶, (SO₂)_(f)NR²⁷R²⁸,         —P(O)(OR²⁹)(OR³⁰),         -   in which         -   R²⁶ represents a radical of the formula         -    or represents cycloalkyl having 3 to 7 carbon atoms, or             hydrogen or straight-chain or branched alkyl having up to 5             carbon atoms which is optionally substituted by cycloalkyl             having 3 to 7 carbon atoms, straight-chain or branched             alkoxy or alkoxycarbonyl having in each case up to 6 carbon             atoms, hydroxyl, carboxyl or phenyl, which for its part may             be mono- to trisubstituted by identical or different             substituents from the group consisting of straight-chain or             branched alkoxy having up to 4 carbon atoms, hydroxyl and             halogen,             -   f is a number 0 or 1,             -   R²⁷ and R²⁸ have the meaning of R¹⁸ and R¹⁹ given above                 and are identical to or different from this meaning or                 represent a radical of the formula —CO—NH₂,             -   R²⁹ and R³⁰ have the meaning of R¹⁰ and R¹¹ given above                 and are identical to or different from this meaning, -   and/or cycloalkyl, aryl and/or the heterocycle are optionally     substituted by straight-chain or branched alkyl having up to 6     carbon atoms which is optionally substituted by hydroxyl, carboxyl,     by a 5- to 7-membered heterocycle having up to 3 heteroatoms from     the group consisting of S, N and/or O or by groups of the formulae     —SO₂—R³¹, P(O)(OR³²)(OR³³) or —NR³⁴R³⁵,     -   in which     -   R³¹ is hydrogen or has the meaning of R⁹ given above and is         identical to or different from this meaning,     -   R³² and R³³ have the meaning of R¹⁰ and R¹¹ given above and are         identical to or different from this meaning,     -   R³⁴ and R³⁵ are identical or different and represent hydrogen or         straight-chain or branched alkyl having up to 6 carbon atoms         which is optionally substituted by hydroxyl or straight-chain or         branched alkoxy having up to 4 carbon atoms, or     -   R³⁴ and R³⁵ together with the nitrogen atom form a 5- to         6-membered saturated heterocycle which may contain a further         heteroatom from the group consisting of S and O or a radical of         the formula —NR³⁶,         -   in which         -   R³⁶ has the meaning of R¹⁶ given above and is identical to             or different from this meaning, or -   R³ and R⁴ together with the nitrogen atom form a 5- to 7-membered     unsaturated or saturated or partially unsaturated, optionally     benzo-fused heterocycle which may optionally contain up to 3     heteroatoms from the group consisting of S, N, O or a radical of the     formula —NR³⁷,     -   in which     -   R³⁷ represents hydrogen, hydroxyl, formyl, trifluoromethyl,         straight-chain or branched acyl, alkoxy or alkoxycarbonyl having         in each case up to 4 carbon atoms, or represents cycloalkyl         having 3 to 8 carbon atoms, or represents straight-chain or         branched alkyl having up to 6 carbon atoms which is optionally         mono- to trisubstituted by identical or different substituents         from the group consisting of hydroxyl, trifluoromethyl, pyridyl,         carboxyl, straight-chain or branched alkoxy and alkoxycarbonyl         having in each case up to 6 carbon atoms, or     -   R³⁷ represents a radical of the formula —(CO)_(g)-G,         -   in which         -   g represents a number 0 or 1,         -   G represents aryl having 6 to 10 carbon atoms or a 5- to             6-membered aromatic heterocycle having up to 4 heteroatoms             from the group consisting of S, N and/or O, where the ring             systems listed above are optionally mono- to trisubstituted             by identical or different substituents from the group             consisting of halogen, straight-chain or branched alkoxy,             alkyl or alkylthio having in each case up to 6 carbon atoms,             hydroxyl and trifluoromethyl, -   and the heterocycle mentioned under R³ and R⁴, formed via the     nitrogen, is optionally mono- to trisubstituted, optionally also     geminally, by identical or different substituents from the group     consisting of hydroxyl, formyl, carboxyl, straight-chain or branched     acyl and alkoxycarbonyl having in each case up to 6 carbon atoms and     groups of the formulae —P(O)(OR³⁸)(OR³⁹) and —(CO)_(g))—NR⁴⁰R⁴¹,     -   in which     -   R³⁸ and R³⁹ have the meaning of R¹⁰ and R¹¹ given above and are         identical to or different from this meaning,     -   g represents a number 0 or 1, and     -   R⁴⁰ and R⁴¹ are identical or different and have the meaning of         R¹⁸ and R¹⁹ given above, -   and/or the heterocycle mentioned under R³ and R⁴, formed via the     nitrogen, is optionally substituted by straight-chain or branched     alkyl having up to 6 carbon atoms which is optionally mono- to     trisubstituted by identical or different substituents from the group     consisting of hydroxyl, halogen, carboxyl, cycloalkyl or     cycloalkyloxy having in each case 3 to 8 carbon atoms,     straight-chain or branched alkoxy and alkoxycarbonyl having in each     case up to 6 carbon atoms or by a radical of the formula —SO₃H,     —NR⁴²R⁴³ or P(O)OR⁴⁴OR⁴⁵,     -   in which     -   R⁴² and R⁴³ are identical or different and represent hydrogen,         phenyl, carboxyl, benzyl or straight-chain or branched alkyl or         alkoxy having in each case up to 6 carbon atoms,     -   R⁴⁴ and R⁴⁵ are identical or different and have the meaning of         R¹⁰ and R¹¹ given above, -   and/or the alkyl is optionally substituted by benzyloxy or aryl     having 6 to 10 carbon atoms, which for its part may be mono- to     trisubstituted by identical or different substituents from the group     consisting of halogen, hydroxyl, straight-chain or branched alkoxy     or alkylthio having in each case up to 6 carbon atoms, or by a group     of the formula —NR^(42′)R^(43′),     -   in which     -   R^(42′) and R^(43′) have the meaning of R⁴² and R⁴³ given above         and are identical to or different from this meaning, -   and/or the heterocycle mentioned under R³ and R⁴, formed via a     nitrogen atom, is optionally substituted by aryl having 6 to 10     carbon atoms or by a 5- to 7-membered saturated, partially     unsaturated or unsaturated heterocycle having up to 3 ring     heteroatoms from the group consisting of S, N and/or O, optionally     also attached via an N function, where the ring systems for their     part may be substituted by halogen, hydroxyl or by straight-chain or     branched alkyl, alkylthio or alkoxy having in each case up to 6     carbon atoms, or -   R³ and R⁴ together with the nitrogen atom form radicals of the     formulae -    in which     -   R⁴⁴ represents hydrogen or straight-chain or branched alkyl or         alkoxycarbonyl having in each case up to 6 carbon atoms,     -   R⁴⁵ and R^(45′) are identical or different and represent         hydrogen or straight-chain or branched alkyl having up to 3         carbon atoms,     -   R⁴⁶ represents hydroxyl or straight-chain or branched alkoxy         having up to 6 carbon atoms, -   R⁵ and R⁶ are identical or different and represent hydrogen,     straight-chain or branched alkyl having up to 6 carbon atoms,     hydroxy or represents straight-chain or branched alkoxy having up to     6 carbon atoms, -   and their salts and isomeric forms.

The compounds according to the invention may exist in stereoisomeric forms which are either like image and mirror image (enantiomers), or which are not like image and mirror image (diastereomers). The invention relates both to the enantiomers or diastereomers and to their respective mixtures. The racemic forms can, just like the diastereomers, be separated in a known manner into the stereoisomerically uniform constituents.

The substances according to the invention may also be present as salts. In the context of the invention, preference is given to physiologically acceptable salts.

Physiologically acceptable salts can be salts of the compounds according to the invention with inorganic or organic acids. Preference is given to salts with inorganic acids, such as, for example, hydrochloric acid, hydrobromic acid, phosphoric acid or sulphuric acid, or to salts with organic carboxylic or sulphonic acids, such as, for example, acetic acid, maleic acid, fumaric acid, malic acid, citric acid, tartaric acid, lactic acid, benzoic acid, or methanesulphonic acid, ethanesulphonic acid, phenylsulphonic acid, toluenesulphonic acid or naphthalenedisulphonic acid.

Physiologically acceptable salts can also be metal or ammonium salts of the compounds according to the invention. Particular preference is given to, for example, sodium, potassium, magnesium or calcium salts, and also to ammonium salts which are derived from ammonia or organic amines, such as, for example, ethylamine, di- or triethylamine, di- or triethanolamine, dicyclohexylamine, dimethylaminoethanol, arginine, lysine, ethylenediamine or 2-phenylethylamine.

In the context of the invention and depending on the various substituents, optionally benzo-fused heterocycle generally represents an aromatic, saturated, partially unsaturated or unsaturated 5- to 7-membered or 5- to 6-membered heterocycle which may contain up to 4 heteroatoms from the group consisting of S, N and O. Examples which may be mentioned are: azepine, diazepine, indolyl, isoquinolyl, quinolyl, benzo[b]thiophene, benzo[b]furanyl, pyridyl, thienyl, tetrahydrofuranyl, tetrahydropyranyl, furyl, pyrrolyl, thiazolyl, triazolyl, tetrazolyl, isoxazolyl, imidazolyl, morpholinyl, thiomorpholinyl, pyrrolidinyl, piperazinyl, N-methylpiperazinyl or piperidinyl. Preference is given to quinolyl, furyl, pyridyl, thienyl, piperidinyl, pyrrolidinyl, piperazinyl, azepine, diazepine, thiazolyl, triazolyl, tetrazolyl, tetrahydrofuranyl, tetrahydropyranyl, morphholinyl and thiomorpholinyl.

Preference is given to compounds of the general formula (I) according to the invention

in which

-   R¹ represents straight-chain or branched alkyl having up to 3 carbon     atoms, -   R² represents straight-chain [lacuna] having 5 to 15 carbon atoms or     branched alkyl having 3 to 15 carbon atoms, or represents     cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl or     cyclooctyl, -   R³ and R⁴ are identical or different and represent hydrogen, or     represent straight-chain or branched alkenyl having up to 4 carbon     atoms, or represent a straight-chain or branched alkyl chain having     up to 6 carbon atoms which is optionally interrupted by an oxygen     atom and which is optionally mono- to trisubstituted by identical or     different substituents from the group consisting of hydroxyl,     carboxyl, straight-chain or branched alkoxy, alkoxycarbonyl and     alkylthio having in each case up to 4 carbon atoms and/or by     radicals of the formulae —SO₃H, -(A)_(a)—NR⁷R⁸, —O—CO—NR^(7′)R^(8′),     —S(O)_(b)—R⁹, HN═SO—R^(9′), —P(O)(OR¹⁰)(OR¹¹),     -   in which     -   a and b are identical or different and represent a number 0 or         1,     -   A represents a radical CO or SO₂,     -   R⁷, R^(7′), R⁸ and R^(8′) are identical or different and         represent hydrogen, or represent phenyl, naphthyl, or pyridyl,         where the ring systems listed above are optionally mono- to         disubstituted by identical or different substituents from the         group consisting of hydroxyl, nitro, trifluoromethyl,         trifluoromethoxy, carboxyl, halogen, straight-chain or branched         alkoxy and alkoxycarbonyl having in each case up to 4 carbon         atoms, or represent straight-chain or branched alkoxy having up         to 4 carbon atoms, or represent straight-chain or branched alkyl         having up to 6 carbon atoms which is optionally mono- or         polysubstituted by identical or different substituents from the         group consisting of hydroxyl, fluorine, chlorine, bromine,         phenyl, straight-chain or branched alkoxy and alkoxycarbonyl         having in each case up to 4 carbon atoms or by a group of the         formula —(CO)_(d)—NR¹⁴R¹⁵,         -   in which         -   R¹⁴ and R¹⁵ are identical or different and represent             hydrogen or straight-chain or branched alkyl having up to 3             carbon atoms, and         -   d represents a number 0 or 1, or     -   R⁷ and R⁸ and/or R^(7′) and R^(8′) together with the nitrogen         atom form a pyrrolidinyl, piperidinyl or morpholinyl ring or a         radical of the formula     -    in which         -   R¹⁶ represents hydrogen, phenyl, naphthyl or straight-chain             or branched alkyl having up to 4 carbon atoms, which is             optionally substituted by hydroxyl,     -   R⁹ and R^(9′) are identical or different and represent phenyl or         benzyl, or represent straight-chain or branched alkyl having up         to 3 carbon atoms,     -   R¹⁰ and R¹¹ are identical or different and represent hydrogen or         straight-chain or branched alkyl having up to 3 carbon atoms,     -   and/or the alkyl chain mentioned above under R³/R⁴ is optionally         substituted by phenyl, naphthyl, morpholinyl, pyridyl,         tetrahydropyranyl, tetrahydrofuranyl or thienyl, where the         radical may optionally also be attached to the alkyl chain via a         ring nitrogen atom, -   and where aryl and the heterocycle are optionally mono- to     disubstituted by identical or different substituents from the group     consisting of nitro, fluorine, chlorine, bromine, —SO₃H,     straight-chain or branched monohydroxy-substituted alkyl, alkylthio     or alkoxy having in each case up to 4 carbon atoms, hydroxyl,     trifluoromethyl, trifluoromethoxy and/or by a radical of the formula     —(SO₂)_(e)—NR¹⁸R¹⁹,     -   in which     -   e represents a number 0 or 1,     -   R¹⁸ and R¹⁹ are identical or different and represent hydrogen,         phenyl, benzyl or straight-chain or branched alkyl or acyl         having in each case up to 4 carbon atoms, and/or -   R³ and R⁴ represent radicals of the formulae —NR²⁰R²¹ or     —(O)-E-NR²²R²³,     -   in which     -   R²⁰ and R²¹ have the meaning of R¹⁸ and R¹⁹ given above and are         identical to or different from this meaning, or together with         the nitrogen atom form a morpholinyl ring, pyrrolidinyl ring or         a radical of the formula         -   in which         -   R²⁴ has the meaning of R¹⁶ given above and is identical to             or different from this meaning,     -   E represents a straight-chain alkylene group having up to 4         carbon atoms,     -   R²² and R²³ have the meaning of R¹⁸ and R¹⁹ given above and are         identical to or different from this meaning, and/or -   R³ or R⁴ represent radicals of the formulae -    or represent cyclopentyl, cyclohexyl, naphthyl, phenyl, pyridyl, or     quinolyl or tetrazolyl attached via the phenyl ring, and where the     ring systems given above are optionally mono- to disubstituted by     identical or different substituents from the group consisting of     fluorine, chlorine, trifluoromethyl, trifluoromethoxy, carboxyl,     straight-chain or branched acyl and alkoxycarbonyl having in each     case up to 4 carbon atoms and/or by groups of the formulae —SO₃H,     —OR²⁶, (SO₂)_(f)NR²⁷R²⁸, —P(O)(OR²⁹)(OR³⁰),     -   in which     -   R²⁶ represents a radical of the formula     -    or represents cyclopentyl or cyclohexyl, or represents hydrogen         or straight-chain or branched alkyl having up to 4 carbon atoms         which is optionally substituted by straight-chain or branched         alkoxy or alkoxycarbonyl having in each case up to 4 carbon         atoms, hydroxyl, carboxyl or phenyl, which for its part may be         mono- to disubstituted by identical or different substituents         from the group consisting of straight-chain or branched alkoxy         having up to 3 carbon atoms, hydroxyl and halogen,     -   f represents a number 0 or 1,     -   R²⁷ and R²⁸ have the meaning of R¹⁸ and R¹⁹ given above and are         identical to or different from this meaning or represent a         radical of the formula —CO—NH₂,     -   R²⁹ and R³⁰ have the meaning of R¹⁰ and R¹¹ given above and are         identical to or different from this meaning, -   and/or the ring systems given above are optionally substituted by     straight-chain or branched alkyl having up to 4 carbon atoms, which     are optionally substituted by hydroxyl, carboxyl, morpholine,     pyridyl or by groups of the formula —SO₂—R³¹, P(O)(OR³²)(OR³³) or     —NR³⁴R³¹,     -   in which     -   R³¹ represents hydrogen or has the meaning of R⁹ given above and         is identical to or different from this meaning,     -   R³² and R³³ have the meaning of R¹⁰ and R¹¹ given above and are         identical to or different from this meaning,     -   R³⁴ and R³⁵ are identical or different and represent hydrogen or         straight-chain or branched alkyl having up to 4 carbon atoms         which is optionally substituted by hydroxyl or straight-chain or         branched alkoxy having up to 3 carbon atoms, or     -   R³⁴ and R³⁵ together with the nitrogen atom form a morpholinyl,         pyrrolidinyl, piperidinyl ring or a radical of the formula     -    in which         -   R³⁶ has the meaning of R¹⁶ given above and is identical to             or different from this meaning, or -   R³ and R⁴ together with the nitrogen atom form a piperidinyl,     pyrrolidinyl or morpholinyl ring, or a radical of the formula -    in which     -   R³⁷ represents hydrogen, hydroxyl, formyl, trifluoromethyl,         straight-chain or branched acyl, alkoxy or alkoxycarbonyl having         in each case up to 4 carbon atoms, or represents cyclopropyl,         cyclobutyl, cyclopentyl or cyclohexyl, or represents         straight-chain or branched alkyl having up to 4 carbon atoms         which is optionally mono- to trisubstituted by identical or         different substituents from the group consisting of hydroxyl,         trifluoromethyl, pyridyl, carboxyl, straight-chain or branched         alkoxy and alkoxycarbonyl having in each case up to 4 carbon         atoms, or     -   R³⁷ represents a radical of the formula —(CO)_(g)-G,         -   in which         -   g represents a number 0 or 1,         -   G represents naphthyl, phenyl, pyridyl or pyrimidyl, where             the ring systems listed above are optionally mono- to             trisubstituted by identical or different substituents from             the group consisting of fluorine, chlorine, straight-chain             or branched alkoxy, alkyl or alkylthio having in each case             up to 4 carbon atoms, hydroxyl and trifluoromethyl, -   and the heterocycles listed above under R³ and R⁴ are optionally     mono- to trisubstituted, optionally also geminally, by identical or     different substituents from the group consisting of hydroxyl,     formyl, carboxyl, straight-chain or branched acyl or alkoxycarbonyl     having in each case up to 4 carbon atoms and groups of the formulae     —P(O)(OR³⁸)(OR³⁹) or —(CO)_(g))—NR⁴⁰R⁴¹,     -   in which     -   R³⁸ and R³⁹ have the meaning of R¹⁰ and R¹¹ given above and are         identical to or different from this meaning,     -   g represents a number 0 or 1, and     -   R⁴⁰ and R⁴¹ are identical or different and have the meaning of         R¹⁸ and R¹⁹ given above, -   and/or the heterocycles listed under R³ and R⁴ are optionally     substituted by straight-chain or branched alkyl having up to 4     carbon atoms which is optionally mono- to trisubstituted by     identical or different substituents from the group consisting of     hydroxyl, fluorine, chlorine, carboxyl, cyclopropyl, cyclobutyl,     cyclopentyl, cyclohexyl, cyclopentyloxy, cyclohexyloxy,     straight-chain or branched alkoxy and alkoxycarbonyl having in each     case up to 4 carbon atoms or by a radical of the formula —SO₃H,     —NR⁴²R⁴³ or P(O)OR⁴⁴OR⁴⁵,     -   in which     -   R⁴² and R⁴³ are identical or different and represent hydrogen,         phenyl, carboxyl, benzyl or straight-chain or branched alkyl or         alkoxy having in each case up to 4 carbon atoms,     -   R⁴⁴ and R⁴⁵ are identical or different and have the meaning of         R¹⁰ and R¹¹ given above, -   and/or the alkyl is optionally substituted by benzyloxy, naphtyl or     phenyl, which for its part may be mono- to trisubstituted by     identical or different substituents from the group consisting of     fluorine, chlorine, hydroxyl, straight-chain or branched alkoxy and     alkylthio having in each case up to 4 carbon atoms, or by a group of     the formula —NR⁴²R⁴³,     -   in which     -   R^(42′) and R^(43′) have the meaning of R⁴² and R⁴³ given above         and are identical to or different from this meaning, -   and/or the heterocycles listed under R³ and R⁴ are optionally     substituted by phenyl, naphthyl or by radicals of the formulae -    where the ring systems for their part may be substituted by     fluorine, chlorine, hydroxyl or by straight-chain or branched alkyl,     alkylthio or alkoxy having in each case up to 4 carbon atoms, or -   R³ and R⁴ together with the nitrogen atom form radicals of the     formulae -    in which     -   R⁴⁴ represents hydrogen or straight-chain or branched alkyl or         alkoxycarbonyl having in each case up to 3 carbon atoms,     -   R⁴⁵ and R^(45′) are identical or different and represent         hydrogen or methyl,     -   R⁴⁶ represents hydroxyl or straight-chain or branched alkoxy         having up to 4 carbon atoms, -   R⁵ and R⁶ are identical or different and represent hydrogen,     straight-chain or branched alkyl having up to 4 carbon atoms,     hydroxyl or represent straight-chain or branched alkoxy having up to     4 carbon atoms,     and their salts and isomeric forms.

Particular preference is given to compounds of the general formula (I) according to the invention,

in which

-   R¹ represents straight-chain or branched alkyl having up to 3 carbon     atoms, -   R² represents straight-chain [lacuna] having 5 to 12 carbon atoms or     branched alkyl having 3 to 12 carbon atoms, or represents     cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl or     cyclooctyl, -   R³ and R⁴ are identical or different and represent hydrogen, or     represent straight-chain or branched alkenyl having up to 4 carbon     atoms, or represent a straight-chain or branched alkyl chain having     up to 6 carbon atoms which is optionally interrupted by an oxygen     atom and which is optionally mono- to trisubstituted by identical or     different substituents from the group consisting of hydroxyl,     carboxyl, straight-chain or branched alkoxy, alkoxycarbonyl and     alkylthio having in each case up to 4 carbon atoms and/or by     radicals of the formulae —SO₃H, -(A)_(a)-NR⁷R⁸, —O—CO—NR^(7′)R^(8′),     —S(O)_(b)—R⁹, HN═SO—R^(9′), —P(O)(OR¹⁰)(OR¹¹), -    in which     -   a and b are identical or different and represent a number 0 or         1,     -   A represents a radical CO or SO₂,     -   R⁷, R^(7′), R⁸ and R^(8′) are identical or different and         represent hydrogen, or represent phenyl, naphthyl, or pyridyl,         where the ring systems listed above are optionally mono- to         disubstituted by identical or different substituents from the         group consisting of hydroxyl, nitro, trifluoromethyl,         trifluoromethoxy, carboxyl, halogen, straight-chain or branched         alkoxy and alkoxycarbonyl having in each case up to 4 carbon         atoms, or represent straight-chain or branched alkoxy having up         to 4 carbon atoms, or represent straight-chain or branched alkyl         having up to 6 carbon atoms which is optionally mono- or         polysubstituted by identical or different substituents from the         group consisting of hydroxyl, fluorine, chlorine, bromine,         phenyl, straight-chain or branched alkoxy and alkoxycarbonyl         having in each case up to 4 carbon atoms or by a group of the         formula —(CO)_(d)—NR¹⁴R¹⁵,         -   in which         -   R¹⁴ and R¹⁵ are identical or different and represent             hydrogen or straight-chain or branched alkyl having up to 3             carbon atoms, and         -   d represents a number 0 or 1, or     -   R⁷ and R⁸ and/or R^(7′) and R^(8′) together with the nitrogen         atom form a pyrrolidinyl, piperidinyl or morpholinyl ring or a         radical of the formula     -    in which         -   R¹⁶ represents hydrogen, phenyl, naphthyl or straight-chain             or branched alkyl having up to 4 carbon atoms which is             optionally substituted by hydroxyl,     -   R⁹ and R^(9′) are identical or different and represent phenyl or         benzyl, or represent straight-chain or branched alkyl having up         to 3 carbon atoms,     -   R¹⁰ and R¹¹ are identical or different and represent hydrogen or         straight-chain or branched alkyl having up to 3 carbon atoms,     -   and/or the alkyl chain listed above under R³/R⁴ is optionally         substituted by phenyl, naphthyl, morpholinyl, pyridyl,         tetrahydropyranyl, tetrahydrofuranyl or thienyl, where the         attachment to the alkyl chain may optionally also take place via         a ring nitrogen atom, -   and where aryl and the heterocycle are optionally mono- to     disubstituted by identical or different substituents from the group     consisting of nitro, fluorine, chlorine, bromine, —SO₃H,     straight-chain or branched monohydroxy-substituted alkyl, alkylthio     or alkoxy having in each case up to 4 carbon atoms, hydroxyl,     trifluoromethyl, trifluoromethoxy and/or by a radical of the formula     —(SO₂)_(e)—NR¹⁸R¹⁹,     -   in which     -   e represents a number 0 or 1,     -   R¹⁸ and R¹⁹ are identical or different and represent hydrogen,         phenyl, benzyl or straight-chain or branched alkyl or acyl         having in each case up to 4 carbon atoms, and/or -   R³ or R⁴ represents radicals of the formulae —NR²⁰R²¹ or     —(O)-E-NR²²R²³,     -   in which     -   R²⁰ and R²¹ have the meaning of R¹⁸ and R¹⁹ given above and are         identical to or different from this meaning, or together with         the nitrogen atom form a morpholinyl ring, pyrrolidinyl ring or         a radical of the formula     -    in which         -   R²⁴ has the meaning of R¹⁶ given above and is identical to             or different from this meaning,     -   E represents a straight-chain alkylene group having up to 4         carbon atoms,     -   R²² and R²³ have the meaning of R¹⁸ and R¹⁹ given above and are         identical to or different from this meaning and/or -   R³ or R⁴ represent the radicals of the formulae -    or represent cyclopentyl, cyclohexyl, naphthyl, phenyl, pyridyl, or     quinolinyl or tetrazolyl attached via the phenyl ring, and where the     ring systems given above are optionally mono- to disubstituted by     identical or different substituents from the group consisting of     fluorine, chlorine, trifluoromethyl, trifluoromethoxy, carboxyl,     straight-chain or branched acyl and alkoxycarbonyl having in each     case up to 4 carbon atoms and/or by groups of the formulae —SO₃H,     —OR²⁶, (SO₂)_(f)NR²⁷R²⁸, —P(O)(OR²⁹)(OR³⁰),     -   in which     -   R²⁶ represents a radical of the formula     -    or represents cyclopentyl or cyclohexyl, or represents hydrogen         or straight-chain or branched alkyl having up to 4 carbon atoms         which is optionally substituted by straight-chain or branched         alkoxy or alkoxycarbonyl having in each case up to 4 carbon         atoms, hydroxyl, carboxyl or phenyl, which for its part may be         mono- to disubstituted by identical or different substituents         from the group consisting of straight-chain or branched alkoxy         having up to 3 carbon atoms, hydroxyl and halogen,     -   f represents a number 0 or 1,     -   R²⁷ and R²⁸ have the meaning of R¹⁸ and R¹⁹ given above and are         identical to or different from this meaning or represent a         radical of the formula —CO—NH₂,     -   R²⁹ and R³⁰ have the meaning of R¹⁰ and R¹¹ given above and are         identical to or different from this meaning, -   and/or the ring systems given above are optionally substituted by     straight-chain or branched alkyl having up to 4 carbon atoms which     are optionally substituted by hydroxyl, carboxyl, morpholine,     pyridyl or by groups of the formula —SO₂—R³¹, P(O)(OR³²)(OR³³) or     —NR³⁴R³⁵,     -   in which     -   R³¹ represents hydrogen or has the meaning of R⁹ given above and         is identical to or different from this meaning,     -   R³² and R³³ have the meaning of R¹⁰ and R¹¹ given above and are         identical to or different from this meaning,     -   R³⁴ and R³⁵ are identical or different and represent hydrogen or         straight-chain or branched alkyl having up to 4 carbon atoms         which is optionally substituted by hydroxyl or straight-chain or         branched alkoxy having up to 3 carbon atoms, or     -   R³⁴ and R³⁵ together with the nitrogen atom form a morpholinyl,         pyrrolidinyl, piperidinyl ring or a radical of the formula     -    in which         -   R³⁶ has the meaning of R¹⁶ given above and is identical to             or different from this meaning, or -   R³ and R⁴ together with the nitrogen atom form a piperidinyl,     pyrrolidinyl or morpholinyl ring, or a radical of the formula -    in which     -   R³⁷ represents hydrogen, hydroxyl, formyl, trifluoromethyl,         straight-chain or branched acyl, alkoxy or alkoxycarbonyl having         in each case up to 4 carbon atoms, or represents cyclopropyl,         cyclobutyl, cyclopentyl or cyclohexyl, or represents         straight-chain or branched alkyl having up to 4 carbon atoms         which is optionally mono- to trisubstituted by identical or         different substituents from the group consisting of hydroxyl,         trifluoromethyl, pyridyl, carboxyl, straight-chain or branched         alkoxy and alkoxycarbonyl having in each case up to 4 carbon         atoms, or     -   R³⁷ represents a radical of the formula —(CO)_(g)-G,         -   in which         -   g represents a number 0 or 1,         -   G represents naphthyl, phenyl, pyridyl or pyrimidyl, where             the ring systems listed above are optionally mono- to             trisubstituted by identical or different substituents from             the group consisting of fluorine, chlorine, straight-chain             or branched alkoxy, alkyl or alkylthio having in each case             up to 4 carbon atoms, hydroxyl and trifluoromethyl, -   and the heterocycles listed under R³ and R⁴ are optionally mono- to     trisubstituted, optionally also geminally, by identical or different     substituents from the group consisting of hydroxyl, formyl,     carboxyl, straight-chain or branched acyl or alkoxycarbonyl having     in each case up to 4 carbon atoms and groups of the formulae     —P(O)(OR³⁸)(OR³⁹) or —(CO)_(g))—NR⁴⁰R⁴¹,     -   in which     -   R³⁸ and R³⁹ have the meaning of R¹⁰ and R¹¹ given above and are         identical to or different from this meaning,     -   g represents a number 0 or 1, and     -   R⁴⁰ and R⁴¹ are identical or different and have the meaning of         R¹⁸ and R¹⁹ given above, -   and/or the heterocycles listed under R³ and R⁴ are optionally     substituted by straight-chain or branched alkyl having up to 4     carbon atoms which is optionally mono- to trisubstituted by     identical or different substituents from the group consisting of     hydroxyl, fluorine, chlorine, carboxyl, cyclopropyl, cyclobutyl,     cyclopentyl, cyclohexyl, cyclopentyloxy, cyclohexyloxy,     straight-chain or branched alkoxy and alkoxycarbonyl having in each     case up to 4 carbon atoms or by a radical of the formula —SO₃H,     —NR⁴²R⁴³ or P(O)OR⁴⁴OR⁴⁵,     -   in which     -   R⁴² and R⁴³ are identical or different and represent hydrogen,         phenyl, carboxyl, benzyl or straight-chain or branched alkyl or         alkoxy having in each case up to 4 carbon atoms,     -   R⁴⁴ and R⁴⁵ are identical or different and have the meaning of         R¹⁰ and R¹¹ given above,     -   and/or the alkyl is optionally substituted by benzyloxy, naphtyl         or phenyl, which for its part may be mono- to trisubstituted by         identical or different substituents from the group consisting of         fluorine, chlorine, hydroxyl, straight-chain or branched alkoxy         or alkylthio having in each case up to 4 carbon atoms, or by a         group of the formula NR^(42′)R^(43′)     -   in which     -   R^(42′) and R^(43′) have the meaning of R⁴² and R⁴³ given above         and are identical to or different from this meaning, -   and/or the heterocycles listed under R³ and R⁴ are optionally     substituted by phenyl, naphthyl or by radicals of the formulae -    where the ring systems for their part may be substituted by     fluorine, chlorine, hydroxyl or by straight-chain or branched alkyl,     alkylthio or alkoxy having in each case up to 4 carbon atoms, or -   R³ and R⁴ together with the nitrogen atom form radicals of the     formulae -    in which     -   R⁴⁴ represents hydrogen or straight-chain or branched alkyl or         alkoxycarbonyl having in each case up to 3 carbon atoms,     -   R⁴⁵ and R^(45′) are identical or different and represent         hydrogen or methyl,     -   R⁴⁶ represents hydroxyl or straight-chain or branched alkoxy         having up to 4 carbon atoms, -   R⁵ and R⁶ are identical or different and represent hydrogen,     straight-chain or branched alkyl having up to 4 carbon atoms,     hydroxyl or represent straight-chain or branched alkoxy having up to     4 carbon atoms,     and their salts and isomeric forms.

Particular preference is also given to compounds of the general formula (I) in which

-   R¹ represents methyl or ethyl, -   R² represents straight-chain [lacuna] having 5 to 11 carbon atoms or     branched alkyl having 3 to 11 carbon atoms, or represents     cyclopentyl, cyclohexyl, cycloheptyl, -   R³ and R⁴ are identical or different and represent straight-chain or     branched alkyl having up to 4 carbon atoms which is optionally     substituted by hydroxyl, morpholinyl, methoxy, ethoxy,     N,N-dimethylamino, N,N-diethylamine or phenyl, which for its part     may be substituted up to 3 times by identical or different     substituents from the group consisting of methoxy, or represents     cyclopropyl, or or represents phenyl which is optionally substituted     up to 3 times by identical or different substituents from the group     consisting of fluorine, chlorine or hydroxyl, methoxy, ethoxy,     fluorine or by straight-chain or branched alkyl having up to 3     carbon atoms, which for its part may be substituted by hydroxyl, or -   R³ and R⁴ together with the nitrogen atom form a morpholinyl,     pyrrolidinyl or piperidinyl ring which are optionally substituted by     hydroxyl or by radicals of the formulae —P(O)(OC₂H₅)₂ or     —CH₂—P(O)OH(OC₂H₅) or by straight-chain or branched alkyl having up     to 3 carbon atoms, which for its part may be substituted by hydroxyl     or methoxy, or or -   R³ and R⁴ together with the nitrogen atom form a radical of the     formula -    in which     -   R³⁷ represents pyrimidyl, ethoxycarbonyl or a radical of the         formula —CH₂—P(O)(OCH₃)₂ or represents straight-chain or         branched alkyl having up to 3 carbon atoms which is optionally         substituted by hydroxyl or methoxy, -   R⁵ represents hydrogen, and -   R⁶ represents ethoxy,     and their salts and isomeric forms.

Particular preference is furthermore given to compounds of the general formula (I) according to the invention in which R⁵ represents hydrogen and the ethoxy group is in the O position to the point of attachment of the heterocycle.

Very particular preference is given to compounds according to the invention having the following structures:

Structure

Moreover, we have found a process for preparing the compounds of the general formula (I) according to the invention, characterized in that

[A] initially compounds of the general formula (II)

in which

-   R¹ and R² are as defined above and -   L represents straight-chain or branched alkyl having up to 4 carbon     atoms, -   are converted with compounds of the general formula (III)     in which -   R⁵ and R⁶ are as defined above -   in a two-step reaction, preferably using the system ethanol and then     phosphorus oxytrichloride/dichloroethane, into the compounds of the     general formula (IV)     in which -   R¹, R², R⁵ and R⁶ are as defined above, -   in a further step reacted with chlorosulphonic acid to give the     compounds of the general formula (V) -    in which -   R¹, R², R¹ and R⁶ are as defined above, -   and then reacted with amines of the general formula (VI)     HN³R⁴  (VI)     in which -   R³ and R⁴ are as defined above -   in inert solvents.

The process according to the invention can be illustrated in an exemplary manner by the equations below:

Solvents which are suitable for the individual steps are the customary organic solvents which do not change under the reaction conditions. These preferably include ethers, such as diethyl ether, dioxane, tetrahydrofuran, glycol dimethyl ether, or hydrocarbons, such as benzene, toluene, xylene, hexane, cyclohexane or mineral oil fractions, or halogenated hydrocarbons, such as dichloromethane, trichloromethane, carbon tetrachloride, dichloroethane, trichloroethylene or chlorobenzene, or ethyl acetate, dimethylformamide, hexamethylphosphoric triamide, acetonitrile, acetone, dimethoxyethane or pyridine. It is also possible to use mixtures of the above-mentioned solvents. Particular preference is given to ethanol for the first step and dichloroethane for the second step.

The reaction temperature can generally be varied within a relatively wide range. In general, the reaction is carried out in a range of from −20° C. to 200° C., preferably of from 0° C. to 70° C.

The process steps according to the invention are generally carried out under atmospheric pressure. However, it is also possible to operate under superatmospheric pressure or under reduced pressure (for example, in a range of from 0.5 to 5 bar).

The reaction to give the compounds of the general formula (V) is carried out in a temperature range of from 0° C. to room temperature, and at atmospheric pressure.

The reaction with the amines of the general formula (VI) is carried out in one of the abovementioned chlorinated hydrocarbons, preferably in dichloromethane.

The reaction temperature can generally be varied within a relatively wide range. In general, the reaction is carried out at temperatures in a range of from −20° C. to 200° C., preferably of from 0° C. to room temperature.

The reaction is generally carried out at atmospheric pressure. However, it is also possible to operate under superatmospheric pressure or under reduced pressure (for example in a range of from 0.5 to 5 bar).

Some of the compounds of the general formula (II) are known, or they are novel, and they can then be prepared by

-   converting compounds of the general formula (VII)     R²—CO-T  (VII)     in which -   R² is as defined above and -   T represents halogen, preferably represents chlorine, -   initially by reaction with compounds of the general formula (VIII)     in which -   R¹ is as defined above -   in inert solvents, if appropriate in the presence of a base and     trimethylsilyl chloride, into the compounds of the general formula     (IX)     in which -   R¹ and R² are each as defined above, -   and finally reacting with the compound of the formula (X)     in inert solvents, if appropriate in the presence of a base.

Suitable solvents for the individual steps of the process are the customary organic solvents which do not change under the reaction conditions. These preferably include ethers, such as diethyl ether, dioxane, tetrahydrofuran, glycol dimethyl ether, or hydrocarbons, such as benzene, toluene, xylene, hexane, cyclohexane or mineral oil fractions, or halogenated hydrocarbons, such as dichloromethane, trichloromethane, carbon tetrachloride, dichloroethylene, trichloroethylene or chlorobenzene, or ethyl acetate, dimethylformamide, hexamethylphosphoric triamide, acetonitrile, acetone, dimethoxyethane or pyridine. It is also possible to use mixtures of the above-mentioned solvents. Particular preference is given to dichloromethane for the first step and to a mixture of tetrahydrofuran and pyridine for the second step.

Suitable bases are generally alkali metal hydrides or alkali metal alkoxides, such as, for example, sodium hydride or potassium tert-butoxide, or cyclic amines, such as, for example, piperidine, pyridine, dimethylaminopyridine or C₁-C₄ alkylamines, such as, for example, triethylamine. Preference is given to triethylamine, pyridine and/or dimethylaminopyridine.

The base is generally employed in an amount of from 1 mol to 4 mol, preferably from 1.2 mol to 3 mol, in each case based on 1 mol of the compound of the formula (X).

The reaction temperature can generally be varied within a relatively wide range. In general, the reaction is carried out in a range of from −20° C. to 200° C., preferably of from 0° C. to 100° C.

The compounds of the general formulae (VII), (VIII), (IX) and (X) are known per se, or they can be prepared by customary methods.

The compounds of the general formula (II) can be prepared by

-   reacting compounds of the general formula (XI)     in which -   R⁵ and R⁶ are each as defined above -   with ammonium chloride in toluene and in the presence of     trimethylaluminium in hexane in a temperature range of from −20° C.     to room temperature, preferably at 0° C. and atmospheric pressure,     and reacting the resulting amidine, if appropriate in situ, with     hydrazine hydrate, to give the compounds of the general formula     (III).

The compounds of the general formula (XI) are known per se, or they can be prepared by customary methods.

Most of the compounds of the general formula (IV) and (V) are novel, and they can be prepared as described above.

The amines of the general formula (VI) are known or can be prepared by customary methods.

The compounds of the general formula (I) according to the invention have an unforeseeable useful pharmacological activity spectrum.

They inhibit either one or more of the cGMP-metabolizing phosphodiesterases (PDE I, PDE II and PDE V). This results in an increase of cGMP. The differentiated expression of the phosphodiesterases in different cells, tissues and organs, as well as the differentiated subcellular localization of these enzymes, in combination with the selective inhibitors according to the invention make it possible to selectively address the various cGMP-regulated processes.

Moreover, the compounds according to the invention enhance the activity of substances such as, for example EDRF (endothelium derived relaxing factor), ANP (atrial natriuretic peptide), of nitrovasodilators and all other substances which increase the cGMP concentration in a manner different from that of phosphodiesterase inhibitors.

They can therefore be employed in pharmaceuticals for treating cardiovascular disorders, such as, for example, for treating hypertension, neuronal hypertonia, stable and unstable angina, peripheral and cardial vasculopathies, arrhythmiae, for treating thromboembolic disorders and ischaemias such as myocardial infarction, stroke, transistory and ischaemic attacks, angina pectoris, obstruction of peripheral circulation, prevention of restenoses after thrombolysis therapy, percutaneous transluminal angioplasty (PTA), percutaneous transluminal coronary angioplasties (PTCA) and bypass. Furthermore, they may also be of significance for cerebrovascular disorders.

They are also suitable for treating all disorders in which a relaxing action on smooth muscles is of importance, such as, for example, erectile dysfunction and female sexual dysfunction.

Activity of the Phosphodiesterases (PDEs)

The cGMP-stimulated PDE II, the cGMP-inhibited PDE III and the cAMP-specific PDE IV were isolated either from porcine or bovine heart myocardium. The Ca²⁺-calmodulin-stimulated PDE I was isolated from porcine aorta, porcine brain or, preferably, from bovine aorta. The cGMP-specific PDE V was obtained from porcine small intestine, porcine aorta, human platelets and, preferably, from bovine aorta.

Purification was carried out by anion exchange chromatography over MonoQ® Pharmacia, essentially following the method of M. Hoey and Miles D. Houslay, Biochemical Pharmacology, Vol. 40, 193-202 (1990) and C. Lugman et al., Biochemical Pharmacology, Vol. 35, 1743-1751 (1986).

The “phosphodiesterase [³H] cAMP-SPA enzyme assay” and the “phosphodiesterase [³H] cGMP-SPA enzyme assay” from Amersham Life Science were used for determining enzyme activity and IC₅₀ values of the various substances. The test was carried out according to the test protocol of the manufacturer. To determine the activity of PDE2, the [³H]cAMP SPA assay was used, and 10⁻⁶ M cGMP were added to the reaction mixture to activate the enzyme. To measure PDE1, 10⁻⁷ M calmodulin and 1 mM CaCl₂ were added to the reaction mixture. PDE5 was measured using the [³H]cGMP SPA assay.

The substances preferably inhibit phosphodiesterases I and V. For both enzymes, the IC₅₀ values are in the range from 500 [lacuna] to 1 mM for PDE V preferably in the range from 1 to 100, for PDE I preferably in the range from 10 to 300 mM.

In principle, inhibition of one or more phosphodiesterases of this type results in an increase of the cGMP concentration. Thus, the compounds are of interest for all therapies in which an increase in the cGMP concentration is considered to be beneficial.

The cardiovascular effects were investigated using SH rats and dogs. The substances were administered intravenously or orally.

The novel active compounds and their physiologically acceptable salts (for example hydrochlorides, maleates or lactates) can be converted in a known manner into the customary formulations, such as tablets, coated tablets, pills, granules, aerosols, syrups, emulsions, suspensions and solutions, using inert non-toxic, pharmaceutically suitable excipients or solvents. In this case the therapeutically active compound should in each case be present in a concentration of from approximately 0.5 to 90% by weight of the total mixture, i.e. in amounts which are sufficient in order to achieve the dosage range indicated.

The formulations are prepared, for example, by extending the active compounds using solvents and/or excipients, if appropriate using emulsifiers and/or dispersants, it optionally being possible, for example, to use organic solvents as auxiliary solvents if the diluent used is water.

Administration is carried out in a customary manner, preferably orally, transdermally or parenterally, for example perlingually, buccally, intravenously, nasally, rectally or inhalatively.

In spite of this, if appropriate it may be necessary to depart from the amounts mentioned, namely depending on the body weight or the type of administration route, on the individual response towards the medicament, the manner of its formulation and the time or interval at which administration takes place. Thus, in some cases it may be adequate to manage with less than the abovementioned minimum amounts, while in other cases the upper limit mentioned has to be exceeded. In the case of the administration of relatively large amounts, it may be advisable to divide these into several individual doses over the course of the day.

For human use, in the case of oral administration, doses of from 0.001 to 30 mg/kg, preferably of 0.01 mg/kg-10 mg/kg are administered. In the case of parenteral administration, it is good practice to use doses of 0.001 mg/kg--½ mg/kg.

The compounds according to the invention are also suitable for use in veterinary medicine. For use in veterinary medicine, the compounds or their non-toxic salts can be administered in a suitable formulation in accordance with general veterinary practice. Depending on the kind of animal to be treated, the veterinary surgeon can determine the nature of use and the dosage.

STARTING MATERIALS Example 1A 2-Cyclopentanoylamino-propionic acid

16.8 g (0.189 mol) of D,L-alanine and 41.98 g (0.415 mol) of triethylamine are initially charged in 200 ml of dichloromethane. At 0° C., 45.07 g (0.415 mol) of trimethylsilyl chloride are added dropwise, and the mixture is then stirred at room temperature for 1 h and then at 40° C. for 1 h. The solution is cooled to −10° C. and 25 g (0.189 mol) of cyclopentanecarbonyl chloride are added dropwise. The mixture is stirred at −10° C. for 2 h and at room temperature for 1 h. With ice-cooling, 100 ml of water are added, and the mixture is then stirred for 10 min and the resulting precipitate is filtered off with suction. The precipitate is washed with 300 ml of water and then with 300 ml of diethyl ether and subsequently dried at 60° C.

Yield: 25.8 g (73.9% of theory) ¹H-NMR (CD₃OD): 1.35 (d, 3H); 1.5-1.9 (m, 8H); 2.7 (quin, 1H); 4.5 (quar., 1H):

Example 2A 2-Cyclopentanoylamino-butyric acid

10.31 g of 2-aminobutyric acid (100 mmol) and 22.26 g (220 mmol) of triethylamine are dissolved in 100 ml of dichloromethane, and the solution is cooled to 0° C. 23.90 g (220 mmol) of trimethylsilyl chloride are added dropwise, and the solution is stirred at room temperature for 1 hour and at 40° C. for 1 hour. After cooling to −10° C., 13.26 g (100 mmol) of cyclopentanecarbonyl chloride are added dropwise, and the resulting mixture is stirred at −10° C. for 2 hours and at room temperature for 1 hour.

With ice-cooling, 50 ml of water are added dropwise and the reaction mixture is stirred at room temperature for 15 minutes. The mixture is diluted with water and dichloromethane and the resulting precipitate is filtered off with suction: 11.1 g (55%) of a colourless solid. The dichloromethane phase is dried over sodium sulphate and the solvent is removed under reduced pressure. The residue is stirred with toluene and the precipitate is filtered off with suction: 5.75 g (28%) of a colourless solid:

200 MHz ¹H-NMR (DMSO-d₆): 0.88 (t, 3H); 1.61 (m, 10H); 2.66 (m, 1H); 4.09 (hex., 1H); 7.97 (d, 1H); 12.44 (s, 1H).

Example 3A 2-(2-Ethyl)-butanoylaminopropionic acid

24.5 g (0.275 mol) of D,L-alanine are initially charge in 250 ml of dichloromethane, and 61.2 g (0.605 mol) of triethylamine are added. The mixture is cooled to 0° C. and 65.7 g (0.605 mol) of trimethylsilyl chloride are added. The mixture is stirred at room temperature for 1 hour and at 40° C. for 1 hour. The mixture is cooled to −10° C., and 37 g (0.275 mol) of 2-ethylbutyryl chloride are added dropwise. The mixture is stirred at −10° C. for 2 hours and at room temperature overnight. The mixture is cooled in an ice-bath and 150 ml of water are added dropwise. 50 g (1.25 mol) of NaOH dissolved in 100 ml of water, are added, and the aqueous phase is separated off and concentrated. The residue is again taken up in water and acidified with concentrated hydrochloric acid, the aqueous solution is extracted repeatedly with dichloromethane and the organic phase is dried over Na₂SO₄ and concentrated.

Yield: 43.55 g (84.6% of theory) 200 MHz ¹H-NMR (CDCl₃): 0.91 (t, 6H); 1.5 (d, 3H); 1.52-1.73 (m, 4H); 1.99 (m, 1H); 4.61 (p, 1H); 6.25 (d, 1H); 6.76 (bs, 1H).

Example 4A 2-(2-Ethyl)-octanoylamino-propionic acid

18.6 g (0.211 mol) of D,L-alanine and 46.6 g (0.41 mol) of triethylamine are initially charged in 300 ml of dichloromethane. at 0° C., 50.09 g (0.461 mol) of trimethylsilyl chloride are added dropwise, and the mixture is stirred at room temperature for 1 h and then at 40° C. for 1 h. The solution is cooled to −10° C., and 40 g (0.21 mol) of 2-ethyloctanoyl chloride in 50 ml of dichloromethane are added dropwise. The mixture is stirred at room temperature overnight, and 100 ml of water are then added dropwise with ice-cooling, and the mixture is stirred for another 10 minutes. The phases are separated, the aqueous phase is extracted twice with in each case 100 ml of dichloromethane and the combined organic phases are dried over sodium sulphate and evaporated under reduced pressure. The residue is recrystallized from toluene by adding n-hexane and dried at 60° C.

Yield: 3.9 g (78.2%) ¹H-NMR (CDCl₃): 0.9 (m, 6h); 1.25 (pseudo s, 8H); 1.45 (d, 3H); 1.4-1.7 (m, 4H); 2.0 (m, 1H); 4.6 (quin. 1H); 6.1 (d, 1H).

Example 5A 2-Hexanoylamino-propionic acid

The preparation is carried out analogously to the procedure of Example 4A using 16.5 g (0.185 mol) of D,L-alanine, 41.23 g (0.407 mol) of triethylamine, 44.27 g (0.407 mol) of trimethylsilyl chloride and 24.93 g (0.185 mol) of hexanoyl chloride. The product crystallizes from toluene/n-hexane.

Yield: 33 g (95.2%) ¹H-NMR (CD₃OD): 0.9 (t, 3H); 1.2-1.4 (m, 7H); 1.6 (quin, 2H); 2.2 (t, 2H); 4.35 (quin, 1H).

Example 6A 2-Octanoylamino-propionic acid

The preparation is carried out analogously to the procedure of Example 4A using 16.5 g (0.185 mol) of D,L-alanine, 41.23 g (0.407 mol) of triethylamine, 44.27 g (0.407 mol) of trimethylsilyl chloride and 30.12 g (0.185 mol) of octanoyl chloride. The product crystallizes from toluene/n-hexane.

Yield: 34.3 g (86%) ¹H-NMR (CD₃OD): 0.9 (t, 3H); 1.2-1.4 (m, 11H); 1.6 (quin. 2H); 2.2 (t, 2H); 4.35 (quin. 1H).

Example 7A 2-Heptanoylamino-propionic acid

30 g (291 mmol) of methyl D,L-alaninate hydrochloride and 64.77 g (640 mmol) of triethylamine are initially charged in 300 ml of dry methylene chloride, at 0° C. 43.24 g (291 mmol) of heptanoyl chloride in 50 ml of methylene chloride are added dropwise. The mixture is allowed to warm to room temperature and stirred at this temperature for 2 h. The precipitate is filtered off, and the methylene chloride phase is extracted with saturated sodium bicarbonate solution and with saturated sodium chloride solution and dried over sodium sulphate. The solvent is removed under reduced pressure and the residue is dissolved in 300 ml of methanol. 300 ml of water, in which 46.55 g (1164 mmol) of sodium hydroxide are dissolved, is added to this solution, and the mixture is stirred at RT for 2 h. The mixture is filtered, the methanol is removed using a rotary evaporator and the aqueous phase that remains is acidified with conc. Hcl to pH 1-2. The precipitated product is filtered off and dried. A second product fraction is obtained by extracting the aqueous phase with ethyl acetate.

Yield: 50 g (85.4%) ¹H-NMR (CD₃OD): 0.9 (t, 3H); 1.2-1.4 (m, 9H); 1.6 (quin., 2H); 2.2 (t, 2H); 4.38 (quar., 1H).

Example 8A 2-Decanoylamino-propionic acid

The preparation is carried out analogously to the procedure of Example 7A using 19.0 g (184 mmol) of methyl D,L-alaninate hydrochloride and 35.14 g (184 mmol) of decanoyl chloride.

Yield: 37.3 g (83.2%) ¹H-NMR (CD₃OD): 0.9 (t, 3H); 1.2-1.4 (m, 15H); 1.6 (m, 2H); 2.2 (t, 2H); 4.35 (quar., 1H).

Example 9A 2-(2-n-Propyl)-pentanoylamino-propionic acid

The preparation is carried out analogously to the procedure of Example 7A using 20.94 g (150 mmol) of methyl D,L-alaninate hydrochloride and 24.4 g (150 mmol) of 2-n-propylpentanoyl chloride.

Yield: 21.7 g (88.9%) ¹H-NMR (CD₃OD): 0.9 (t, 6H); 1.2-1.4 (m, 9H); 1.55 (m, 2H); 2.25 (m, 1H); 4.4 (quar., 1H).

Example 10A 2-Cycloheptanoylamino-propionic acid

The preparation is carried out analogously to the procedure of Example 7A using 20 g (143 mmol) of methyl D,L-alaninate hydrochloride and 23.02 g (143 mmol) of cycloheptanoyl chloride.

Yield: 16 g (52.4%) ¹H-NMR (CD₃OD): 1.35 (d, 3H); 1.45-1.65 (m, 8H); 1.7-1.95 (m, 4H); 2.35 (m, 1H); 4.25 (quar., 1H).

Example 11A 2-Ethoxy-benzonitrile

25 g (210 mmol) of 2-hydroxybenzonitrile, 87 g of potassium carbonate and 34.3 g (314.8 mmol) of ethyl bromide in 500 ml of acetone are refluxed overnight. The solid is filtered off, the solvent is removed under reduced pressure and the residue is distilled under reduced pressure. This gives 30.0 g (97%) of a colourless liquid.

200 MHz ¹H-NMR (DMSO-d₆): 1.48 (t, 3H); 4.15 (quart., 2H); 6.99 (dt, 2H); 7.51 (dt, 2H).

Example 12A 2-Ethoxy-benzamidine hydrochloride

21.4 g (400 mmol) of ammonium chloride are suspended in 375 ml of toluene, and the suspension is cooled to 0° C. 200 ml of a 2M solution of trimethylaluminium in hexane are added dropwise, and the mixture is stirred at room temperature until evolution of gas has ceased. 29.44 g (200 mmol) of 2-ethoxybenzonitrile are added, and the reaction mixture is then stirred at 80° C. (bath) overnight. The cooled reaction mixture is, with ice-cooling, added to a suspension of 100 g of silica gel and 950 ml of chloroform, and the mixture is stirred at room temperature for 30 minutes. The mixture is filtered off with suction and the filter residue is washed with the same amount of methanol. The mother liquor is evaporated, the resulting residue is stirred with a mixture of dichloromethane and methanol (9:1), the solid is filtered off with suction and the mother liquor is evaporated. This gives 30.4 g (76%) of a colourless solid.

200 MHz ¹H-NMR (DMSO-d₆): 1.36 (t, 3H); 4.12 (quart., 2H); 7.10 (t, 1H); 7.21 (d, 1H); 7.52 (m, 2H); 9.30 (s, broad, 4H).

Example 13A 2-Propoxybenzonitrile

75 g (630 mmol) of 2-hydroxybenzonitrile, 174 g (1.26 mol) of potassium carbonate and 232.3 g (1.89 mol) of n-propyl bromide in 11 of acetone are refluxed overnight. The solid is filtered off, the solvent is removed under reduced pressure and the residue is distilled under reduced pressure.

B.p.: 89° C. (0.7 mbar) Yield: 95.1 g (93.7% of theory)

Example 14A 2-Propoxybenzamidine hydrochloride

21.41 g (400 ml) of ammonium chloride are suspended in 400 ml of toluene and cooled to from 0 to 5° C. 200 ml of a 2M solution of triethylaluminium in hexane are added dropwise, and the mixture is stirred at room temperature until evolution of gas has ceased. 32.2 g (200 mmol) of 2-propoxybenzonitrile are added, and the reaction mixture is then stirred at 80° C. (bath) overnight. The cooled reaction mixture is, with ice-cooling, added to a suspension of 300 g of silica gel and 2.85 ml of ice-cold chloroform and stirred for 30 minutes. The mixture is filtered off with suction and the filter residue is washed with the same amount of methanol. The solvent is distilled off under reduced pressure, the residue is stirred with 500 ml of a mixture of dichloromethane and methanol (9:1), the solid is filtered off and the mother liquor is evaporated. The residue is stirred with petroleum ether and filtered off with suction. This gives 22.3 g (52%) of product.

200 MHz ¹H-NMR (CD₃OD): 1.05 (t, 3H); 1.85 (sex, 2H); 4.1 (t, 2H); 7.0-7.2 (m, 2H); 7.5-7.65 (m, 2H).

Example 15A 2-(2-Ethoxyphenyl)-5-methyl-7-cyclopentyl-3H-imidazo[5,1-f][1,2,4]-triazin-4-one

19.9 g (0.1 mol) of 2-cyclopentanoylamino-propionic acid (Example 1A), 24 ml of pyridine and 0.5 g of 4-dimethylaminopyridine are refluxed in 100 ml of absolute tetrahydrofuran, and 27.27 g (0.2 mol) of ethyl oxalyl chloride are added dropwise. The mixture is boiled at reflux for 90 minutes, cooled and put into 200 ml of ice-water. The mixture is extracted 3 times with ethyl acetate and the combined ethyl acetate phases are dried over sodium sulphate and evaporated. The residue is taken up in 30 ml of methanol and, after addition of 4.75 g of sodium bicarbonate, refluxed for 2.5 h. The mixture is filtered off and the resulting methanolic solution of the α-keto ester is directly reacted further, without further purification.

With ice-cooling, 4.99 g (0.1 mol) of hydrazine monohydrate are added dropwise to a solution of 20 g (0.1 mol) of 2-ethoxy-benzamidine hydrochloride (Example 12A) in 120 ml of ethanol, and the mixture is stirred at room temperature for 10 minutes. The methanolic solution of the α-keto ester described above is added dropwise to the suspension, and the mixture is stirred at 70° C. for 4 h. Following filtration, the solution is evaporated, the residue is partitioned between dichloromethane and water and the organic phase is, after drying over sodium sulphate, evaporated.

The residue is taken up in 150 ml of 1,2-dichloroethane, and 17 ml of phosphorus oxychloride are added dropwise. The mixture is stirred under reflux for 2 h and then cooled, washed twice with saturated sodium bicarbonate solution and dried over sodium sulphate. The organic phase is evaporated and the residue is chromatographed over silica gel using the mobile phase dichloromethane/methanol 50:1. The product-containing fractions are combined and evaporated. The product can be crystallized from ethyl acetate/petroleum ether.

Yield: 7.1 g (20.9%), white solid ¹H-NMR (CD₃OD): 1.45 (t, 3H); 1.65-1.8 (m, 2H); 1.8-2.0 (m, 4H); 2.05-2.2 (m, 2H); 2.6 (s, 3H); 3.65 (quin., 1H); 4.2 (quar, 2H); 7.1 (t, 1H); 7.15 (d, 1H); 7.5 (t, 1H); 7.7 (d, 1H).

Example 16A 2-(2-Ethoxyphenyl)-5-ethyl-7-cyclopentyl-3H-imidazo[5,1-f][1,2,4]triazin-4-one

The preparation is carried out analogously to the procedure of Example 15A using 8.77 g (44 mmol) of 2-cyclopentanoylamino-butyric acid (Example 2A) and 8.83 g (44 mmol) of 2-ethoxy-benzamidine hydrochloride (Example 12A). The product is purified by silica gel chromatography using the mobile phase cyclohexane/ethyl acetate (6:4).

Yield: 0.355 g (6.7%), white solid ¹H-NMR (CDCl₃): 1.32 (t, 3H); 1.57 (t, 3H); 1.94 (m, 8H); 3.03 (quar, 2H); 3.64 (quin, 1H); 4.27 (quar, 2H), 7.06 8d, 1H); 7.12 (t, 1H); 7.50 (t, 1H); 8.16 (dd, 1H); 9.91 (s, 1H).

Example 17A 2-(2-Propoxyphenyl)-5-methyl-7-cyclopentyl-3H-imidazo[5,1-f][1,2,4]triazin-4-one

The preparation is carried out analogously to the procedure of Example 15A using 8.33 g (45 mmol) of 2-cyclopentanoylamino-propionic acid (Example 1A) and 9.65 g (45 mmol) of 2-propoxybenzamidine hydrochloride (Example 14A). The product is purified by silica gel chromatography using the mobile phase dichloromethane/methanol (50:1). The product can be crystallized from ethyl acetate/petroleum ether.

Yield: 1.82 g (11.5%), white solid ¹H-NMR (CDCl₃): 1.15 (t, 3H); 1.7 (m, 2H); 1.95 (m, 4H); 2.15 (m, 2H); 2.65 (s, 3H); 3.65 (quin, 1H); 4.15 (t, 2H); 7.05 (d, 1H); 7.1 (t, 1H); 7.5 (td, 1H); 8.2 (dd, 1H).

Example 18A 2-(2-Ethoxyphenyl)-5-methyl-7-(2-ethylpropyl)-3H-imidazo[5,1-f][1,2,4]-triazin-4-one

The preparation is carried out analogously to the procedure of Example 15A using 21.45 g (0.1 mol) of 2-(2-ethyl)-butyrylamino-propionic acid (Example 3A) and 20.6 g (0.1 mol) of 2-ethoxybenzamidine hydrochloride (Example 12A). The product is purified by silica gel chromatography using the mobile phase dichloromethane/methanol 60:1.

Yield: 7.22 g (21.3%) 200 MHz ¹H-NMR (CDCl₃): 0.87 (t, 6H); 1.57 (t, 3H); 1.88 (m, 4H); 2.67 (s, 3H); 3.28 (m, 1 h); 4.28 (q, 2H); 7.05 (d, 1H); 7.13 (dt, 1H); 8.15 (dd, 1H).

Example 19A 2-(2-Ethoxyphenyl)-5-methyl-7-(2-ethylheptyl)-3H-imidazo[5,1-f][1,2,4]triazin-4-one

The preparation is carried out analogously to the procedure of Example 15A using 10.95 g (45 mmol) of 2-(2-ethyl)octanoylamino-propionic acid (Example 4A) and 9.03 g (45 mmol) of 2-ethoxybenzamidine hydrochloride (Example 12A). The product is purified by silica gel chromatography using the mobile phase dichloromethane/methanol 100:1.

Yield: 2.76 g (15.5%), yellow oil ¹H-NMR (CDCl₃): 0.75-0.9 (m, 6H); 1.1-1.4 (m, 8H); 1.5 (t, 3h); 1.8-2.05 (m, 4h); 2.7 (s, 3H); 3.4 (quin, 1H); 4.3 (t, 2H); 7.05-7.2 (pseudo quar 2h); 7.5 (td, 1H); 8.2 (dd, 1H); 10.4 (broad, 1H).

Example 20A 2-(2-Propoxyphenyl)-5-methyl-7-(2-ethylheptyl)-3H-imidazo[5,1-f][1,2,4]triazin-4-one

The preparation is carried out analogously to the procedure of Example 15A using 10.95 g (45 mmol of 2-(2-ethyl)-octanoylamino-propionic acid (Example 4A) and 9.66 g (45 mmol) of 2-propoxybenzamidine hydrochloride (Example 14A). The product is purified by silica gel chromatography using the mobile phase dichloro-methane/methanol 60:1.

Yield: 3.7 g (20%), yellow oil ¹H-NMR (CDCl₃): 0.75-0.9 (m, 6H); 1.15 (t, 3h); 1.1-1.35 (m, 8H); 1.75-2.1 (m, 6h); 2.7 (s, 3H); 3.4 (quin, 1H); 4.2 (t, 2H); 7.05-7.2 (pseudo quar, 2H); 7.5 (td, 1H), 8.2 (dd, 1H); 10.2 (broad, 1H).

Example 21A 2-(2-Ethoxyphenyl)-5-methyl-7-pentyl-3H-imidazo[5,1-f][1,2,4]triazin-4-one

The preparation is carried out analogously to the procedure of Example 15A using 9.36 g (50 mmol of 2-hexanoylamino-propionic acid (Example 5A) and 10.1 g (50 mmol) of 2-ethoxybenzamidine hydrochloride (Example 12A). The product is purified by silica gel chromatography using the mobile phase dichloromethane/methanol 50:1.

Yield: 3.1 g (18.3%), oil ¹H-NMR (CD₃OD): 0.9 (t, 3H); 1.3-1.4 (m, 4h); 1.45 (t, 3H); 1.8 (quin, 2H); 2.1 (s, 3H); 3.0 (t, 2H); 4.2 (quar, 2H); 7.1 (t, 1H); 7.15 (d, 1H); 7.5 (td, 1H); 7.7 (dd, 1H).

Example 22A 2-(2-Ethoxyphenyl)-5-methyl-7-heptyl-3H-imdazo-[5,1-f][1,2,4]triazin-4-one

The preparation is carried out analogously to the procedure of Example 15A using 14.7 g (68.1 mmol) of 2-octanoylamino-propionic acid (Example 6A) and 13.66 g (68.1 mmol) of 2-ethoxybenzamidine hdyrochloride (Example 12A). The product is purified by silica gel chromatography using the mobile phase dichloromethane/methanol 50:1.

Yield: 4.65 g (18.5%), oil ¹H-NMR (CD₃OD): 0.85 (t, 3H); 1.2-1.4 (m, 8H); 1.45 (t, 3H); 2.8 (quin, 2H); 2.6 (s, 3H); 3.0 (t, 2H); 4.2 (quar, 2H); 7.1 (t, 1H); 7.2 (d, 1H); 7.55 (td, 1H), 7.7 (dd, 1H).

Example 23A

The preparation is carried out analogously to the procedure of Example 15A using 14.1 g (70 mmol) of 2-heptanoylamino-propionic acid (Example 7A) and 14.05 g (70 mmol) of 2-ethoxybenzamidine hydrochloride (Example 12A). The product is purified by silica gel chromatography using the mobile phase petroleum ether/ethyl acetate 1:1.

Yield: 3.5 g (14.1%) ¹H-NMR (CD₃OD): 0.9 (t, 3H); 1.3-1.45 (m, 6H); 1.4 (t, 3H); 1.7-1.9 (m, 2H); 2.15 (s, 3H); 3.1 (t, 2H); 4.2 (quar., 2H); 7.1 (t, 1H); 7.15 (d, 1H); 7.05 (td, 1H); 7.7 (dd, 1H).

Example 24A 2-(2-Ethoxyphenyl)-5-methyl-7-n-3H-imidazo[5,1-f]-[1,2,4-]-triazin-4-one

The preparation is carried out analogously to the procedure of Example 15A using 17.0 g (70 mmol) of 2-decanoylamino-propionic acid (Example 8A) and 14.05 g (70 mmol) of 2-ethoxybenzamidine hydrochloride (Example 12A). The product is purified by silica gel chromatography using the mobile phase petroleum ether/ethyl acetate 1:1.

Yield: 3.5 g (14.1%) ¹H-NMR (CD₃OD): 0.9 (t, 3H); 1.3-1.45 (m, 6H); 1.4 (t, 3H); 1.7-1.9 (m, 2H); 2.15 (s, 3H); 3.1 (t, 2H); 4.2 (quar., 2H); 7.1 (t, 1H); 7.15 (d, 1H); 7.05 (td, 1H), 7.7 (dd, 1H).

Example 24B 2-(2-Ethoxyphenyl)-5-methyl-7-n-3H-imidazo[5,1-f][1,2,4]-triazin-4-one

The preparation is carried out analogously to the procedure of Example 15A using 17.0 g (70 mmol) of 2-decanoylamino-propionic acid (Example 8A) and 14.05 g (70 mmol) of 2-ethoxybenzamidine hydrochloride (Example 12A). The product is purified by silica gel chromatography using the mobile phase methylene chloride/methanol 50:1. The product can then be crystallized from petroleum ether.

Yield: 4.64 g (16.7%) ¹H-NMR (CD₃OD): 0.85 (t, 3H); 1.2-1.4 (m, 12H), 1.45 (t, 3H); 1.86 (quin., 2H); 2.6 (s, 3H); 3.0 (t, 2H); 4.2 (quar., 2H); 7.05 (t, 1H); 7.15 (d, 1H); 7.5 (td, 1H); 7.7 (dd, 1H).

Example 25A 2-(2-Ethoxyphenyl)-5-methyl-7-(2-n-propylbutyl)-3H-imidazo[5,1-f][1,2,4]-triazin-4-one

The preparation is carried out analogously to the procedure of Example 15A using 10.72 g (49.8 mmol) of 2-(2-n-propyl)-pentanoylamino-propionic acid (Example 9A) and 10.0 g (49.8 mmol) of 2-ethoxybenzamidine hydrochloride (Example 12A). The product is purified by silica gel chromatography using the mobile phase methylene chloride/methanol 100:1, then 50:1. The product can be recrystallized from diethyl ether.

Yield: 1.8 g (9.8%) M.p.: 150° C.

Example 26A 2-(Ethoxyphenyl)-5-methyl-7-cycloheptyl-3H-imidazo[5,1-f][1,2,4]-triazin-4-one

The preparation is carried out analogously to the procedure of Example 15A using 14.9 g (70 mmol) of 2-cycloheptanoylamino-propionic acid (Example 10A) and 14 g (70 mmol) of 2-ethoxybenzamidine hydrochloride (Example 12A). The product is purified by silica gel chromatography using the mobile phase methylene chloride/methanol 10:1, and then 50:1.

Yield: 5.35 g (20.9%) ¹H-NMR (CD₃OD): 1.45 (t, 3H); 1.6-2.0 (m, 10H); 2.1-2.2 (m, 2H); 2.7 (s, 3H); 3.65 (quin., 1H); 4.2 (quar., 2H); 7.1 (t, 1H); 7.2 (d, 1H); 7.6 (td, 1H); 7.75 (dd, 1H).

Example 27A 4-Ethoxy-3-(5-methyl-4-oxo-7-cyclopentyl-3,4-dihydro-imidazo[5,1-f][1,2,4]-triazin-2-yl)-benzenesulphonyl chloride

At 0° C., 7.0 g (20.7 mmol) of 2-(2-ethoxyphenyl)-5-methyl-7-cyclopentyl-3H-imidazo[5,1-f][1,2,4]-triazin-4-one (Example 15A) are added carefully to 24.1 g (207 mmol) of chlorosulphuric acid. The mixture is allowed to warm to room temperature and stirred overnight. The solution is carefully added to 200 ml of ice-water and extracted twice with dichloromethane. The combined organic phases are dried over sodium sulphate and the solvent is distilled off under reduced pressure. The sulphonyl chloride is dried under reduced pressure and reacted further to the sulphonamides without further purification.

Yield: 7.95 g (88%), white foam ¹H-NMR (CDCl₃): 1.6 (t, 3H); 1.7 (m, 2H); 1.95 (m, 4H); 2.15 (m, 2H); 2.65 (s, 3H); 3.71 (quin, 1H); 4.4 (quar, 2H); 7.25 (d, 1H); 8.2 (dd, 1H); 8.7 (d, 1H); 9.9 (s, 1H).

Example 28A 4-Ethoxy-3-(5-ethyl-4-oxo-7-cyclopentyl-3,4-dihydro-imidazo[5,1-f][1,2,4]-triazin-2-yl)-benzenesulphonyl chloride

The preparation is carried out analogously to the procedure of Example 27A using 0.34 g (0.96 mmol) of 2-(2-ethoxyphenyl)-5-ethyl-7-cyclopentyl-3H-imidazo-[5,1-f][1,2,4]triazin-4-one (Example 16A). This gives 0.43 g (98%) of sulphonyl chloride as a colourless foam which is directly reacted further.

Example 29A 4-Propoxy-3-(5-methyl-4-oxo-7-cyclopentyl-3,4-dihydro-imidazo[5,1-f][1,2,4]-triazin-2-yl)-benzenesulphonyl chloride

The preparation is carried out analogously to the procedure of Example 27A using 0.7 g (2 mmol) of 2-(2-propoxyphenyl)-5-methyl-7-cyclopentyl-3H-imidazo-[5,1-f][12,4]triazin-4-one (Example 17A). This gives 0.8 g (89.3%) of sulphonyl chloride as a white foam which is directly reacted further.

Example 30A 4-Ethoxy-3-(5-methyl-4-oxo-7-(2-ethylpropyl)-3,4-dihydro-imidazo[5,1-f][1,2,4]-triazin-2-yl-benzenesulphonyl chloride

The preparation is carried out analogously to the procedure of Example 27A using 7.23 g (0.12 mmol) of 2-(2-ethoxyphenyl)-5-methyl-7-(2-ethylpropyl)-3H-imidazo-[5,1-f][1,2,4]-triazin-4-one (Example 18A). This gives 8.56 g (91.9%) of sulphonyl chloride as a white solid which is directly reacted further.

Example 31A 4-Ethoxy-3-(5-methyl-4-oxo-7-(2-ethylheptyl)-3,4-dihydro-imidazo[5,1f][1,2,4]-triazin-2-yl)-benzenesulphonyl chloride

The preparation is carried out analogously to the procedure of Example 27A using 5.6 g (14.1 mmol) of 2-(2-ethoxyphenyl)-5-methyl-7-(2-ethylheptyl)-3H-imidazo-[5,1-f][1,2,4]-triazin-4-one (Example 19A). This gives 3.7 g (52.9%) of sulphonyl chloride as a slightly yellow foam which is directly reacted further.

Example 32A 4-Propoxy-3-(5-methyl-4-oxo-7-(2-ethylheptyl)-3,4-dihydro-imidazo[5,1-f][1,2,4]triazin-2-yl)-benzenesulphonyl chloride

The preparation is carried out analogously to the procedure of Example 27A using 1.4 g (3.41 mmol) of 2-(2-propoxyphenyl)-5-methyl-7-(2-ethylheptyl)-3H-imidazo-[5,1-f]-[1,2,4]-triazin-4-one (Example 20A). This gives 1.4 g (80.6%) of sulphonyl chloride as a white foam which is directly reacted further.

Example 33A 4-Ethoxy-3-(5-methyl-4-oxo-7-pentyl-3H-imidazo-[5,1f][1,2,4]triazin-2-yl)-benzenesulphonyl chloride

The preparation is carried out analogously to the procedure of Example 27A using 0.3 g (0.88 mmol) of 2-(2-ethoxyphenyl)-5-methyl-7-pentyl-3H-imidazo[5,1-f][1,2,4]triazin-4-one (Example 21A). This gives 0.3 g (77.6%) of sulphonyl chloride as a white foam which is directly reacted further.

Example 34A 4-Ethoxy-3-(5-methyl-4-oxo-7-heptyl-3H-imidazo[5,1-f][1,2,4]-triazin-2-yl)-benzenesulphonyl chloride

The preparation is carried out analogously to the procedure of Example 27A using 0.3 g (0.81 mmol) of 2-(2-ethoxyphenyl)-5-methyl-7-heptyl-3H-imidazo-[5,1-f][1,2,4]triazin-4-one (Example 22A). This gives 0.3 g (78.9%) of sulphonyl chloride as a white foam which is directly reacted further.

Example 35A 4-Ethoxy-3-(5-methyl-4-oxo-7-n-hexyl-3,4-dihydro-imidazo[5,1-f][1,2,4]-triazin-2-yl)-benzenesulphonyl chloride

The preparation is carried out analogously to the procedure of Example 27A using 300 mg (0.84 mmol) of 2-(2-ethoxyphenyl)-5-methyl-7-n-hexyl-3H-imidazo-[5,1-f][1,2,4]-triazin-4-one (Example 23A) and 0.98 g (8.4 mmol) of chlorosulphuric acid. This gives 300 mg (78.7%) of sulphonyl chloride which is directly reacted further.

Example 36A 4-Ethoxy-3-(5-methyl-4-oxo-7-n-nonyl-3,4-dihydro-imidazo[5,1-f][1,2,4]-triazin-2-yl)-benzenesulphonyl chloride

The preparation is carried out analogously to the procedure of Example 27A using 400 mg (1 mmol) of 2-(2-ethoxyphenyl)-5-methyl-7-n-nonyl-3H-imidazo-[5,1-f][1,2,4]triazin-4-one (Example 24A) and 1.18 g (10 mmol) of chlorosulphuric acid. This gives 402 mg (80.1%) of sulphonyl chloride which is directly reacted further.

Example 37A 4-Ethoxy-3-(5-methyl-4-oxo-7-(2-n-propylbutyl)-3,4-dihydro-imidazo[5,1-f][1,2,4]-triazin-2-yl-benzenesulphonyl chloride

The preparation is carried out analogously to the procedure of Example 27A using 300 mg (0.81 mmol) of 2-(2-ethoxyphenyl)-5-methyl-7-(2-n-propylbutyl)-3H-imidazo[5,1-f][1,2,4]-triazin-4-one (Example 25A) and 950 mg (8.1 mmol) of chlorosulphuric acid. This gives 300 g (78.9%) of sulphonyl chloride which is directly reacted further.

Example 38A 4-Ethoxy-(5-methyl-4-oxo-7-cycloheptyl-3,4-dihydro-imidazo[5,1-f][1,2,4]-triazin-2-yl)-benzenesulphonyl chloride

The preparation is carried out analogously to the procedure of Example 27A using 400 mg (1.1 mmol) of 2-(2-ethoxyphenyl)-5-methyl-7-cycloheptyl-3H-imidazo-[5,1-f][1,2,4]triazin-4-one (Example 26A) and 1.27 g (11 mmol) of chlorosulphuric acid. This gives 402 mg (78.6%) of sulphonyl chloride which is directly reacted further.

PREPARATION EXAMPLES Example 1 2-[2-Ethoxy-5-(4-methylpiperazine-1-sulphonyl)-phenyl]-5-methyl-7-cyclopentyl-3H-imidazo[5,1-f][1,2,4]-triazin-4-one

60 mg (0.137 mmol) of 4-ethoxy-3-(5-methyl-4-oxo-7-cyclopentyl-3,4-dihydro-[5,1-f]-[1,2,4]triazin-2-yl)-benzenesulphonyl chloride are dissolved in 10 ml of dichloromethane. 30 mg (0.343 mmol) of N-methylpiperazine are added, and the mixture is stirred at room temperature overnight. The mixture is washed twice with saturated ammonium chloride solution, dried over sodium sulphate and evaporated. The residue is purified by silica gel flash chromatography (dichloro-methane/methanol 50:1).

Yield: 52 mg (75.6%) R_(f)=0.52 (CH₂Cl₂/MeOH 10:1) ¹H-NMR (CD₃OD): 1.45 (t, 3H); 1.6-1.75 (m, 2H); 1.8-2.0 (m, 4H); 2.05-2.2 (m, 2H); 2.3 (s, 3H); 2.5-2.55 (m, 4H); 2.6 (m, 3H); 3.0 (s broad, 3H); 3.6 (quin, 1H); 4.3 (quar, 2H); 7.4 (d, 1H); 7.6 (dd, 1H); 8.0 (d, 1H).

Example 2 2-[2-Ethoxy-5-(N,N-bis-2-hydroxyethyl-sulphonyl)-phenyl]-5-methyl-7-cyclopentyl-3H-imidazo[5,1-f][1,2,4]-triazin-4-one

The preparation is carried out analogously to the procedure of Example 1 using 800 mg (1.83 mmol) of 4-ethoxy-3-(5-methyl-4-oxo-7-cyclopentyl-3,4-dihydro-[5,1-f][1,2,4]triazin-2-yl)-benzenesulphonyl chloride and 420 mg (4.03 mmol) of N,N-bis-2-hydroxyethylamine. This gives 530 mg (57.3%) of sulphonamide.

R_(f)=0.51 (CH₂Cl₂/MeOH 10:1) ¹H-NMR (CD₃OD): 1.45 (t, 3H); 1.65-1.75 (m, 2H); 1.8-1.95 (m, 4H); 2.05-2.2 (m, 2H); 2.6 (s, 3H); 3.2-3.3 (m, 4H); 3.6 (quin 1H); 3.7 (t, 4H); 4.3 (quar, 2H); 7.35 (d, H); 8.0 (dd, 1H); 8.13 (d, 1H).

Example 3 2-[2-Ethoxy-5-(3-(4-morpholino)-propyl)-sulphonyl)-phenyl]-5-methyl-7-cyclopentyl-3H-imidazo[5,1-f][1,2,4]-triazin-4-one

The preparation is carried out analogously to the procedure of Example 1 using 2.0 g (4.58 mmol) of 4-ethoxy-3-(5-methyl-4-oxo-7-cyclopentyl-3,4-dihydro[5,1-f]-[1,2,4]triazin-2-yl)-benzenesulphonyl chloride and 2.2 g (10.07 mmol) of 4-(3-aminopropyl)-morpholine. This gives 1.67 g (67%) of sulphonamide.

R_(f)=0.45 (CH₂Cl₂/MeOH 10:1) ¹H-NMR (CD₃OD): 1.45 (t, 3H); 1.55-2.2 (m, 10H); 2.3-2.45 (m, 4H); 2.6 (s, 3H); 2.9 (t, 2H); 3.55-3.7 (m, 4H); 4.3 (quar. 2H); 7.3 (d, 1H); 8.0 (dd,); 8.1 (d, 1H).

Example 4 2-[2-Ethoxy-5-(4-(2-hydroxyethyl)-piperazine-1-sulphonyl)-phenyl]-5-methyl-7-cyclopentyl-3H-imidazo[5,1-f][1,2,4]-triazin-4-one

The preparation is carried out analogously to the procedure of Example 1 using 2.0 g (4.58 mmol) of 4-ethoxy-3-(5-methyl-4-oxo-7-cyclopentyl-3,4-dihydro[5,1-f][1,2,4]-triazin-2-yl)-benzenesulphonyl chloride and 2.2 g (10.1 mmol) of N-(2-hydroxyethyl)piperazine. This gives 1.8 g (74.1%) of sulphonamide.

R_(f)=0.51 (CH₂Cl₂/MeOH 10:1) ¹H-NMR (CD₃OD): 1.45 (t, 3H); 1.6-2.2 (m, 8H); 2.5 (t, 2H); 2.55-2.65 (m, 7H); 3.0-3.1 (m, 4H); 3.6 (t, +quin. 3H); 4.3 (quar. 2H); 7.35 (d, 1H); 7.9 (dd, 1H); 8.0 (d, 1H).

Example 5 2-[2-Ethoxy-5-(4-N-ethoxycarbonylmethyl-piperazine-1-sulphonyl)-phenyl]-5-methyl-7-cyclopentyl-3H-imidazo[5,1-f][1,2,4]-triazin-4-one

The preparation is carried out analogously to the procedure of Example 1 using 100 mg (0.23 mmol) of 4-ethoxy-3-(5-methyl-4-oxo-7-cyclopentyl-3,4-dihydro-[5,1-f][1,2,4]triazin-2-yl)-benzenesulphonyl chloride and 90 mg (0.504 mmol) of N-(carboethoxymethyl)piperazine. This gives 57 mg (43.5%) of sulphonamide.

R_(f)=0.53 (CH₂Cl₂/MeOH 10:1) ¹H-NMR (CD₃OD): 1.25 (t, 3H); 1.45 (t, 3H); 1.65-2.2 (m, 8H); 2.5 (s, 3H); 2.6-2.7 (m, 4H); 3.0-3.1 (m, 4H); 3.25 (s, 2H); 3.6 (quin., 1H); 4.15 (quar, 2h); 4.3 (quar, 2H); 7.35 (d, 1H); 7.95 (dd, 1H); 8.0 (d, 1H).

Example 6 2-[2-Ethoxy-5-(4-N-carboxymethyl-piperazine-1-sulphonyl)-phenyl]-5-methyl-7-cyclopentyl-3H-imidazo[5,1-f][1,2,4]-triazin-4-one

50 mg (0.084 mmol) of the ester from Example 5 and 10 mg (0.335 mmol) of sodium hydride are stirred at room temperature in 4 ml of methanol/water 3:1 for 30 minutes. The mixture is evaporated and the residue is purified by silica gel chromatography (mobile phase: methanol/dichloromethane 10:1).

Yield: 39 mg (85.4%) R_(f)=0.671 (CH₂Cl₂/MeOH 10:1+1% AcOH) ¹H-NMR (CD₃OD): 1.45 (t, 3H); 1.65-2.2 (m, 2H); 2.1 (s, 3H); 2.15-2.25 (m, 4H); 3.05 (s, 2H); 3.05-3.15 (m, 4H); 3.6 (quin, 1H); 4.3 (quar, 2H); 7.4 (d, 1H); 7.95 (dd, 1H); 8.05 (d, 1H).

Example 7 2-[2-Ethoxy-5-(N-methyl-N-(2-dimethylaminoethyl)-sulphonamido)-phenyl]-5-methyl-7-cyclopentyl-3H-imidazo[5,1-f][1,2,4]-triazin-4-one

The preparation is carried out analogously to the procedure of Example 1 using 60 mg (0.137 mmol) of 4-ethoxy-3-(5-methyl-4-oxo-7-cyclopentyl-3,4-dihydro-[5,1-f][1,2,4]triazin-2-yl)-benzenesulphonyl chloride and 40 mg (0.343 mmol) of N-methyl-N-(2-dimethylamino-ethyl)-amine. This gives 52 mg (75.3%) of sulphonamide.

R_(f)=0.29 (CH₂Cl₂/MeOH 10:1) ¹H-NMR (CD₃OD): 1.45 (t, 3H); 1.65-2.2 (m, 8H); 2.3 (s, 6H); 2.55 (t, 2H); 2.6 (s, 3H); 2.8 (s, 3H); 3.15 (t, 2H); 3.6 (quin, 1H); 4.3 (quar, 2H); 7.4 (d, 1H); 7.95 (dd, 1H); 8.1 (d, 1H).

Example 8 2-[2-Ethoxy-5-(4-ethoxycarbonylpiperidine-1-sulphonyl)-phenyl]-5-methyl-7-cyclopentyl-3H-imidazo[5,1-f][1,2,4]-triazin-4-one

The preparation is carried out analogously to the procedure of Example 1 using 200 mg (0.458 mmol) of 4-ethoxy-3-(5-methyl-4-oxo-7-cyclopentyl-3,4-dihydro[5,1-f][1,2,4]triazin-2-yl)-benzenesulphonyl chloride and 160 mg (1 mmol) of methyl piperidine-4-carboxylate. This gives 190 mg (74.4%) of sulphonamide.

¹H-NMR (CD₃OD): 1.2 (t, 3H); 1.45 (t, 3H); 1.65-2.2 (m, 10H); 2.3 (m, 1H); 2.5-2.6 (m, 2H); 2.6 (s, 3H); 3.55-3.7 (m, 3H); 4.1 (quar, 2H); 4.3 (quar, 2H); 7.4 (d, 1H); 7.9 (dd, 1H); 8.0 (d, 1H).

Example 9 2-[2-Ethoxy-5-(4-carboxypiperidine-1-sulphonyl)-phenyl]-5-methyl-7-cyclopentyl-3H-imidazo[5,1-f][1,2,4]-triazin-4-one

180 mg (0.323 mmol) of the ester from Example 8 and 50 mg (1.29 mmol) of sodium hydroxide are stirred at room temperature in 20 ml of methanol/water 3:1 for 30 minutes. 10 ml of water are added and the mixture is extracted once with dichloromethane. The aqueous phase is acidified using 2 n HCl and extracted twice with dichloromethane. The combined dichloromethane phases are dried over sodium sulphate and evaporated. The residue is recrystallized from diethyl ether.

Yield: 120 mg (70.2%) M.p.: 170° C. (decomp.)

Example 10 2-[2-Ethoxy-5-(4-hydroxymethylpiperidine-1-sulphonyl)-phenyl]-5-methyl-7-cyclopentyl-3H-imidazo[5,1-f][1,2,4]-triazin-4-one

The preparation is carried out analogously to the procedure of Example 1 using 60 mg (0.137 mmol) of 4-ethoxy-3-(5-methyl-4-oxo-7-cyclopentyl-3,4-dihydro[5,1-f][1,2,4]triazin-2-yl)-benzenesulphonyl chloride and 30 mg (0.302 mmol) of 4-hydroxymethylpiperidine. This gives 55 mg (77.7%) of sulphonamide.

R_(f)=0.46 (toluene/acetone 1:1)

Example 11 2-[2-Ethoxy-5-(N-methyl-N-(2-(3,4-dimethoxyphenyl)ethyl)-sulphonamido)-phenyl]-5-methyl-7-cyclopentyl-3H-imidazo[5,1-f][1,2,4]-triazin-4-one

The preparation is carried out analogously to the procedure of Example 1 using 60 mg (0.137 mmol) of 4-ethoxy-3-(5-methyl-4-oxo-7-cyclopentyl-3,4-dihydro[5,1-f][1,2,4]triazin-2-yl)-benzenesulphonyl chloride and 60 mg (0.302 mmol) of N-methyl-N-(2-(3,4-dimethoxyphenyl)ethylamine. This gives 66 mg (80.9%) of sulphonamide.

R_(f)=0.64 (toluene/acetone 1:1) ¹H-NMR (CD₃OD): 1.45 (t, 3H); 1.6-2.15 (m, 8H); 2.55 (s, 3H); 2.75 (s, 3H); 2.8 (t, 2H); 3.3 (t, 2H); 3.55 (quin, 1H); 3.8 (s, 6H); 4.25 (quar, 2H); 6.7-6.85 (m, 3H); 7.3 (d, 1H); 7.9 (dd, 1H); 8.0 (d, 1H).

Example 12 2-[2-Ethoxy-5-(4-ethoxyphenyl-sulphonamido)-phenyl]-5-methyl-7-cyclopentyl-3H-imidazo[5,1-f][1,2,4]-triazin-4-one

The preparation is carried out analogously to the procedure of Example 1 using 100 mg (0.229 mmol) of 4-ethoxy-3-(5-methyl-4-oxo-7-cyclopentyl-3,4-dihydro[5,1-f][1,2,4]triazin-2-yl)-benzenesulphonyl chloride and 70 mg (0.504 mmol) of 4-ethoxy-aniline. This gives 62 mg (50.4%) of sulphonamide which is purified by recrystallization from ethyl acetate/petroleum ether.

Yield: 62 mg (50.4%) M.p.: 245° C.

Example 13 2-[2-Ethoxy-5-(3-fluoro-4-methoxyphenyl-sulphonamido)-phenyl]-5-methyl-7-cyclopentyl-3H-imidazo[5,1-f][1,2,4]-triazin-4-one

The preparation is carried out analogously to the procedure of Example 1 using 100 mg (0.229 mmol) of 4-ethoxy-3-(5-methyl-4-oxo-7-cyclopentyl-3,4-dihydro[5,1-f][1,2,4]triazin-2-yl)-benzenesulphonyl chloride and 70 mg (0.5 mmol) of 3-fluoro-4-methoxyaniline. This gives 73 mg (58.9%) of sulphonamide which is purified by recrystallization from diethyl ether.

Yield: 73 mg (58.9%) M.p.: 180° C. (decomp.)

Example 14 2-[2-Ethoxy-5-(2-methoxyethyl-sulphonamido)-phenyl]-5-methyl-7-cyclopentyl-3H-imidazo[5,1-f][1,2,4]-triazin-4-one

The preparation is carried out analogously to the procedure of Example 1 using 100 mg (0.229 mmol) of 4-ethoxy-3-(5-methyl-4-oxo-7-cyclopentyl-3,4-dihydro[5,1-f][1,2,4]triazin-2-yl)-benzenesulphonyl chloride and 37.5 mg (0.05 mmol) of 2-methoxy-ethylamine. This gives 80 mg (73.2%) of sulphonamide.

R_(f)=0.47 (toluene/acetone 4:1) ¹H-NMR (CD₃OD): 1.45 (t, 3H); 1.65-2.2 (m, 8H); 2.6 (s, 3H); 3.05 (t, 2H); 3.25 (s, 3H); 3.4 (t, 2H); 3.65 (quin, 1H); 4.3 (quin, 2H); 7.3 (d, 1H); 8.0 (dd, 1H); 8.1 (d, 1H).

Example 15 2-[2-Ethoxy-5-(N-(4-morpholinyl)-sulphonamido)-phenyl]-5-methyl-7-cyclopentyl-3H-imidazo[5,1-f][1,2,4]-triazin-4-one

The preparation is carried out analogously to the procedure of Example 1 using 100 mg (0.229 mmol) of 4-ethoxy-3-(5-methyl-4-oxo-7-cyclopentyl-3,4-dihydro[5,1-f][1,2,4]triazin-2-yl)-benzenesulphonyl chloride and 50 mg (0.5 mmol) of 4-aminomorpholine. This gives 108 mg (93.9%) of sulphonamide.

R_(f)=0.24 (toluene/acetone 4:1) ¹H-NMR (CD₃OD): 1.45 (t, 3H); 1.65-2.2 (m, 8H); 2.6 (s, 3H); 2.9-3,0 (m, 4H); 3.65 (quin, 1H); 3.65-3.75 (m, 4H); 4.3 (quar, 2H); 7.4 (d, 1H); 7.95 (dd, 1H); 8.05 (d, 1H).

Example 16 2-[2-Ethoxy-5-(4-methoxybenzyl-sulphonamido)-phenyl]-5-methyl-7-cyclopentyl-3H-imidazo[5,1-f][1,2,4]-triazin-4-one

The preparation is carried out analogously to the procedure of Example 1 using 400 mg (0.915 mmol) of 4-ethoxy-3-(5-methyl-4-oxo-7-cyclopentyl-3,4-dihydro[5,1-f][1,2,4]triazin-2-yl)-benzenesulphonyl chloride and 310 mg (2.29 mmol) of 4-methoxybenzylamine. This gives 260 mg (52.8%) of sulphonamide.

R_(f)=0.25 (toluene/acetone 4:1) ¹H-NMR (CD₃OD): 1.45 (t, 3H); 1.65-1.75 (m, 2H); 1.8-1.95 (m, 4H); 2.1-2.2 (m, 2H); 2.55 (s, 3H); 3.63 (quin, 1H); 3.67 (s, 3H); 4.05 (s, 2H); 4.25 (quar, 2H); 6.75 (d, 2H); 7.1 (d, 2H); 7.25 (d, 1H); 7.9 (dd, 1H); 7.95 (d, 1H).

Example 17 2-[2-Ethoxy-5-(3-ethoxypropyl-sulphonamido)-phenyl]-5-methyl-7-cyclopentyl-3H-imidazo[5,1-f][1,2,4]-triazin-4-one

The preparation is carried out analogously to the procedure of Example 1 using 300 mg (0.687 mmol) of 4-ethoxy-3-(5-methyl-4-oxo-7-cyclopentyl-3,4-dihydro[5,1-f][1,2,4]triazin-2-yl)-benzenesulphonyl chloride and 180 mg (1.717 mmol) of 3-ethoxy-propylamine. This gives 230 mg (66.5%) of sulphonamide.

R_(f)=0.19 (toluene/acetone) ¹H-NMR (CD₃OD): 1.1 (t, 3H); 1.45 (t, 3H); 1.65-2.2 (m 10H); 2.6 (s, 3H; 2.95 (t, 2H); 3.35-3.5 (m, 4H); 3.65 (quin, 1H); 4.25 (quar, 2H); 7.3 (d, 1H); 7.95 (dd, 1H); 8.1 (d, 1H).

Example 18 2-[2-Ethoxy-5-(3,4-dimethoxyphenyl-sulphonamido)-phenyl]-5-methyl-7-cyclopentyl-3H-imidazo[5,1-f][1,2,4]-triazin-4-one

The preparation is carried out analogously to the procedure of Example 1 using 100 mg (0.229 mmol) of 4-ethoxy-3-(5-methyl-4-oxo-7-cyclopentyl-3,4-dihydro[5,1-f][1,2,4]triazin-2-yl)-benzenesulphonyl chloride and 80 mg (0.5 mmol) of 3,4-dimethoxyaniline. This gives 70 mg (55.2%) of sulphonamide.

R_(f)=0.17 (toluene/acetone 4:1) ¹H-NMR (CD₃OD): 1.45 (t, 3H); 1.75-1.95 (m, 6H); 2.15-2.3 (m, 2H), 2.7 (s, 3H); 3.65-3.8 (m, 7H); 4.2 (quar, 2H); 6.55 (dd, 1H); 6.7-6.8 (m, 2H); 7.3 (d, 1H); 7.9-8.0 (m, 2H).

Example 19 2-[2-Ethoxy-5-(2,3,4-trimethoxyphenyl-sulphonamido)-phenyl]-5-methyl-7-cyclopentyl-3H-imidazo[5,1-f][1,2,4]-triazin-4-one

The preparation is carried out analogously to the procedure of Example 1 using 100 mg (0.229 mmol) of 4-ethoxy-3-(5-methyl-4-oxo-7-cyclopentyl-3,4-dihydro[5,1-f][1,2,4]triazin-2-yl)-benzenesulphonyl chloride and 90 mg (0.5 mmol) of 2,3,4-trimethoxyaniline. This gives 61 mg (45.7%) of sulphonamide.

R_(f)=0.25 (toluene/acetone 4:1) ¹H-NMR (CD₃OD): 1.4 (t, 3H); 1.65-1.95 (m, 6H); 2.05-2.2 (m, 2H); 2.55 (s, 3H); 3.5 (s, 3H); 36 (quin, 1H); 3.7 (s, 3H); 3.8 (s, 3H); 4.2 (quar, 2H); 6.7 (d, 1H); 7.15 (d, 1H); 7.2 (d, 1H); 7.8 (dd, 1H); 8.0 (d, 1H).

Example 20 2-[2-Ethoxy-5-(3-picolyl-sulphonamido)-phenyl]-5-methyl-7-cyclopentyl-3H-imidazo[5,1-f][1,2,4]-triazin-4-one

The preparation is carried out analogously to the procedure of Example 1 using 100 mg (0.229 mmol) of 4-ethoxy-3-(5-methyl-4-oxo-7-cyclopentyl-3,4-dihydro[5,1-f][1,2,4]triazin-2-yl)-benzenesulphonyl chloride and 50 mg (0.5 mmol) of 3-picolylamine. This gives 50 mg (43%) of sulphonamide which is purified by recrystallization from ethyl acetate/diethyl ether.

M.p.: 128-130° C. (decomp.)

Example 21 2-[2-Ethoxy-5-(2-(2,6-dichlorophenyl)ethyl-sulphonamido)-phenyl]-5-methyl-7-cyclopentyl-3H-imidazo[5,1-f][1,2,4]-triazin-4-one

The preparation is carried out analogously to the procedure of Example 1 using 400 mg (0.915 mmol) of 4-ethoxy-3-(5-methyl-4-oxo-7-cyclopentyl-3,4-dihydro[5,1-f][1,2,4]triazin-2-yl)-benzenesulphonyl chloride and 440 mg (2.29 mmol) of 2-(2,6-dichlorophenyl)ethylamine. This gives 380 mg (70.3%) of sulphonamide which is purified by recrystallization from ethyl acetate/diethyl ether.

M.p.: 202° C.

Example 22 2-[2-Ethoxy-5-(N-ethyl-N-(2-hydroxyethyl)-sulphonamido)-phenyl]-5-methyl-7-cyclopentyl-3H-imidazo[5,1-f][1,2,4]-triazin-4-one

The preparation is carried out analogously to the procedure of Example 1 using 100 mg (0.229 mmol) of 4-ethoxy-3-(5-methyl-4-oxo-7-cyclopentyl-3,4-dihydro[5,1-f][1,2,4]triazin-2-yl)-benzenesulphonyl chloride and 50 mg (0.57 mmol) of N-ethyl-N-(2-hydroxyethyl)amine. This gives 57 mg (50.9%) of sulphonamide which is recrystallization from ethyl acetate/diethyl ether.

M.p.: 193° C.

Example 23 2-[2-Ethoxy-5-(2-(4-sulphonamidophenyl)-ethyl-sulphonamido)-phenyl]-5-methyl-7-cyclopentyl-3H-imidazo[5,1-f][1,2,4]-triazin-4-one

The preparation is carried out analogously to the procedure of Example 1 using 100 mg (0.229 mmol) of 4-ethoxy-3-(5-methyl-4-oxo-7-cyclopentyl-3,4-dihydro[5,1-f][1,2,4]triazin-2-yl)-benzenesulphonyl chloride and 110 mg (0.572 mmol) of 2-(4-sulphonamidophenyl)-ethylamine. This gives 67 mg (48.7%) of sulphonamide which is purified by recrystallization from ethyl acetate/diethyl ether.

M.p.: 141-143° C. (decomp.)

Example 24 2-[2-Ethoxy-5-(7-quinolinyl-sulphonamido)-phenyl]-5-methyl-7-cyclopentyl-3H-imidazo[5,1-f][1,2,4]-triazin-4-one

The preparation is carried out analogously to the procedure of Example 1 using 400 mg (0.915 mmol) of 4-ethoxy-3-(5-methyl-4-oxo-7-cyclopentyl-3,4-dihydro[5,1-f][1,2,4]triazin-2-yl)-benzenesulphonyl chloride and 290.4 mg (2.014 mmol) of 7-aminoquinoline. This gives 264 mg (52.9%) of sulphonamide which is purified by recrystallization from ethyl acetate.

M.p.: 184° C.

Example 25 2-[2-Ethoxy-5-(1-(4-diethoxyphosphonylmethyl-piperidinyl)-sulphonyl)-phenyl]-5-methyl-7-cyclopentyl-3H-imidazo[5,1-f][1,2,4]-triazin-4-one

The preparation is carried out analogously to the procedure of Example 1 using 100 mg (0.229 mmol) of 4-ethoxy-3-(5-methyl-4-oxo-7-cyclopentyl-3,4-dihydro[5,1-f][1,2,4]triazin-2-yl)-benzenesulphonyl chloride and 120 mg (0.5 mmol) of 4-dimethoxyphosphonyl-methyl-piperidine. This gives 62 mg (42.6%) of sulphonamide.

¹H-NMR (CD₃OD): 1.25 (t, 6H); 1.45 (t, 3H); 1.5-2.2 (m, 15H); 2.3 (t, 2H); 2.6 (s, 3H); 3.5-3.8 (m, 3H); 4.05 (m, 4H); 4.8 (quar, 2H); 7.35 (d, 1H); 7.9 (dd, 1H); 8.0 (d, 1H).

Example 26 2-[2-Ethoxy-5-(1-(4-dimethoxyphosphonylmethyl-piperazinyl-sulphonyl)-phenyl]-5-methyl-7-cyclopentyl-3H-imidazo[5,1-f][1,2,4]-triazin-4-one

The preparation is carried out analogously to the procedure of Example 1 using 100 mg (0.229 mmol) of 4-ethoxy-3-(5-methyl-4-oxo-7-cyclopentyl-3,4-dihydro[5,1-f][1,2,4]triazin-2-yl)-benzenesulphonyl chloride and 100 mg (0.5 mmol) of (4-dimethoxyphosphonylmethyl)-piperazine. This gives 53 mg (38%) of sulphonamide.

R_(f)=0.57 (dichloromethane/methanol 10:1) ¹H-NMR (CD₃OD): 1.45 (t, 3H); 1.65-2.0 (m, 6H); 2.05-2.2 (m, 2H); 2.55 (s, 3H); 2.65-2.75 (m, 4H); 2.9 (d, 3H); 3.0-3.1 (m, 4H); 3.6 (quin, 1H); 3.7 (s, 3H); 3.75 (s, 6H); 4.3 (quar, 2H); 7.35 (d, 1H); 7.9 (dd, 1H); 8.0 (d, 1H).

Example 27 2-[2-Ethoxy-5-(methylpiperazine-1-sulphonyl)-phenyl]-5-methyl-7-cyclopentyl-3H-imidazo[5,1-f][1,2,4]-triazin-4-one hydrochloride

220 mg (0.42 mmol) of 2-[2-ethoxy-5-(4-methylpiperazine-1-sulphonyl)-phenyl]-5-methyl-7-cyclopentyl-3H-imidazo[5,-f][1,2,4]-triazin-4-one (Example 1) are suspended in 20 ml of diethyl ether and, after addition of 20 mg (0.462 mmol) of 1 molar ethereal HCl solution, stirred at room temperature for 30 minutes. The solvent is distilled off under reduced pressure and the residue is dried under high vacuum.

Yield: 236 mg (99%)

Example 28 2-[2-Ethoxy-5-(4-methylpiperazine-1-sulphonyl)-phenyl]-5-ethyl-7-cyclopentyl-3H-imidazo[5,1-f][1,2,4]triazin-4-one

0.42 g (0.92 mmol) of 3-(7-cyclopentyl-5-ethyl-4-oxo-3,4-dihydroimidazo-[5,1-f][1,2,4]triazin-2-yl)-4-ethoxybenzenesulphonyl chloride are dissolved in 15 ml of dichloromethane and cooled to 0° C. After addition of a spatula tip of 4-dimethylaminopyridine, 0.28 g (2.76 mmol) of N-methylpiperazine are added, and the reaction mixture is stirred at room temperature overnight. The mixture is diluted with dichloromethane, the organic phase is washed with ammonium chloride solution and dried over sodium sulphate and the solvent is removed under reduced pressure. Crystallization from ether gives 0.395 g (80%) of a colourless solid.

200 MHz ¹H-NMR (DMSO-d₆): 1.21 (t, 3H); 1.32 (t, 3H); 1.79 (m, 8H); 2.13 (s, 3H); 2.48 (s, 4H); 2.86 (m, 6H); 4.21 (quart., 2H); 7.48 (m, 1H); 7.85 (m, 2H); 11.70 (s, 1H).

Example 29 2-[2-Ethoxy-5-N-ethyl-N-(2-hydroxyethyl)-amino-1-sulphonyl)-phenyl]-5-ethyl-7-cyclopentyl-3H-imidazo[5,1-f][1,2,4]triazin-4-one

In an analogous manner, starting from 1.35 g (3 mmol) of 3-(7-cyclopentyl-5-ethyl-4-oxo-3,4-dihydroimidazo[5,1-f][1,2,4]triazin-2-yl)-4-ethoxybenzene-sulphonyl chloride and 800 mg (9 mmol) of N-ethyl-N-(2-hydroxyethyl)-amine, 1.07 g (71%) of 2-[2-ethoxy-5-N-ethyl-N-(2-hydroxyethyl)-amino-1-sulphonyl)-phenyl]-5-ethyl-7-cyclopentyl-3H-imidazo[5,1-f][1,2,4]triazin-4-one are obtained.

R_(f)=0.31 (dichloromethane/methanol=19:1) 200 MHz ¹H-NMR (CDCl₃): 1.20 (t, 3H); 1.32 (t, 3H); 1.61 (t, 3H); 1.95 (m, 9H); 2.41 (m, 1H); 3.02 (quart., 2H); 3.35 (m, 4H); 3.65 (m, 1H); 3.80 (m, 2H); 4.33 (quart., 2H); 7.15 (d, 1H); 7.95 (dd, 1H); 8.50 (d, 1H); 9.81 (s, 1H).

Example 30 2-[2-Ethoxy-5-(4-(2-hydroxyethyl)-piperazine)-1-sulphonyl)-phenyl]-5-ethyl-7-cyclopentyl-3H-imidazo[5,1-f][1,2,4]triazin-4-one

In an analogous manner, starting from 1.35 g (3 mmol) of 3-(7-cyclopentyl-5-ethyl-4-oxo-3,4-dihydroimidazo[5,1-f][1,2,4]triazin-2-yl)-4-ethoxybenzenesulphonyl chloride and 1.17 g (9 mmol) of 4-(2-hydroxyethyl)-piperazine, 1.21 g (74%) of 2-[2-ethoxy-5-(4-(2-hydroxyethyl)-piperazine)-1-sulphonyl)-phenyl]-5-ethyl-7-cyclopentyl-3H-imidazo[5,1-f][1,2,4]triazin-4-one are obtained.

R_(f)=0.21 (dichloromethane/methanol=19:1) 200 MHz ¹H-NMR (CDCl₃): 1.31 (t, 3H); 1.60 (t, 3H); 1.96 (m, 9H); 2.58 (m, 7H); 3.02 (quart., 2H); 3.10 (m, 4H); 3.61 (m, 3H); 4.35 (quart., 2H); 7.19 (d, 1H); 7.89 (dd, 1H); 8.45 (d, 1H); 9.75 (s, 1H).

Example 31 2-[2-Ethoxy-5-(3-(4-morpholino)-propyl)-sulphonamido)-phenyl]-5-ethyl-3H-7-cyclopentyl-imidazo[5,1-j][1,2,4]triazin-4-one

In an analogous manner, starting from 1.35 g (3 mmol) of 3-(7-cyclopentyl-5-ethyl-4-oxo-3,4-dihydroimidazo[5,1-f][1,2,4]triazin-2-yl)-4-ethoxybenzenesulphonyl chloride and 1.30 g (9 mmol) of 4-(3-aminopropyl)-morpholine, 1.44 g (86%) of 2-[2-ethoxy-5-(3-(1-morpholino)-propyl)-sulphonamido)-phenyl]-5-ethyl-7-cyclopentyl-3H-imidazo[5,1-f][1,2,4]triazin-4-one are obtained.

R_(f)=0.29 (dichloromethane/methanol=19:1) 200 MHz ¹H-NMR (CDCl,): 1.31 (t, 3H); 1.60 (t, 3H); 2.02 (m, 12H); 2.46 (m, 8H); 3.02 (quart., 2H); 3.13 (t, 2H); 3.62 (m, 5H); 4.35 (quart., 2H); 7.15 (d, 1H); 7.89 (dd, 1H); 8.55 (d, 1H); 9.82 (s).

Example 32 2-[2-Propoxy-5-(4-hydroxypiperidine-1-sulphonyl)-phenyl]-5-methyl-7-cyclopentyl-3H-imidazo[5,1-f][1,2,4]-triazin-4-one

The preparation is carried out analogously to the procedure of Example 1 using 50 mg (0.111 mmol) of 4-propoxy-3-(5-methyl-4-oxo-7-cyclopentyl-3,4-dihydro[5,1-f][1,2,4]triazin-2-yl)-benzenesulphonyl chloride and 28 mg (0.227 mmol) of 4-hydroxypiperidine. This gives 46 mg (80.5%) of sulphonamide.

R_(f)=0.53 (CH₂Cl₂/MeOH 10:1) ¹H-NMR (CD₃OD): 1.05 (t, 3H);1.5-1.6 (m, 2H); 1.65-1.75 (m, 2H); 1.8-2.0 (m, 8H); 1.05-2.2 (m, 2H); 2.6 (s, 3H); 2.8-2.9 (m, 2H); 3.3-3.4 (m, 2H); 3.6-3.7 (m, 2H); 4.15 (t, 2H); 7.35 (d, 1H); 7.9 (dd, 1H); 8.0 (d, 1H).

Example 33 2-[2-Propoxy-5-(4-(2-hydroxyethyl)-piperazine-1-sulphonyl)-phenyl]-5-methyl-7-cyclopentyl-3H-imidazo[5,1-f][1,2,4]-triazin-4-one

The preparation is carried out analogously to the procedure of Example 1 using 50 mg (0.1111 mmol) of 4-propoxy-3-(5-methyl-4-oxo-7-cyclopentyl-3,4-dihydro-[5,1-f][1,2,4]triazin-2-yl)-benzenesulphonyl chloride and 32.4 mg (0.249 mmol) of N-(2-hydroxyethyl)-piperazine. This gives 40 mg (73.6%) of sulphonamide which is purified by recrystallization from ethyl acetate/diethyl ether.

M.p.: 210° C.

Example 34 2-[2-Propoxy-5-(4-methylpiperazine-1-sulphonyl)-phenyl]-5-methyl-7-cyclopentyl-3H-imidazo[5,1-f][1,2,4]-triazin-4-one

The preparation is carried out analogously to the procedure of Example 1 using 50 mg (0.111 mmol) of 4-propoxy-3-(5-methyl-4-oxo-7-cyclopentyl-3,4-dihydro[5,1-f][1,2,4]triazin-2-yl)-benzenesulphonyl chloride and 24.9 mg (0.249 mmol) of N-methylpiperazine. This gives 49 mg (95.4%) of sulphonamide.

R_(f)=0.49 (CH₂Cl₂/MeOH 10:1) ¹H-NMR (CD₃OD): 1.05 (t, 3H); 1.65-2.2 (m, 2H); 2.3 (s, 3H); 2.45-2.55 (m, 4H); 2.6 (s, 3H); 3.0-3.1 (m, 4H); 3.6 (quin, 1H); 4.2 (t, 2H); 7.4 (d, 1H); 7.95 (dd, 1H); 8.0 (d, 1H).

Example 35 2-[2-Propoxy-5-(3-(4-morpholino)-propyl-sulphonamido)-phenyl]-5-methyl-7-cyclopentyl-3H-imidazo[5,1-f][1,2,4]-triazin-4-one

The preparation is carried out analogously to the procedure of Example 1 using 50 mg (0.111 mmol) of 4-propoxy-3-(5-methyl-4-oxo-7-cyclopentyl-3,4-dihydro[5,1-f][1,2,4]triazin-2-yl)-benzenesulphonyl chloride and 36.7 mg (0.255 mmol) of 3-(4-morpholino)-propylamine. This gives 16 mg (28.1%) of sulphonamide.

R_(f)=0.41 (CH₂Cl₂/MeOH 10:1) ¹H-NMR (CD₃OD): 1.05 (t, 3H); 1.6-2.2 (m, 12H); 2.3-2.45 (m, 6H); 2.6 (s, 3H); 2.95 (t, 2H); 3.6-3.7 (m, 5H); 4.15 (t, 2H); 7.35 (d, 1H); 8.0 (d, 1H); 8.1 (d, 1H).

Example 36 2-[2-Propoxy-5-(4-hydroxymethylpiperidine-1-sulphonyl)-phenyl]-5-methyl-7-cyclopentyl-3H-imidazo[5,1-f][1,2,4]-triazin-4-one

The preparation is carried out analogously to the procedure of Example 1 using 50 mg (0.111 mmol) of 4-propoxy-3-(5-methyl-4-oxo-7-cyclopentyl-3,4-dihydro[5,1-f][1,2,4]triazin-2-yl)-benzenesulphonyl chloride and 29.3 mg (0.255 mmol) of 4-hydroxymethylpiperidine. This gives 46 mg (85.1%) of sulphonamide.

R_(f)=0.46 (CH₂Cl₂/MeOH 10:1) ¹H-NMR (CD₃OD): 1.05 (t, 3H); 1.65-2.0 (m, 13H); 2.05-2.15 (m, 2H); 2.3 (t, 2H); 2.6 (s, 3H); 3.4 (d, 2H); 3.65 (m, 1H); 3.8 (d, 2H); 4.2 (t, 2H); 7.4 (d, 1H); 7.9 (dd, 1H); 8.0 (d, 1H).

Example 37 2-[2-Propoxy-5-(N,N-bis-2-hydroxyethyl-sulphonamide)-phenyl]-5-methyl-7-cyclopentyl-3H-imidazo[5,1-f][1,2,4]-triazin-4-one

The preparation is carried out analogously to the procedure of Example 1 using 50 mg (0.111 mmol) of 4-propoxy-3-(5-methyl-4-oxo-7-cyclopentyl-3,4-dihydro[5,1-f][1,2,4]triazin-2-yl)-benzenesulphonyl chloride and 26.8 mg (0.255 mmol) of diethanolamine. This gives 30 mg (56.6%) of sulphonamide.

R_(f)=0.43 (CH₂Cl₂/MeOH 10:1) ¹H-NMR (CD₃OD): 1.05 (t, 3H); 1.65-2.2 (m, 10H); 2.6 (s, 3H); 3.3 (m, 4H); 3.65 (quin, 1H); 3.7 (t, 4H); 4.2 (t, 2H); 7.35 (d, 1H); 8.0 (dd, 1H); 8.1 (d, 1H).

Example 38 2-[2-Propoxy-5-(N-methyl-N-(2-dimethylaminoethyl)-sulphonamido)-phenyl]-5-methyl-7-cyclopentyl-3H-imidazo[5,1-f][1,2,4]-triazin-4-one

The preparation is carried out analogously to the procedure of Example 1 using 50 mg (0.111 mmol) of 4-propoxy-3-(5-methyl-4-oxo-7-cyclopentyl-3,4-dihydro-[5,1-f][1,2,4]triazin-2-yl)-benzenesulphonyl chloride and 26 mg (0.255 mmol) of N-methyl-N-(2-dimethylaminoethyl)-amine. This gives 26 mg (49.3%) of sulphonamide.

R_(f)=0.3 (CH₂Cl₂/MeOH 10:1) ¹H-NMR (CD₃OD): 1.05 (t, 3H);, 165-2.2 (m, 10H); 2.3 (s, 6H); 2.55 (t, 2H); 2.6 (s, 3H); 2.8 (s, 3h); 3.15 (t, 2H); 3.65 (quin., 1H); 4.2 (t, 2H); 7.4 (d, 1H); 7.95 (dd, 1H); 8.05 (d, 1H).

Example 39 2-[2-Propoxy-5-(4-ethoxycarbonylpiperidine-1-sulphonyl)-phenyl]-5-methyl-7-cyclopentyl-3H-imidazo[5,1-f][1,2,4]-triazin-4-one

The preparation is carried out analogously to the procedure of Example 1 using 50 mg (0.111 mmol) of 4-propoxy-3-(5-methyl-4-oxo-7-cyclopentyl-3,4-dihydro-[5,1-f][1,2,4]triazin-2-yl)-benzenesulphonyl chloride and 48.7 mg (0.31 mmol) of ethyl 4-piperidinecarboxylate. This gives 80 mg (90.1%) of sulphonamide.

¹H-NMR (CD₃OD): 1.05 (t, 2H); 1.2 (t, 2H); 1.65-2.0 (m, 12H); 2.15-2.35 (m, 3H); 2.6 (td, 2H); 2.7 (s, 3H); 3.5-3.6 (, 2H); 3.75 (quin., 1H); 4.1 (quar., 2H); 4.2 (quar., 2H); 7.4 (d, 1H); 7.95 dd, 1H); 8.05 (d, 1H).

Example 40 2-[2-Propoxy-5-(4-carboxypiperidine-1-sulphonyl)-phenyl]-5-methyl-7-cyclopentyl-3H-imidazo[5,1-f][1,2,4]-triazin-4-one

80 mg (0.14 mmol) of the ester from Example 39 are stirred at room temperature in a mixture of 5 ml of methanol and 1 ml of 4 n NaOH for 30 minutes. 10 ml of dichloromethane are added, the mixture is extracted with 10 ml of 2 n HCl solution and the organic phase is separated off, dried over sodium sulphate and evaporated. The residue is recrystallized from diethyl ether.

Yield: 50 mg (65.7%) R_(f)=0.47 (CH₂Cl₂/MeOH 10:1) ¹H-NMR (CD₃OD): 1.05 (t, 3H); 1.65-2.0 (m, 12H); 2.2-2.35 (m, 3h); 2.6 (td, 2H); 2.7 (s, 3H); 3.55-3.6 (m, 2H); 3.75 (quin., 1H); 4.2 (t, 2H); 7.4 (d, 1H); 7.95 (dd, 1H); 8.05 (d, 1H).

Example 41 2-[2-Ethoxy-5-(4-methylpiperazine-1-sulphonyl)-phenyl]-7-(1-ethylpropyl)-5-methyl-3H-imidazo[5,1-f][1,2,4]triazin-4-one

50 mg (0.114 mmol) of 4-ethoxy-3-(5-methyl-4-oxo-7-(1-ethylpropyl)-3,4-dihydro-imidazo[5,1-f][1,2,4]triazin-2-yl)-benzenesulphonyl chloride are initially charged in 5 ml of dichloromethane and a spatula tip of 4 dimethylaminopyridine is added, followed by 30 mg (0.342 mmol) of N-methylpiperazine. The mixture is stirred at room temperature overnight, diluted with dichloromethane, washed twice with saturated ammonium chloride solution, dried over sodium sulphate, concentrated and filtered through silica gel (methanol).

Yield: 45 mg (78.6% of theory) 200 MHz ¹H-NMR (CDCl₃): 0.85 (t, 6H); 1.63 (t, 3H); 1.85 (m, 4H); 2.39 (s, 3H); 2.65 (m, 7H); 3.17 (m, 5H); 4.35 (q, 2H); 7.18 (d, 1H); 7.88 (dd, 1H); 8.49 (d, 1H); 9.64 (bs, 1H).

Example 42 2-[2-Ethoxy-5-(4-(2-hydroxyethyl)-piperazine-1-sulphonyl)-phenyl]-7-(1-ethylpropyl)-5-methyl-3H-imidazo[5,1-f][1,2,4]triazin-4-one

Analogously, using 100 mg (0.221 mmol) of 4-ethoxy-3-(5-methyl-4-oxo-7-(1-ethylpropyl)-3,4-dihydroimidazo[5,1-f][1,2,4]triazin-2-yl)-benzenesulphonyl chloride and 90 mg (0.662 mmol) of N-(2-hydroxyethyl)-piperazine, 99 mg (84.2% of theory) of 2-[2-ethoxy-5-(4-(2-hydroxyethyl)-piperazine-1-sulphonyl)-phenyl]-7-(1-ethylpropyl)-5-methyl-3H-imidazo[5,1-f]-[1,2,4]triazin-4-one are obtained.

200 MHz ¹H-NMR (CDCl₃): 0.87 (t, 6H); 1.62 (t, 3H); 1.84 (m, 4H); 2.56-2.74 (m, 9H); 3.08-3.32 (m, 5H); 3.63 (t, 2H); 4.37 (q, 2H); 7.18 (d, 1H); 7.9 (dd, 1H); 8.5 (d, 1H); 9.67 (bs, 1H).

Example 43 2-[2-Ethoxy-5-(4-(2,2,2-trifluoroethyl)-piperazine-1-sulphonyl)-phenyl]-7-(1-ethylpropyl)-5-methyl-3H-imidazo[5,1-f][1,2,4]triazin-4-one

Analogously, using 100 mg (0.228 mmol) of 4-ethoxy-3-(5-methyl-4-oxo-7-(1-ethylpropyl)-3,4-dihydroimidazo[5,1-f][1,2,4]triazin-2-yl)-benzenesulphonyl chloride and 120 mg (0.69 mmol) of (2,2,2-trifluoroethyl)-piperazine, 72 mg (18.2% of theory) of 2-[2-ethoxy-5-(4-(2,2,2-trifluoroethyl)-piperazine-1-sulphonyl)-phenyl]-7-(1-ethylpropyl)-5-methyl-3H-imidazo-[5,1-f][1,2,4]triazin-4-one are obtained.

200 MHz ¹H-NMR (CDCl₃): 0.87 (t, 6H); 1.63 (t, 3H); 1.89 (m, 4H); 2.71 (s, 3H); 2.8 (m, 4H); 2.97 (q, 2H); 3.1 (m, 4H); 3.25 (m, 1H); 4.38 (q, 2H); 7.19 (s, 1H); 7.89 (dd, 1H); 8.49 (d, 1H); 9.71 (bs, 1H).

Example 44 2-[2-Ethoxy-5-(1-(4-diethoxyphosphonylmethylpiperidinyl)-sulphonyl)-phenyl]-7-(1-ethylpropyl)-5-methyl-3H-imid-azo[5,1-f]-[1,2,4]-triazin-4-one

Analogously, using 100 mg (0.228 mmol) of 4-ethoxy-3-(5-methyl-4-oxo-7-(1-ethylpropyl)-3,4-dihydroimidazo[5,1-f][1,2,4]triazin-2-yl)-benzenesulphonyl chloride and 161 mg (0.683 mmol) of 4-diethoxyphosphonylmethyl-piperidine, 96.2 mg (66.2% of theory) of 2-[2-ethoxy-5-(1-(4-diethoxyphosphonylmethyl-piperidine)-sulphonyl)-phenyl]-7-(1-ethylpropyl)-5-methyl-3H-imidazo[5,1-f][1,2,4]-triazin-4-one are obtained.

200 MHz ¹H-NMR (CDCl₃): 0.86 (t, 6H); 1.3 (t, 6H); 1.38-2.02 (m, 14H); 2.35 (dt, 2H); 2.68 (s, 3H); 3.23 (m, 1H); 3.8 (d, 2H); 4.08 (m, 4H); 4.36 (q, 2H); 7.17 (d, 1H); 7.88 (dd, 1H); 8.49 (d, 1H); 9.7 (bs, 1H).

Example 45 2-[2-Ethoxy-5-(1-(4-monoethoxyphosphonylmethylpiperidinyl)-sulphonyl)-phenyl]-7-(1-ethylpropyl)-5-methyl-3H-imidazo[5,1-f][1,2,4]-triazin-4-one

61.4 mg (96.2 μmol) of 2-[2-ethoxy-5-(1-(4-diethoxyphosphonylmethylpiperidinyl)-sulphonyl)-phenyl]-7-(1-ethylpropyl)-5-methyl-3H-imidazo[5,1-f][1,2,4]-triazin-4-one are heated under reflux with 21.6 mg (0.385 mmol) of KOH powder in 5 ml of ethanol overnight. The mixture is concentrated, taken up in water, acidified with 1N hydrochloric acid and extracted three times with dichloromethane. The extracts are dried and concentrated.

Yield: 42 mg (71.6% of theory)

Example 46 2-[2-Ethoxy-5-(4-oxopiperidine-1-sulphonyl)-phenyl]-7-(1-ethylpropyl)-5-methyl-3H-imid-azo[5,1-f][1,2,4]triazin-4-one

Analogously using 300 mg (0.683 mmol) of 4-ethoxy-3-(5-methyl-4-oxo-7-(1-ethylpropyl)-3,4-dihydroimidazo[5,1-f][1,2,4]triazin-2-yl)-benzenesulphonyl chloride and 310 mg (2.05 mmol) of 4,4-dihydroxipiperidine hydrochloride, 18 mg (5.2% of theory) of 2-[2-ethoxy-5-(4-oxopiperidine-1-sulphonyl)-phenyl]-7-(1-ethylpropyl)-5-methyl-3H-imidazo[5,1-f][1,2,4]triazin-4-one are obtained.

Example 47 2-[2-Ethoxy-5-(3-hydroxypyrrolidine-1-sulphonyl)-phenyl]-7-(1-ethylpropyl)-5-methyl-3H-imidazo[5,1-f][1,2,4]triazin-4-one

Analogously, using 100 mg (0.228 mmol) of 4-ethoxy-3-(5-methyl-4-oxo-7-(1-ethylpropyl)-3,4-dihydroimidazo[5,1-f][1,2,4]triazin-2-yl)-benzenesulphonyl chloride and 60 mg (0.683 mmol) of 3-hydroxypyrrolidine, 55 mg (49.1% of theory) of 2-[2-ethoxy-5-(3-hydroxy-pyrrolidine-1-sulphonyl)-phenyl]-7-(1-ethylpropyl)-5-methyl-3H-imidazo[5,1-f][1,2,4]triazin-4-one are obtained.

200 MHz ¹H-NMR (CDCl₃): 0.85 (t, 6H); 1.61 (t, 3H); 1.72-2.1 (m, 7H); 2.69 (s, 3H); 3.22-3.55 (m, 5H); 4.35 (q, 2H); 4.45 (m, 1H); 7.18 (d, 1H); 7.99 (dd, 1H); 8.57 (d, 1H); 9.8 (bs, 1H).

Example 48 2-[2-Ethoxy-5-(N,N-diethyl-sulphonamido)-phenyl]-5-methyl-7-(1-ethylpropyl)-3H-imidazo[5,1-f][1,2,4]triazin-4-one

Analogously, using 100 mg (0.228 mmol) of 4-ethoxy-3-(5-methyl-4-oxo-7-(1-ethylpropyl)-3,4-dihydroimidazo[5,1-f][1,2,4]triazin-2-yl)-benzenesulphonyl chloride and 50 mg (0.683 mmol) of diethylamine, 78 mg (72.3% of theory) of 2-[2-ethoxy-5-(N,N-diethyl-sulphonamido)-phenyl]-5-methyl-7-(1-ethylpropyl)-3H-imidazo[5,1-f][1,2,4]triazin-4-one are obtained.

200 MHz ¹H-NMR (CDCl₃): 0.87 (t, 6H); 1.2 (t, 6H); 1.62 (t, 3H); 1.88 (m, 4H); 2.69 (s, 3H); 3.3 (m, 5H); 4.35 (q, 2H); 7.14 (d, 1H); 7.96 (dd, 1H); 8.57 (d, 1H); 9.78 (bs, 1H).

Example 49 2-[2-Ethoxy-5-(3-hydroxy-3-methoxymethylpyrrolidine-1-sulphonyl)-phenyl]-7-(1-ethylpropyl)-5-methyl-3H-imidazo[5,1-f][1,2,4]triazin-4-one

Analogously, using 100 mg (0.228 mmol) of 4-ethoxy-3-(5-methyl-4-oxo-7-(1-ethylpropyl)-3,4-dihydroimidazo[5,1-f][1,2,4]triazin-2-yl)-benzenesulphonyl chloride and 90 mg (0.683 mmol) of 3-hydroxy-3-methoxymethylpyrrolidine, 89 mg (72.9% of theory) of 2-[2-ethoxy-5-(3-hydroxy-3-methoxymethylpyrrolidine-1-sulphonyl)-phenyl]-7-(1-ethylpropyl)-5-methyl-3H-imidazo[5,1-f][1,2,4]triazin-4-one are obtained.

200 MHz ¹H-NMR (CDCl₃): 0.88 (t, 6H); 1.62 (t, 3H); 1.72-2.08 (m, 6H); 2.47 (s, 1H); 2.7 (s, 3H); 3.13-3.63 (m, 10H); 4.36 (q, 2H); 7.17 (d, 1H); 7.98 (dd, 1H); 8.57 d, 1H); 9.78 (bs, 1H).

Example 50 2-[2-Ethoxy-5-(N-2-methoxyethyl-sulphonamido)-phenyl]-5-methyl-7-(1-ethylpropyl)-3H-imidazo[5,1-f][1,2,4]-triazin-4-one

Analogously, using 350 mg (0.797 mmol) of 4-ethoxy-3-(5-methyl-4-oxo-7-(1-ethylpropyl)-3,4-dihydroimidazo[5,1-f][1,2,4]triazin-2-yl)-benzenesulphonyl chloride and 180 mg (2.392 mmol) of methoxyethylamine, 251 mg (66% of theory) of 2-[2-ethoxy-5-(N-2-methoxyethyl-sulphonamide)-phenyl]-5-methyl-7-(1-ethylpropyl)-3H-imidazo[5,1-f][1,2,4]-triazin-4-one are obtained.

200 MHz ¹H-NMR (DMSO-d₆): 0.75 (t, 6H); 1.32 (t, 3H); 1.61-1.72 (m, 4H); 2.93 (q, 2H); 3.1 (m, 1H); 3.18 (s, 3H); 3.26-3.4 (m, 5H); 4.19 (q, 2H); 7.35 (d, 1H); 7.76 t, 1H); 7.86-7.96 (m, 2H); 11.7 (bs, 1H).

Example 51 2-[2-Ethoxy-5-(N-ethyl-N-(2-hydroxyethyl)-sulphonamido)-phenyl]-5-methyl-7-(1-ethylpropyl)-3H-imidazo[5,1-f][1,2,4]-triazin-4-one

Analogously, using 400 mg (0.911 mmol) of 4-ethoxy-3-(5-methyl-4-oxo-7-(1-ethylpropyl)-3,4-dihydroimidazo[5,1-f][1,2,4]triazin-2-yl)-benzenesulphonyl chloride and 240 mg (2.734 mmol) of 2-(ethylamino)-ethanol, 261 mg (58.3% of theory) of 2-[2-ethoxy-5-(N-2-ethyl-N-(2-hydroxyethyl)-sulphonamide)-phenyl]-5-methyl-7-(1-ethylpropyl)-3H-imidazo[5,1-f][1,2,4]-triazin-4-one are obtained.

200 MHz ¹H-NMR (DMSO-d₆): 0.78 (t, 6H); 1.08 (t, 3H); 1.33 (t, 3H); 1.6-1.88 (m, 4H); 2.99-3.28 (m, 7H); 3.38 (m, 1H); 3.52 (q, 2H); 4.2 (q, 2H); 4.81 (t, 1H); 7.34 (d, 1H); 7.86-8.0 (m, 2H); 11.69 (bs, 1H).

Example 52 2-[2-Ethoxy-5-(N-(4-morpholinyl)sulphonamido)-phenyl]-5-methyl-7-(1-ethylpropyl)-3H-imidazo[5,1-f][1,2,4]-triazin-4-one

Analogously, using 400 mg (0.911 mmol) of 4-ethoxy-3-(5-methyl-4-oxo-7-(1-ethylpropyl)-3,4-dihydroimidazo[5,1-f][1,2,4]triazin-2-yl)-benzenesulphonyl chloride and 280 mg (2.734 mmol) of 4-aminomorpholine, 109 mg (21.1% of theory) of 2-[2-ethoxy-5-(N-(4-morpholinyl)sulphonamido)-phenyl]-5-methyl-7-(1-ethylpropyl)-3H-imidazo[5,1-f][1,2,4]-triazin-4-one are obtained.

200 MHz ¹H-NMR (CDCl₃): 0.88 (t, 6H); 1.63 (t, 3H); 1.85-2.28 (m, 4H); 2.88 (s, 3H); 3.05 (m, 4H); 3.45 (m, 1H); 3.76 (m, 4H); 4.42 (q, 2H); 7.2-7.35 (m, 2H); 7.96 (m, 1H); 8.45 (m, 1H); 10.23 (bs, 1H).

Example 53 2-[2-Ethoxy-5-(4-hydroxymethylpiperidine-1-sulphonyl)-phenyl]-7-(1-ethylpropyl)-5-methyl-3H-imidazo[5,1-f][1,2,4]triazin-4-one

Analogously, using 400 mg (0.911 mmol) of 4-ethoxy-3-(5-methyl-4-oxo-7-(1-ethylpropyl)-3,4-dihydroimidazo[5,1-f][1,2,4]triazin-2-yl)-benzenesulphonyl chloride and 310 mg (2.734 mmol) of 4-hydroxymethylpiperidine, 270 mg (57.3% of theory) of 2-[2-ethoxy-5-(4-hydroxy-methylpiperidine-1-sulphonyl)-phenyl]-7-(1-ethylpropyl)-5-methyl-3H-imidazo[5,1-f][1,2,4]triazin-4-one.

200 MHz ¹H-NMR (DMSO-d₆): 0.77 (t, 6H); 1.05-1.43 (m, 6H); 1.58-1.85 (m, 6H); 2.12-2.38 (m, 2H); 2.52 (s, 3H); 3.08 (m, 1H); 3.22 (t, 2H); 3.55-3.72 (m, 2H); 4.2 (q, 2H); 4.51 (t, 1H); 7.38 (d, 1H); 7.78-7.92 (m, 2H); 11.7 (bs, 1H).

Example 54 2-[2-Ethoxy-5-(3-(1-morpholino)-propyl)-sulphonamido)-phenyl]-5-methyl-7-(1-ethylpropyl)-3H-imidazo[5,1-f][1,2,4]triazin-4-one

In an analogous manner, starting from 0.44 g (1 mmol) of 3-(1-ethylpropyl)-5-methyl-4-oxo-3,4-dihydroimidazo[5,1-f][1,2,4]triazin-2-yl)-4-ethoxy-benzenesulphonyl chloride and 0.43 g (3 mmol) of 4-(3-aminopropyl)-morpholine 0.45 g (81%) of 2-[2-ethoxy-5-(3-(1-morpholino)-propyl)-sulphonamido)-phenyl]-5-methyl-7-(1-ethylpropyl)-3H-imidazo[5,1-f][1,2,4]triazin-4-one are obtained.

R_(f)=0.18 (dichloromethane/methanol=19:1) 200 MHz ¹H-NMR (CDCl₃): 1.31 (t, 3H); 1.61 (t, 3H); 1.87 (m, 14H); 2.66 (s, 3H); 3.00 (m 2H); 3.28 (m, 3H); 3.85 (m, 1H); 4.35 (quart., 2H); 7.17 (d, 1H); 7.90 (dd, 1H); 8.50 (d, 1H); 9.72 (s, 1H).

Example 55 2-[2-Ethoxy-5-(4-hydroxypiperidine-1-sulphonyl)-phenyl]-5-methyl-7-(1-ethylpropyl)-3H-imidazo[5,1-j][1,2,4]triazin-4-one

In an analogous manner, starting from 0.44 g (1 mmol) of 3-(7-(1-ethylpropyl)-5-methyl-4-oxo-3,4-dihydroimidazo[5,1-f][1,2,4]triazin-2-yl)-4-ethoxy-benzene-sulphonyl chloride and 0.30 g (3 mmol) of 4-hydroxypiperidine, 0.33 g (65%) of 2-[2-ethoxy-5-(4-hydroxypiperidine-1-sulphonyl)-phenyl]-5-methyl-7-(1-ethylpropyl)-3H-imidazo[5,1-f][1,2,4]triazin-4-one are obtained.

R_(f)=0.25 (dichloromethane/methanol=19:1)

Example 56 2-[2-Ethoxy-5-(bishydroxyethylamino-1-sulphonyl)-phenyl]-5-methyl-7-(1-ethylpropyl)-3H-imidazo-[5,1-f][1,2,4]triazin-4-one

In an analogous manner, starting from 0.3 g (0.68 mmol) of 3-(7-(1-ethylpropyl)-5-ethyl-4-oxo-3,4-dihydroimidazo[5,1-f][1,2,4]triazin-2-yl)-4-ethoxy-benzene-sulphonyl chloride and 0.22 g (2.01 mmol) of diethanolamine, 0.147 g (42%) of 2-[2-ethoxy-5-(bishydroxyethylamino-1-sulphonyl)-phenyl]-5-methyl-7-(1-ethylpropyl)-3H-imidazo-[5,1-f][1,2,4]triazin-4-one are obtained.

R_(f)=0.57 (dichloromethane/methanol=9:1) 200 MHz ¹H-NMR (CDCl₃): 0.98 (t, 6H); 1.62 (t, 3H); 1.89 (m, 4H); 2.67 (s, 3H); 3.23 (m, 3H); 3.36 (t, 4H); 3.90 (t, 4H); 4.36 (quart., 2H); 7.18 (d, 1H); 7.96 (dd, 1H); 8.55 (d, 1H); 9.68 (s, 1H).

Example 57 2-[2-Ethoxy-5-(4-(2-hydroxyethyl)-piperazine-1-sulphonyl)-phenyl]-5-methyl-7-(2-ethylheptyl)-3H-imidazo[5,1-f][1,2,4]triazin-4-one

The preparation is carried out analogously to the procedure of Example 1 using 500 mg (1.01 mmol) of 4-ethoxy-3-(5-methyl-4-oxo-7-(2-ethylheptyl)-3,4-dihydro[5,1-f][1,2,4]-triazin-2-yl)-benzenesulphonyl chloride and 290 mg (2.2 mmol) of 4-(2-hydroxyethyl)-piperazine. This gives 170 mg (28.6%) of sulphonamide.

R_(f)=0.56 (CH₂Cl₂/MeOH 10:1) ¹H-NMR (CD₃OD): 0.75-0.85 (2t, 6H); 1.1-1.35 (m, 8H); 1.45 (t, 3H); 1.65-1.95 (m, 4H); 2.0 (t, 2H); 2.55-2.65 (m, 7H); 3.0-3.1 (m, 4H); 3.3 (quin., 1H); 3.6 (t, 2H); 4.3 (quar., 2H); 7.4 (d, 1H); 7.95 (dd, 1H); 8.0 (d, 1H).

Example 58 2-[2-Ethoxy-5-(N-methyl-N-(2-(3,4-dimethoxyphenyl)-ethyl)sulphonamido-phenyl]-5-methyl-7-(2-ethylheptyl)-3H-imidazo[5,1-f][1,2,4]triazin-4-one

The preparation is carried out analogously to the procedure of Example 1 using 500 mg (1.01 mol) of 4-ethoxy-3-(5-methyl-4-oxo-7-(2-ethylheptyl)-3,4-dihydro-[5,1-f][1,2,4]-triazin-2-yl)-benzenesulphonyl chloride and 433 mg (2.2 mmol) of N-methyl-N-2-(3,4-dimethoxyphenyl)-ethylamine. This gives 153 mg (23.2%) of sulphonamide.

R_(f)=0.78 (CH₂Cl₂/MeOH 10:1) ¹H-NMR (CD₃OD): 0.7-0.5 (t, 6H); 1.0-1.35 (m, 8H); 1.45 (t, 2H); 1.6-1.95 (m, 4H); 2.6 (s, 3h); 2.75 (s, 3H); 2.8 (t, 2H); 3.15-3.35 (m, 3H); 3.75 (s, 6H); 4.3 (quar. 2H); 6.7-6.85 (m, 3H); 7.3 (d, 1H); 7.9 (dd, 1H); 8.0 (d, 1H).

Example 59 2-[2-Ethoxy-5-(3-(4-morpholino)-propyl-sulphonamido)-phenyl]-5-methyl-7-(2-ethylheptyl)-3H-imidazo[5,1-f][1,2,4]triazin-4-one

The preparation is carried out analogously to the procedure of Example 1 using 500 mg (1.01 mmol) of 4-ethoxy-3-(5-methyl-4-oxo-7-(2-ethylheptyl)-3,4-dihydro-[5,1-f][1,2,4]-triazin-2-yl)-benzenesulphonyl chloride and 320 mg (2.2 mmol) of 3-(4-morpholino)-propylamine. This gives 175 mg (28.7%) of sulphonamide.

R_(f)=0.58 (CH₂Cl₂/MeOH 10:1) ¹H-NMR (CD₃OD): 0.5-0.9 (t, 6H); 1.1-1.35 (m, 8H); 1.45 (t, 3H); 1.65 (quin., 2H); 1.7-1.9 (m, 4H); 2.3-2.45 (m, 6h); 2.6 (s, 3H); 2.95 (t, 2H); 3.35 (m, 1H); 3.665 (2t, 4H); 4.3 (quar., 2h); 7.35 (d, 1H); 8.0 (dd, 1H); 8.1 (D, 1H).

Example 60 2-[2-Propoxy-5-(N-methyl-N(2-(3,4-dimethoxyphenyl)-ethyl)-sulphonamido)-phenyl]-5-methyl-7-(2-ethylheptyl)-3H-imidazo[5,1-f][1,2,4]triazin-4-one

The preparation is carried out analogously to the procedure of Example 1 using 50 mg (0.1 mmol) of 4-propoxy-3-(5-methyl-4-oxo-7-(2-ethylheptyl)-3,4-dihydro-[5,1-f][1,2,4]-triazin-2-yl)-benzenesulphonyl chloride and 50 mg (0.25 mmol) of N-methyl-N-2-(3,4-dimethoxyphenyl)-ethylamine. This gives 45 mg (66%) of sulphonamide.

R_(f)=0.74 (CH₂Cl₂/MeOH 10:1) ¹H-NMR (CD₃OD): 0.75 (t, 3H); 0.8 (t, 3h);, 105 (t, 3H);, 10-1.3 (m, 8H); 1.6-1.9 (m, 6h); 2.6 (s, 3H); 2.8 (s, 3H); 2.85 (t, 2H); 3.2-3.4 (m, 3H); 3.8 (s, 6H); 4.2 (t, 2H); 6.7-6.85 (m, 3H); 7.3 (d, 1H); 7.9 (dd, 1H); 8.0 (d, 1H).

Example 61 2-[2-Propoxy-5-(4-pyridyl-sulphonamido)-phenyl]-5-methyl-7-(2-ethylheptyl)-3H-imidazo[5,1-f][1,2,4]triazin-4-one

The preparation is carried out analogously to the procedure of Example 1 using 100 mg (0.196 mmol) of 4-propoxy-3-(5-methyl-4-oxo-7-(2-ethylheptyl)-3,4-dihydro[5,1-f][1,2,4]-triazin-2-yl)-benzenesulphonyl chloride and 22 mg (0.236 mmol) of 4-aminopyridine in the presence of 40 mg (0.4 mmol) of triethylamine. This gives 35 mg (31.4%) of sulphonamide which can be recrystallized from ethyl acetate/diethyl ether.

¹H-NMR (CD₃OD): 0.8 (2t, 6h); 1.0 (t, 3H); 1.05-1.35 (m, 8); 1.7-1.9 (m, 6H); 2.6 s, 3H); 3.35 (m, 1H); 4.15 (t, 2H); 7.1 (d, 1 h); 7.3 (d, 1H); 8.0 (m, 2H); 8.05 (dd, 1H); 8.1 (d, 1H).

Example 62 2-[2-Propoxy-5-(4-hydroxypiperidine-1-sulphonyl)-phenyl]-5-methyl-7-(2-ethylheptyl)-3H-imidazo[5,1-f][1,2,4]triazin-4-one

The preparation is carried out analogously to the procedure of Example 1 using 50 mg (0.1 mmol) of 4-propoxy-3-(5-methyl-4-oxo-7-(2-ethylheptyl)-3,4-dihydro-[5,1-f][1,2,4]-triazin-2-yl)-benzenesulphonyl chloride and 20 mg (0.2 mmol) of 4-hydroxypiperidine. This gives 43 mg (76.3%) of sulphonamide.

R_(f)=0.51 (CH₂Cl₂/MeOH 10:1)

¹H-NMR (CDCl₃): 0.7-0.85 (m, 6H); 1.05-1.3 (m, 11H); 1.35-2.05 (m, 14H); 2.65 (s, 3H); 2.85-3.0 (m, 2H); 3.15-3.35 (m, 3H); 3.6-3.7 (m, 1H); 4.2 (t, 2H); 7.1 (d, 1 h); 7.85 (dd, 1H); 7.95 (d, 1H); 9.8 (broad, 1H).

Example 63 2-[2-Propoxy-5-(4-(2-hydroxyethyl)-piperazine-1-sulphonyl)-phenyl]-5-methyl-7-(2-ethylheptyl)-3H-imidazo[5,1-f][1,2,4]triazin-4-one

The preparation is carried out analogously to the procedure of Example 1 using 50 mg (0.1 mmol) of 4-propoxy-3-(5-methyl-4-oxo-7-(2-ethylheptyl)-3,4-dihydro-[5,1-f][1,2,4]-triazin-2-yl)-benzenesulphonyl chloride and 26 mg (0.2 mmol) of N-(2-hydroxy-ethyl)-piperazine. This gives 13 mg (22%) of sulphonamide.

R_(f)=0.46 (CH₂Cl₂/MeOH 10:1) ¹H-NMR (CDCl₃): 0.7-0.85 (m, 6H); 1.0-1.3 (m, 11H); 1.6-2.0 (m, 6H); 2.55 (s, 3H); 2.5-2.7 (m, 4H); 3.0-3.1 (m, 3H); 3.15-3.3 (m, 1H); 3.6 (t, 2H); 4.2 (t, 2H); 7.15 (d, 1H); 7.7 (dd, 1H); 7.9 (d, 1H); 9.7 (broad, 1H).

Example 64 2-[2-Propoxy-5-(4-methylpiperazine-1-sulphonyl)-phenyl]-5-methyl-7-(2-ethylheptyl)-3H-imidazo[5,1-f][1,2,4]triazin-4-one

The preparation is carried out analogously to the procedure of Example 1 using 50 mg (0.1 mmol) of 4-propoxy-3-(5-methyl-4-oxo-7-(2-ethylheptyl)-3,4-dihydro-[5,1-f][1,2,4]-triazin-2-yl)-benzenesulphonyl chloride and 20 mg (0.2 mmol) of N-methyl-piperazine. This gives 42 mg (74.7%) of sulphonamide.

R_(f)=0.46 (CH₂Cl₂/MeOH 10:1) ¹H-NMR (CDCl₃): 0.75-0.9 (m, 6H); 1.1-1.35 (m, 11H); 1.6-2.1 (m, 10H); 2.4 (s, 3H); 2.65 (s, 3H); 2.6-2.75 (m, 2H); 3.1-3.4 (m, 4H); 4.25 (t, 2H); 7.2 (d, 1H); 7.9 (d, 1H); 8.5 (d, 1H); 9.7 (broad, 1H):

Example 65 2-[2-Propoxy-5-(4-ethoxycarbonylpiperidine-1-sulphonyl)-phenyl]-5-methyl-7-(2-ethylheptyl)-3H-imidazo[5,1-f][1,2,4]triazin-4-one

The preparation is carried out analogously to the procedure of Example 1 using 70 mg (0.138 mmol) of 4-propoxy-3-(5-methyl-4-oxo-7-(2-ethylheptyl)-3,4-dihydro-[5,1-f][1,2,4]-triazin-2-yl)-benzenesulphonyl chloride and 43 mg of ethyl piperidinecarboxylate. This gives 55 mg (63.5%) of sulphonamide.

¹H-NMR (CD₃OD): 0.85 (t, 3H); 0.9 (t, 3H); 1.1 (t, 3H); 1.2 (t, 3H); 1.2-1.4 (m, 8H); 1.65-2.05 (m, 10H); 2.3 (m, 1H); 2.6 (td, 2H); 2.75 (s, 3H); 3.5 (quin., 1H); 3.6 (m, 2H); 4.1 (quar., 2H); 4.2 (t, 2H); 7.4 (d, 1H); 7.95-8.05 (m, 2H):

Example 66 2-[2-Propoxy-5-(4-carboxypiperidine-1-sulphonyl)-phenyl]-5-methyl-7-(2-ethylheptyl)-3H-imidazo[5,1-f][1,2,4]triazin-4-one

62 mg (0.098 mmol) of the ester from Example 65 are stirred at room temperature in 6 ml of 4 n NaOH/H₂O (1:5) for 30 minutes. 20 ml of dichloromethane are added, the mixture is extracted with 2 n HCl solution, the organic phase is dried with sodium sulphate and the solvent is removed under reduced pressure.

R_(f)=0.44 (CH₂Cl₂/MeOH 10:1) ¹H-NMR (CD₃OD): 0.85 (t, 3H); 0.9 (t, 3H); 1.05 (t, 3H); 1.2-1.4 (m, 8H); 1.7-2.05 (m, 10H); 2.75-2.9 (m, 1H); 2.6 (td, 2H); 2.75 (s, 3H); 3.5 (quin., 1H); 3.55-3.65 (m, 2H); 4.2 (t, 2H); 7.4 (d, 1H); 7.95-8.0 (m, 2H).

Example 67 2-[2-Propoxy-5-(3-(4-morpholino)-propyl)-sulphonamido)-phenyl]-5-methyl-7-(2-ethylheptyl)-3H-imidazo[5,1-f][1,2,4]triazin-4-one

The preparation is carried out analogously to the procedure of Example 1 using 52 mg (0.102 mmol) of 4-propoxy-3-(5-methyl-4-oxo-7-(2-ethylheptyl)-3,4-dihydro-[5,1-f][1,2,4]-triazin-2-yl)-benzenesulphonyl chloride and 37 mg (0.255 mmol) of 3-(4-morpholino)-propylamine. This gives 45 mg (71.4% of sulphonamide.

R_(f)=0.41 (CH₂Cl₂/MeOH 10:1) ¹H-NMR (CD₃OD): 0.75-0.95 (m, 6H); 1.05 (t, 3H); 1.05-1.35 (m, 8H); 1.65 (t, 2H); 1.6-1.95 (m, 6H); 2.3-2.45 (m, 6H); 2.6 (s, 3H); 2.95 (t, 2H); 3.25 (m, 1H); 3.6-3.7 m, 4H); 4.2 (t, 2H); 7.35 (d, 1H); 8.0 (dd, 1H); 8.1 (d, 1H).

Example 68 2-[2-Propoxy-5-(4-hydroxymethylpiperidine-1-sulphonyl)-phenyl]-5-methyl-7-(2-ethylheptyl)-3H-imidazo[5,1-f][1,2,4]triazin-4-one

The preparation is carried out analogously to the procedure of Example 1 using 52 mg (0.102 mmol) of 4-propoxy-3-(5-methyl-4-oxo-7-(2-ethylheptyl)-3,4-dihydro-[5,1-f][1,2,4]-triazin-2-yl)-benzenesulphonyl chloride and 29.3 mg (0.255 mmol) of 4-hydroxymethylpiperidine. This gives 45 mg (74.9%) of sulphonamide.

R_(f)=0.44 (CH₂Cl₂/MeOH 10:1) ¹H-NMR (CD₃OD): 0.75-0.9 (m, 6H); 1.05 (t, 3H); 1.0-1.45 (m, 10H); 1.7-1.95 (m, 8H); 2.35 (t, 2H; 2.6 (s, 3H); 3.2-3.4 (m, 2H); 3.8 (d, 2H); 4.2 (t, 2H); 7.4 (d, 1H); 7.9-8.0 (m, 2H).

Example 69 2-[2-Propoxy-5-(N,N-bis-2-hydroxyethyl-sulphonamido)-phenyl]-5-methyl-7-(2-ethylheptyl)-3H-imidazo[5,1-f][1,2,4]triazin-4-one

The preparation is carried out analogously to the procedure of Example 1 using 52 mg (0.102 mmol) of 4-propoxy-3-(5-methyl-4-oxo-7-(2-ethylheptyl)-3,4-dihydro-[5,1-f][1,2,4]-triazin-2-yl)-benzenesulphonyl chloride and 27 mg (0.255 mmol) of diethanolamine. This gives 41 mg (69.5%) of sulphonamide.

R_(f)=0.36 (CH₂Cl₂/MeOH 10:1) ¹H-NMR (CD₃OD): 0.75-0.9 (m, 6H); 1.05 (t, 3H); 1.0-1.9 (m, 8H); 1.7-1.95 (m, 6H); 2.6 (s, 3H); 3.3 (t, 4H); 3.75 (t, 4H); 4.2 (t, 2H); 7.35 (d, 1H); 8.0 (dd, 1H); 8.1 (d, 1H).

Example 70 2-[2-Propoxy-5-(N-methyl-N-(2-dimethylaminoethyl)-sulphonamido)-phenyl]-5-methyl-7-(2-ethylheptyl)-3H-imidazo[5,1-f][1,2,4]triazin-4-one

The preparation is carried out analogously to the procedure of Example 1 using 52 mg (0.102 mmol) of 4-propoxy-3-(5-methyl-4-oxo-7-(2-ethylheptyl)-3,4-dihydro-[5,1-f][1,2,4]-triazin-2-yl)-benzenesulphonyl chloride and 26 mg (0.255 mmol) of N-methyl-N-(2-dimethylaminoethyl)amine. This gives 42 mg (71.5%) of sulphonamide.

R_(f)=0.29 (CH₂Cl₂/MeOH 10:1) ¹H-NMR (CD₃OD): 0.75-0.85 (m, 6H); 1.05 (t, 3H); 1.1-1.35 (m, 8H); 1.7-1.95 (m, 6H); 2.3 (s, 6H); 2.55 (t, 2H); 2.6 (s, 3H); 2.8 (s, 3H); 3.15 (t, 2H); 3.3 (m, 1H); 4.2 (t, 2H); 7.4 (d, 1H); 8.0 (dd, 1H); 8.05 (d, 1H).

Example 71 2-[2-Ethoxy-5-(N-methyl-N-(2-(3,4-dimethoxyphenyl)-ethyl)-sulphonamido)-phenyl]-5-methyl-7-pentyl-3H-imidazo[5,1-f][1,2,4]triazin-4-one

The preparation is carried out analogously to the procedure of Example 1 using 150 mg (0.342 mmol) of 4-ethoxy-3-(5-methyl-4-oxo-7-pentyl-3,4-dihydro-[5,1-f][1,2,4]-triazin-2-yl)-benzenesulphonyl chloride and 167 mg (0.854 mmol) of N-methyl-N-(2-(3,4-dimethoxyphenyl)-ethylamine. This gives 195 mg (95.5%) of sulphonamide.

R_(f)=0.75 (CH₂Cl₂/MeOH 10:1) ¹H-NMR (CD₃OD): 0.75 (t, 3H); 1.25-1.4 (m, 4H); 1.45 (t, 3H); 1.75 (quin., 2H); 2.55 (s, 3H); 2.75 (s, 3H); 2.8 (t, 2H); 2.95 (t, 2H); 3.75 (s, 6H); 4.25 (quar., 2H); 6.7 (dd, 1H); 6.8 (d, 1H); 6.85 (d, 1H); 7.3 (d, 1H); 7.9 (dd, 1H); 8.0 (d, 1H).

Example 72 2-[2-Ethoxy-5-(4-(2-hydroxyethyl)-piperazine-1-sulphonyl)-phenyl]-5-methyl-7-pentyl-3H-imidazo[5,1-f][1,2,4]triazin-4-one

The preparation is carried out analogously to the procedure of Example 1 using 150 mg (0.342 mmol) of 4-ethoxy-3-(5-methyl-4-oxo-7-pentyl-3,4-dihydro-[5,1-f][1,2,4]-triazin-2-yl)-benzenesulphonyl chloride and 111 mg (0.854 mmol) of 2-hydroxyethyl-piperazine. This gives 95 mg (52.4%) of sulphonamide.

R_(f)=0.55 (CH₂Cl₂/MeOH 10:1) ¹H-NMR (CD₃OD): 0.9 (t, 3H); 1.3-1.4 (m, 4H); 1.45 (t, 3H); 2.95 (t, 2H); 3.05-3.1 (m, 4H); 3.6 (t, 2H); 4.3 (quar., 2H; 7.4 (d, 1H); 7.9 (dd, 1H); 8.0 (d, 1H).

Example 73 2-[2-Ethoxy-5-(N-methyl-N-(2-(3,4-dimethoxyphenyl)-ethyl)-sulphonamido)-phenyl]-5-methyl-7-heptyl-3H-imidazo[5,1-f][1,2,4]triazin-4-one

The preparation is carried out analogously to the procedure of Example 1 using 150 mg (0.321 mmol) of 4-ethoxy-3-(5-methyl-4-oxo-7-heptyl-3,4-dihydro-[5,1-f][1,2,4]-triazin-2-yl)-benzenesulphonyl chloride and 140 mg (0.707 mmol) of N-methyl-N-(2-(3,4-dimethoxyphenyl)-ethylamine. This gives 112 mg (55.7%) of sulphonamide.

R_(f)=0.74 (CH₂Cl₂/MeOH 10:1) ¹H-NMR (CD₃OD): 0.7-0.9 (t, 6H), 1.2-1.35 (m, 8H); 1.45 (t, 3H), 1.75 (quin., wH); 2.6 (s, 3H); 2.75 (s, 3H); 2.8 (t, 2H); 2.95 (t, 2H); 3.8 (s, 6H); 4.3 (quar., 2H); 6.7 (dd, 1H); 6.8-6.9 (m, 2H); 7.3 (d, 1H); 7.9 (dd, 1H); 8.0 (d, 1H).

Example 74 2-[2-Ethoxy-5-(4-(2-hydroxyethyl)-piperazine-1-sulphonyl)-phenyl]-5-methyl-7-heptyl-3H-imidazo[5,1-f][1,2,4]triazin-4-one

The preparation is carried out analogously to the procedure of Example 1 using 150 mg (0.321 mmol) of 4-ethoxy-3-(5-methyl-4-oxo-7-heptyl-3,4-dihydro-[5,1-f][1,2,4]-triazin-2-yl)-benzenesulphonyl chloride and 92 mg (0.707 mmol) of 2-hydroxyethylpiperazine. This gives 160 mg (88.8%) of sulphonamide.

R_(f)=0.55 (CH₂Cl₂/MeOH 10:1) ¹H-NMR (CD₃OD): 1.35 (t, 6H); 1.2-1.4 (m, 8H); 1.45 (t, 3H); 1.8 (quin., 2H); 2.5 (t, 2H); 3.0 (t, 2H); 3.05-3.1 (m, 4H); 3.3 (t, 2H); 3.6 (t, 2H); 4.3 (quar., 2H); 7.4 (d, 1H); 7.9 (dd, 1H); 8.0 (d, 1H).

Example 75 2-[2-Ethoxy-5-(4-(2-hydroxyethylpiperazine-1-sulphonyl)-phenyl]-S-methyl-7-hexyl-3H-imidazo[5,1-f][1,2,4]-triazin-4-one

The preparation is carried out analogously to the procedure of Example 1 using 150 mg (0.33 mmol) of 4-ethoxy-3-(5-methyl-4-oxo-7-n-hexyl-3,4-dihydro-imidazo[5,1-f][1,2,4]-triazin-2-yl)-benzenesulphonyl chloride and 90 mg (0.725 mmol) of 2-hydroxyethylpiperazine. This gives 90 mg (49.8%) of sulphonamide.

R_(f)=0.57 (CH₂Cl₂/MeOH 10:1) ¹H-NMR (CD₃OD): 0.75 (t, 3H); 1.15-1.3 (m, 6H); 1.35 (t, 3H); 1.7 (quin., 2H); 2.4 (t, 2H); 2.5 (s, 3H) 2.5-2.55 (m, 4H); 2.9 (t, 2H); 2.95-3.0 (m, 4H); 3.5 (t, 2H); 2 (quar., 2H); 7.3 (d, 1H); 7.85 (dd, 1H), 7.9 (d, 11H).

Example 76 2-[2-Ethoxy-5-(N-methyl-N-(2-(3,4-dimethoxyphenyl)-ethyl)sulphonamido)-phenyl]-5-methyl-7-hexyl-3H-imidazo[5,1-f][1,2,4]-triazin-4-one

The preparation is carried out analogously to the procedure of Example 1 using 150 mg (0.33 mmol) of 4-ethoxy-3-(5-methyl-4-oxo-7-n-hexyl-3,4-dihydro-imidazo-[5,1-f][1,2,4]-triazin-2-yl)-benzenesulphonyl chloride and 140 mg (0.725 mmol) of N-methyl-N-(2-(3,4-dimethoxyphenyl)-ethylamine. This gives 24.7%) of sulphonamide.

R_(f)=0.72 (CH₂Cl₂/MeOH 10:1) ¹H-NMR (CD₃OD): 0.75 (t, 3H); 1.1-1.25 (m, 6H); 1.35 (t, 3H); 1.65 (quin., 2H); 2.5 (s, 3H); 2.65 (s, 3H); 2.7 (t, 2H); 2.85 (t, 2H); 3.65 (s, 6H); 4.15 (quar., 2H); 6.6-6.75 (m, 3H); 7.2 (d, 1H); 7.75 (dd, 1H); 7.9 (d, 1H).

Example 77 2-[2-Ethoxy-5-(4-(2-hydroxyethylpiperazine-1-sulphonyl)-phenyl]-5-methyl-7-nonyl-3H-imidazo[5,1-f][1,2,4]-triazin-4-one

The preparation is carried out analogously to the procedure of Example 1 using 200 mg (0.4 mmol) of 4-ethoxy-3-(5-methyl-4-oxo-7-n-nonyl-3,4-dihydro-imidazo-[5,1-f][1,2,4]triazin-2-yl)-benzenesulphonyl chloride and 120 mg (0.89 mmol) of 2-hydroxyethyl-piperazine. This gives 85 mg (35.7%) of sulphonamide.

R_(f)=0.45 (CH₂Cl₂/MeOH 10:1) ¹H-NMR (CD₃OD): 0.75 (t, 3H); 1.1-1.3 (m, 12H); 1.4 (t, 3H); 1.7 (quin., 2H); 2.4 (t, 2H); 2.5 (s, 3H); 2.5-2.6 (m, 4H); 2.9 (t, 2H); 2.95-3.05 (m, 4H); 3.5 (t, 2H); 4.3 (quar., 2H); 7.3 (d, 1H); 7.8 (dd, 1H); 7.9 (d, 1H).

Example 78 2-[2-Ethoxy-5-(N-methyl-N-(2-(3,4-dimethoxyphenyl-ethyl)-sulphonamido)-phenyl]-5-methyl-7-nonyl-3H-imidazo[5,1-f][1,2,4]-triazin-4-one

The preparation is carried out analogously to the procedure of Example 1 using 200 mg (0.4 mmol) of 4-ethoxy-3-(5-methyl-4-oxo-7-n-nonyl-3,4-dihydro-imidazo-[5,1-f][1,2,4]triazin-2-yl)-benzenesulphonyl chloride and 170 mg (0.89 mmol) of N-methyl-N-(2-(3,4-dimethoxy)phenyl)-ethylamine. This gives 142 mg (52.8%) of sulphonamide.

R_(f)=0.74 (CH₂Cl₂/MeOH 10:1) ¹H-NMR (CD₃OD): 0.7 (t, 3H); 1.1-1.3 (m, 12H); 1.4 (t, 3H); 1.7 (quin., 2H); 2.5 (s, 3H); 2.7 (s, 3H); 2.75 (t, 2H); 2.9 (t, 2H); 3.3 (t, 2H); 3.7 (s, 6H); 4.7 (quar., 2H); 6.6-6.8 (m, 3H); 7.2 (d, 1H), 7.7 (dd, 1H); 7.95 (d, 1H).

Example 79 2-[2-Ethoxy-5-(4-(2-hdyroxyethylpiperazine-1-sulphonyl)phenyl]-5-methyl-7-(2-n-propylbutyl)-3H-imidazo[5,1-f][1,2,4]-triazin-4-one

The preparation is carried out analogously to the procedure of Example 1 using 150 mg (0.32 mmol) of 4-ethoxy-3-(5-methyl-4-oxo-7-(2-n-propylbutyl)-3,4-dihydro-imidazo[5,1-f][1,2,4]-triazin-2-yl)-benzenesulphonyl chloride and 50 mg (0.385 mmol) of 2-hydroxyethyl-piperazine. This gives 150 mg (83.3%) of sulphonamide.

R_(f)=0.62 (CH₂Cl₂/MeOH 10:1) ¹H-NMR (CD₃OD): 0.75 (t, 6H); 1.1-1.25 (m, 4H); 1.4 (t, 3H); 1.6-1.7 (m, 2H); 1.75-1.85 (m, 2H); 2.45 (t, 2H); 2.5 (s, 3H); 2.5-2.55 (m, 4H); 3.0 (m, 4H); 3.4 (hept., 1H); 2.55 (t, 2H); 4.25 (quar., 2H); 7.35 (d, 1H); 7.85 (dd, 1H); 7.95 (d, 1H).

Example 80 2-[2-Ethoxy-5-(N-methyl-N-(2-(3,4-dimethoxyphenyl)-ethyl)-sulphonamido)-phenyl]-5-methyl-7-(2-n-propylbutyl)-3H-imidazo[5,1-f][1,2,4]-triazin-4-one

The preparation is carried out analogously to the procedure of Example 1 using 150 mg (0.32 mmol) of 4-ethoxy-3-(5-methyl-4-oxo-7-(2-n-propylbutyl)-3,4-dihydro-imidazo[5,1-f][1,2,4]-triazin-2-yl)-benzenesulphonyl chloride and 80 mg (0.385 mmol) of N-methyl-N-(2-(3,4-dimethoxyphenyl)-ethylamine. This gives 166 mg (82.6%) of sulphonamide.

M.p.: 131° C. (ethyl acetate/diethyl ether).

Example 81 2-[2-Ethoxy-5-(4-(2-hydroxyethylpiperazine-1-sulphonyl)-phenyl]-5-methyl-7-cycloheptyl-3H-imidazo[5,1-f][1,2,4]-triazin-4-one

The preparation is carried out analogously to the procedure of Example 1 using 200 mg (0.43 mmol) of 4-ethoxy-3-(5-methyl-4-oxo-7-cycloheptyl-3,4-dihydro-imidazo[5,1-f]-[1,2,4]-triazin-2-yl-benzenesulphonyl chloride and 120 mg (0.946 mmol) of 2-hydroxyethyl-piperazine. This gives 158 mg (65.7%) of sulphonamide.

R_(f)=0.55 (CH₂Cl₂/MeOH 10:1)

Example 82 2-[2-Ethoxy-5-(N-methyl-N-(2-(3,4-dimethoxyphenyl)-ethyl)-sulphonamido)-phenyl]-5-methyl-7-cycloheptyl-3H-imidazo[5,1-f][1,2,4]-triazin-4-one

The preparation is carried out analogously to the procedure of Example 1 using 300 mg (0.645 mmol) of 4-ethoxy-3-(5-methyl-4-oxo-7-cycloheptyl-3,4-dihydro-imidazo[5,1-f]-[1,2,4]-triazin-2-yl-benzenesulphonyl chloride and 280 mg (1.42 mmol) of N-methyl-N-(2-(3,4-dimethoxyphenyl)-ethylamine. This gives 256 mg (63.6%) of sulphonamide.

R_(f)=0.66 (CH₂Cl₂/MeOH 10:1) ¹H-NMR (CD₃OD): 1.45 (t, 2H); 1.5-1.7 (m, 9H); 1.7-2.0 (m,6H); 2.55 (s, 3H); 2.75 (s, 3H); 2.8 (t, 2H); 3.35 (t, 2H); 3.45 (quin., 1H); 3.7 (s, 6H); 4.25 (quar., 2H): 6.65-6.8 (m, 3H); 7.25 (d, 1H); 7.85 (dd, 1H); 8.0 (d, 1H).

The sulphonamides listed in the tables below were prepared by automatic parallel synthesis from the corresponding sulphonyl chlorides and the corresponding amines using one of the three standard procedures below.

The purity of the final product was determined by means of HPLC, and they were characterized by LC-MS. The number given in the column % (HPLC) is the content of the end product characterized by the molecular peak. Standard procedure A was used with amines having acidic functionalities, standard procedure B was used with amines having neutral functionalities, standard procedure C was used with amines having additional basic functionalities.

Compounds listed in the tables below and having optically a free nitrogen valency are, in principle, to be understood as —NH— radical.

Standard Procedure A:

Reaction of Amines Having Acidic Functionalities

0.05 mmol of amine, 0.042 mmol of sulphonyl chloride and 0.10 mmol of Na₂CO₃ are initially charged, and 0.5 ml of a mixture of THF/H₂O is pipetted in by hand. After 24 h at room temperature, the mixture is admixed with 0.5 ml of 1 M H₂SO₄ solution and filtered through a two-phase cartridge (500 mg of Extrelut (upper phase)) and 500 mg of SiO₂, mobile phase ethyl acetate). The product is obtained after concentrating the filtrate under reduced pressure.

Standard Procedure B:

Reaction of Amines Having Neutral Functionalities

0.125 mmol of amine are initially charged and 0.03 mmol of sulphonyl chloride as a solution in 1,2-dichloroethane is pipetted in by the synthesizer. After 24 h, the mixture is admixed with 0.5 ml of 1 M H₂SO₄ and filtered through a two-phase cartridge (500 mg of Extrelut (upper phase) and 500 mg of SiO₂, mobile phase: ethyl acetate). The filtrate is concentrated under reduced pressure.

Standard Procedure C:

Reaction of Amines Having Basic Functionalities

0.05 mmol of amine are initially charged and 0.038 mmol of sulphonyl chloride as a solution in 1,2-dichloroethane and 0.05 mmol of triethylamine as a solution in 1,2-dichloroethane are pipetted in by the synthesizer. After 24 h, the solution is initially admixed with 3 ml of saturated NaHCO₃ solution and the reaction mixture is filtered through a two-phase cartridge. The product is obtained after concentrating the filtrate under reduced pressure.

All reactions are monitored by thin-layer chromatography. If the reaction is not complete after 24 h at room temperature, the mixture is heated at 60° C. for a further 12 h and the experiment is subsequently terminated.

TABLE 1 Ex. No. Structure MW % (HPLC)* 83

505.6 76 84

583.71 89 85

491.57 56 86

570.76 60 87

539.66 87 88

569.69 88 89

567.67 82 90

555.66 91 91

569.69 77 92

553.66 54 93

551.73 62 94

609.73 60 95

537.66 88 96

477.59 97 97

611.74 52 98

533.65 85 99

602.11 NMR 100

543.62 88 101

546.69 82 102

528.68 82 103

530.65 77 104

583.71 91 105

540.69 58 106

541.63 38 107

559.69 60 108

594.74 88 109

548.67 61 110

636.82 85 111

504.66 67 112

506.63 57 113

562.74 84 114

531.68 61 115

475.61 90 116

588.73 82 117

573.69 52 118

505.64 92 119

487.54 >58 120

609.75 86 121

625.77 98 122

560.68 90 123

593.77 46 124

610.8 64 125

593.75 84 126

623.78 85 127

503.63 89 128

559.65 58 129

569.69 70 130

564.71 76 131

591.74 77 132

541.65 66 133

489.6 83 134

595.72 84 135

664.87 70 136

517.65 77 137

563.63 31 138

559.69 88 139

501.65 81 140

607.66 86 141

521.6 37 142

593.75 82 143

517.65 85 144

611.74 67 145

614.17 78 146

613.8 47 147

624.78 52 148

645.8 69 149

583.73 75 150

505.64 78 151

491.61 83 152

535.67 81

The yields are based on the molecular peaks determined by mass spectroscopy.

Ex. No. Structure MW % HPLC* 153

578.7 70 154

580.7 75 155

508.6 62 156

489.6 72 157

565.7 76 158

485.5 42 159

531.6 88 160

537.6 80 161

553.6 78 162

607.7 75 163

561.6 80 164

523.6 83 165

523.6 84 166

565.7 81 167

562.5 63 168

590.5 82 169

581.7 81 170

535.6 79 171

567.7 55 172

605.6 81 173

595.7 79 174

623.8 79 175

597.7 59 176

653.8 41 177

653.8 82 178

557.7 83 179

529.6 83 180

529.6 86 181

560.7 82 182

562.7 81 183

526.7 60 184

592.7 80 185

608.8 80 186

634.8 77 187

528.6 71 188

533.7 87 189

558.7 88 190

593.7 73 191

515.6 80 192

612.2 81 193

591.7 83 194

621.8 79 195

501.6 78 196

557.6 57 197

605.7 80 198

591.7 80 199

607.7 78 200

499.6 83 201

487.6 82 202

501.6 66 203

609.7 79 204

530.7 82 205

489.6 80 206

537.6 63 207

537.6 75 208

537.6 72 209

607.7 50 210

489.6 64 211

551.7 77 212

581.7 85 213

475.6 45 214

528.6 87 215

503.6 74 216

517.7 76 217

503.6 84 218

551.7 74 219

503.6 70 220

551.7 73 221

489.6 57 222

475.6 77 223

593.8 68 224

551.7 77 225

615.8 78 226

503.6 52 227

529.7 59 228

515.6 50 229

584.7 42 230

557.7 82 231

487.6 49 232

533.7 80 233

537.6 81 234

565.7 82 235

565.7 56 236

669.8 82 237

551.7 77 238

517.7 91 *The yields are based on the molecular peaks determined by mass spectroscopy.

MW Ex. No. Structure [g/mol] HPLC Mz + H 239

531,723 77 532 240

533,695 71 534 241

595,767 65 596 242

602,846 53 603 243

634,848 64 635 244

586,803 51 587 245

574,792 61 575 246

628,884 41 629 247

602,846 42 603 248

642,911 44 643 249

652,863 66 653 250

618,845 48 619 251

660,883 71 661 252

682,892 50 683 253

600,83 60 601 254

612,841 68 613 255

622,836 66 623 256

604,818 58 605 257

590,791 56 591 258

600,83 59 601 259

612,841 54 613 260

706,955 72 707 261

574,792 56 575 262

621,808 57 622 263

588,819 52 589 264

547,722 79 548 265

561,749 30 562 266

620,82 68 621 267

626,868 56 627 268

584,787 56 585 269

640,895 69 641 270

634,848 72 635 271

634,848 54 635 272

656,801 64 657 273

638,811 65 639 274

650,847 44 651 275

545,706 60 546 276

558,749 50 559 277

591,776 70 592 278

616,786 53 617 279

588,775 49 589 280

644,84 51 645 281

609,75323 55 610 282

581,73983 66 582 283

581,73983 63 582 284

595,76692 68 596 285

 5,76692 68 596 286

593,79461 70 594 287

609,79401 68 610 288

639,8205 63 640 289

658,84499 61 659 290

581,73983 59 582 291

551,71334 71 552 292

595,76692 69 596 293

609,79401 65 610 294

595,76692 56 596 295

665,85874 54 666 296

638,83577 64 639 297

581,73983 66 582 298

623,77747 63 624 299

611,76632 65 612 300

609,79401 61 610 301

595,76692 65 596 302

581,73983 71 582 303

581,73983 72 582 304

599,73026 69 600 305

639,8205 65 640 306

641,79281 68 642 307

658,66355 75 658 308

595,76692 72 596 309

579,76752 74 580 310

635,71112 69 636 311

586,15837 64 586 312

623,77747 55 624 313

623,8211 69 624 314

609,79401 72 610 315

609,79401 72 610 316

727,92766 65 728 317

623,8211 54 624 318

683,87408 68 684 319

653,84759 71 654 320

653,84759 68 654 321

664,91764 84 665 322

617,86062 60 618

Ex. MW No. Structure [g/mol] HPLC Mz + H 323

650,84692 62 651 324

477,5869 87 478 325

505,6411 89 506 326

539,6586 88 540 327

567,7127 81 566 328

553,6857 81 554 329

553,6857 83 554 330

519,6681 93 520 331

579,7239 77 580 332

502,6404 86 503 333

489,598 83 490 334

523,6592 89 524 335

594,7822 85 595 336

553,6857 85 554 337

579,7675 80 580 338

591,6575 84 592 339

535,6675 89 536 340

504,6563 91 505 341

671,8193 79 672 342

530,6509 89 531 343

516,6238 85 517 344

637,7411 78 638 345

550,685 86 551 346

597,7392 83 598 347

636,6028 82 636 348

611,7663 78 612 349

567,7127 80 568 350

596,7545 82 597 351

594,7822 79 595 352

608,8093 84 609 353

566,728 82 567 354

594,7386 85 595 355

517,6522 85 518 356

560,6774 83 561 357

531,6793 84 532 358

517,6522 85 518 359

489,598 85 490 360

517,6522 84 518 361

593,751 81 594 362

623,7775 50 624 363

475,6146 90 476 364

583,7121 76 584 365

525,6315 69 526 366

539,6586 71 540 367

509,6321 56 510 368

523,6592 86 524 369

583,7121 80 584 370

525,6315 72 526 371

495,605 83 496 372

560,0765 52 560 373

511,6044 73 512 374

537,6863 81 538 375

538,6738 74 539 376

567,7127 74 568 377

566,6844 88 567 378

531,5858 82 532 379

537,6426 47 538 380

513,5954 83 514 381

544,0771 82 545 382

592,5492 72 593 383

580,7115 70 581 384

555,658 81 556 385

553,6857 80 554 386

539,6586 75 540 387

525,6315 86 526 388

530,05 80 531 389

525,6315 86 526 390

543,6219 76 544 391

563,6034 81 564 392

583,7121 79 584 393

585,6845 84 586 394

539,6586 80 540 395

477,5869 87 478 396

530,6509 91 531 397

503,6251 87 504 398

505,6411 90 506 399

530,6946 51 531 400

539,6586 74 540 401

532,6669 70 533 402

545,6655 79 546 403

539,6586 85 540 404

525,6315 81 526 405

564,495 90 565 406

564,495 60 565 407

611,7663 84 612 408

553,6857 79 554 409

567,7127 75 568 410

537,6863 80 538 411

551,7133 86 552 412

630,7908 37 631 413

553,6857 66 554 414

523,6592 82 524 415

588,1307 31 588

HPLC Ex. MW area % at No. Structure [g/mol] 210 nm Mz + H 416

539,6586 77 540 417

565,7404 80 566 418

566,728 68 567 419

595,7669 84 596 420

594,7386 77 595 421

559,64 81 560 422

565,6968 42 566 423

541,6496 82 542 424

572,1313 85 572 425

620,6034 80 620 426

608,7657 84 609 427

583,7121 82 584 428

581,7398 77 582 429

567,7127 80 568 430

553,6857 82 554 431

558,1042 80 558 432

553,6857 85 554 433

571,6761 79 572 434

591,6575 83 592 435

613,7386 77 614 436

613,7386 82 614 437

567,7127 84 568 438

505,6411 85 506 439

558,7051 90 559 440

531,6793 87 532 441

533,6952 90 534 442

558,7487 75 559 443

576,7205 66 577 444

567,7127 77 568 445

560,7211 79 561 446

573,7197 76 574 447

567,7127 80 568 448

553,6857 83 554 449

592,5492 30 592 450

592,5492 43 592 451

609,750 78 610 452

551,670 74 552 453

565,697 65 566 454

535,670 80 536 455

549,697 79 550 456

671,759 83 672 457

551,670 69 552 458

521,643 80 522 459

586,115 34 586 460

537,643 76 538 461

563,724 67 564 462

564,712 73 565 463

593,751 79 594 464

592,723 72 593 465

557,624 78 558 466

563,681 44 564 467

539,634 67 540 468

570,115 75 570 469

618,587 65 618 470

606,750 69 607 471

581,696 80 582 472

579,724 76 580 473

565,697 72 566 474

551,670 78 552 475

556,088 67 556 476

551,670 79 552 477

569,660 77 570 478

589,642 62 590 479

611,723 66 612 480

611,723 86 612 481

565,697 80 566 482

503,625 85 504 483

556,689 88 557 484

529,663 81 530 485

531,679 86 532 486

574,705 33 575 487

565,697 61 566 488

558,705 47 559 489

571,704 59 572 490

565,697 70 566 491

551,670 65 552 492

590,533 46 590 493

590,533 83 590 494

530,65 82 531 495

489,60 49 490 496

537,64 63 538 497

537,64 44 538 498

537,64 72 538 499

607,73 50 608 500

489,60 64 490 501

551,67 70 552 502

551,67 77 552 503

581,70 85 582 504

475,57 45 476 505

503,63 74 504 506

517,65 76 518 507

503,63 59 504 508

551,67 74 552 509

503,63 70 504 510

551,67 73 552 511

489,60 57 490 512

489,60 44 490 513

475,57 42 476 514

593,75 68 594

HPLC Ex. MW area % at No. Structure [g/mol] 210 nm Mz + H 515

551,67 77 552 516

615,75 78 616 517

503,63 52 504 518

529,66 59 530 519

515,64 50 516 520

584,74 42 585 521

557,67 82 558 522

487,58 30 488 523

533,65 60 534 524

537,64 81 538 525

565,70 82 566 526

565,70 56 566 527

669,80 82 670 528

551,67 77 552 529

517,65 91 518 530

597,7392 84 598 531

539,6586 74 540 532

553,6857 77 554 533

523,6592 93 524 534

537,6863 94 538 535

659,74 89 660 536

616,7637 80 617 537

539,6586 73 540 538

509,6321 92 510 539

574,1036 48 574 540

525,6315 75 526 541

551,7133 84 552 542

552,7009 75 553 543

581,7398 83 582 544

580,7115 80 581 545

545,6129 91 546 546

551,6697 54 552 547

527,6225 89 528 548

558,1042 83 558 549

606,5763 55 606 550

594,7386 83 595 551

569,6851 87 570 552

567,7127 79 568 553

553,6857 88 554 554

539,6586 88 540 555

554,0771 83 544 556

539,6586 93 540 557

557,649 88 558 558

577,6305 77 578 559

599,7115 81 600 560

599,7115 88 600 561

553,6857 89 554 562

491,614 92 492 563

517,6086 83 518 564

544,678 94 545 565

517,6522 94 518 566

519,6681 95 520 567

562,6934 74 563 568

553,6857 80 554 569

546,694 87 547 570

559,6926 73 560 571

553,6857 86 554 572

539,6586 90 540 573

578,5221 87 578 574

578,5221 92 578 575

501,6528 50 502 576

643,80875 76 644 577

533,6516 75 534 578

531,67929 88 532 579

517,6522 87 518 580

565,6968 84 566 581

593,75098 88 594 582

579,72389 74 580 583

579,72389 65 580 584

545,70638 85 546 585

697,85754 68 698 586

531,67929 52 532 587

556,68917 88 557 588

542,66208 78 543 589

663,77937 92 664 590

576,72322 85 577 591

653,80396 77 654 592

575,73287 91 576 593

517,6522 86 518 94

589,75996 90 590 595

571,74462 71 572 596

615,7982 92 616 597

593,75098 78 594 598

634,84752 76 635 599

630,81287 81 631 600

582,77104 82 583 601

570,75989 34 571 602

607,77807 82 608 603

591,73789 73 592 604

543,69044 79 544 605

598,72681 68 599 606

592,72547 42 593 607

529,66335 76 530 608

557,71753 88 558 609

543,69044 83 544 610

612,79753 64 613 611

585,72808 88 586 612

515,63626 81 516 613

543,69044 78 544 614

528,67862 30 529 615

489,64 84 490 616

631,80 88 632 617

521,64 87 522 618

519,67 89 520 619

505,64 94 506 620

553,69 90 554 621

581,74 85 582 622

567,71 85 568 623

567,71 86 568 624

533,70 85 534 625

685,85 84 686 626

519,67 83 520 627

544,68 92 545 628

530,65 82 531 629

651,77 89 652 630

564,71 87 565 631

641,79 87 642 632

563,72 85 564 633

505,64 88 506 634

577,75 96 578 635

559,73 79 560 636

603,79 88 604 637

581,74 83 582 638

622,84 90 623 639

618,80 85 619 640

570,76 60 571 641

558,75 40 559 642

595,77 90 596 643

579,73 87 580 644

531,68 91 532 645

586,72 69 587 646

580,71 78 581 647

517,65 86 518 648

545,71 82 546 649

531,68 86 532 650

600,79 57 601 651

573,72 82 574 652

503,63 83 504 653

531,68 83 532 

1. A method of treating hypertension, neuronal hypertonia, stable and unstable angina, peripheral and cardial vasculopathies, arrhythmiae, thromboembolic disorders, myocardial infarction, angina pectoris, peripheral circulation obstruction, restenoses after thrombolysis therapy, percutaneous transluminal coronary angioplasties or bypass, stroke, hypertrophy of the prostate and incontinence, comprising administering to a mammal an effective amount of a compound of the formula (I)

in which R¹ represents s might-chain or branched alkyl having up to 4 carbon atoms, R² represent straight-chain [lacuna] having at least 5 carbon atoms or branched alkyl having at least 3 carbon atoms, or represents cycloalkyl having 3 to 10 carbon atoms, R³ and R⁴ are identical or different and represent hydrogen, or represent straight-chain or branched alkenyl having up to 8 carbon atoms, or represent a straight-chain or branched alkyl chain having up to 10 carbon atoms which is optionally interrupted by an oxygen atom and which is optionally mono- to trisubstituted by identical or different substituents from the group consisting of trifluoromethyl, trifluoromethoxy, hydroxyl, halogen carboxyl, benzyloxycarbonyl, straight-chain or branched alkoxy, alkoxycarbonyl and alkylthio having in each case up to 6 carbon atoms and/or by radicals of the formulae —SO₃H, -(A)_(a)-NR⁷R⁸, —O—CO—NR^(7′)R^(8′), —S(O)_(b)—R⁹, HN═SO—R^(9′), —P(O)(OR¹⁰)(OR¹¹),

 in which a and b are identical or different and represent a number 0 or 1, A represents a radical CO or SO₂, R⁷, R^(7′), R⁸ and R^(8′) are identical or different and represent hydrogen, or represent cycloalkyl having 3 to 8 carbon atoms, aryl having 6 to 10 carbon atoms, a 5- to 6-membered unsaturated, partially unsaturated or saturated, optionally benzo-fused heterocycle having up to 3 heteroatoms from the group consisting of S, N and/or O, where the ring systems listed above are optionally mono- to trisubstituted by identical or different substituents from the group consisting of hydroxyl, nitro, trifluoromethyl, trifluoromethoxy, carboxyl, halogen, straight-chain or branched alkoxy and alkoxycarbonyl having in each case up to 6 carbon atoms or by a group of the formula —(SO₂)_(c)—NR¹²R¹³, in which c represents a number 0 or 1, R¹² and R¹³ are identical or different and represent hydrogen or straight-chain or branched alkyl having up to 5 carbon atoms, or R⁷, R^(7′), R⁸ and R^(8′) represent straight-chain or branched alkoxy having up to 6 carbon atoms, or represent straight-chain or branched alkyl having up to 8 carbon atoms which is optionally mono- or polysubstituted by identical or different substituents from the group consisting of hydroxyl, halogen, aryl having from 6 to 10 carbon atoms, straight-chain or branched alkoxy and alkoxycarbonyl having in each case up to 6 carbon atoms or by a group of the formula —(CO)_(d)—NR¹⁴R¹⁵, in which R¹⁴ and R¹⁵ are identical or different and represent hydrogen or straight-chain or branched alkyl having up to 4 carbon atoms, and d represents a number 0 or 1, or R⁷ and R⁸ and/or R^(7′) and R^(8′) together with the nitrogen atom form a 5- to 7-membered saturated heterocycle which may optionally contain a further heteroatom from the group consisting of S and O or a radical of the formula —NR¹⁶, in which R¹⁶ represents hydrogen, aryl having 6 to 10 carbon atoms, or straight-chain or branched alkyl having up to 6 carbon atoms, which is optionally substituted by hydroxyl, R⁹ and R^(9′) are identical or different and represent aryl having 6 to 10 carbon atoms or benzyl, or represent straight-chain or branched alkyl having up to 4 carbon atoms, R¹⁰ and R¹¹ are identical or different and represent hydrogen or straight-chain or branched alkyl having up to 4 carbon atoms, and/or the alkyl chain listed above under R³/R⁴ is optionally substituted by cycloalkyl having 3 to 8 carbon atoms, aryl having 6 to 10 carbon atoms or by a 5- to 7-membered partially unsaturated, saturated or unsaturated, optionally benzo-fused heterocycle which may contain up to 4 ring heteroatoms from the group consisting of S, N; O or a radical of the formula —NR¹⁷, where the alkyl chain way optionally also be attached via a ring nitrogen atom, in which R¹⁷ represents hydrogen, hydroxyl, formyl, trifluoroxyethyl, straight-chain or branched acyl or alkoxy having in each case up to 4 carbon atoms, or represents straight-chain or branched alkyl having up to 6 carbon atoms which is optionally mono- to polysubstituted by identical or different substituents from the group consisting of hydroxyl and straight-chain or branched alkoxy having up to 6 carbon atoms, and where aryl and the heterocycle are optionally mono- to trisubstituted by identical or different substituents from the group consisting of nitro, halogen, —SO₃H, straight-chain or branched monohydroxy-substituted alkyl, alkylthio or alkoxy having in each case up to 6 carbon atoms, hydroxyl, trifluoromethyl, trifluoromethoxy and/or by a radical of the formula —(SO₂)_(e)—R¹⁸R¹⁹, in which e represents a number 0 or 1, R¹⁸ and R¹⁹ are identical or different and represent hydrogen, phenyl, benzyl or straight-chain or branched alkyl or acyl having in each case up to 6 carbon atoms, and/or R³ or R⁴ represent radicals of the formulae —NR²⁰R²¹ or —(O)-E-NR²²R²³, in which R²⁰ and R²¹ have the meaning of R¹⁸ and R¹⁹ given above and are identical to or different from this meaning, or together with the nitrogen atom form a 5- or 6-membered saturated heterocycle having a further ring heterocycle from the group consisting of S and O or a radical —NR²⁴, in which R²⁴ has the meaning of R¹⁶ given above and is identical to or different from this meaning, E is a straight-chain alkylene group having up to 5 carbon atoms, R²² and R²³ have the meaning of R¹⁸ and R¹⁹ given above and are identical to or different from this meaning, and/or R³ or R⁴ represent radicals of the formulae

 or represent cycloalkyl having 3 to 8 carbon atoms, aryl having 6 to 10 carbon atoms or represent a 5- to 7-membered partially unsaturated, saturated and unsaturated, optionally benzo-fused heterocycle which may contain up to 4 heteroatoms from the group consisting of S, N; O or a radical of the formula —NR²⁵ which may optionally also be attached via a ring nitrogen atom, in which R²⁵ has the meaning of R¹⁶ given above and is identical to or different from this meaning, or represents carboxyl formyl or straight-chain or branched acyl having up to 5 carbon atoms, and where cycloalkyl, aryl and/or the heterocycle are optionally mono- to trisubstituted by identical or different substituents from the group consisting of halogen, trifluoromethyl, trifluoromethoxy, carboxyl, straight-chain or branched acyl or alkoxycarbonyl having in each case up to 6 carbon atoms, nitro and/or by groups of the formulae —SO₃H, —O²⁶, (SO₂)_(c)NR²⁷R²⁸, —P(O)(OR²⁹)(OR³⁰), in which R²⁶ represents a radical of the formula

 or  represents cycloalkyl having 3 to 7 carbon atoms, or hydrogen or straight-chain or branched alkyl having up to 5 carbon atoms which is optionally substituted by cycloalkyl having 3 to 7 carbon atoms, straight-chain or branched alkoxy or alkoxycarbonyl having in each case up to 6 carbon atoms, hydroxyl, carboxyl or phenyl, which for its part may be mono- to trisubstituted by identical or different substituents from the group consisting of straight-chain or branched alkoxy having up to 4 carbon atoms, hydroxyl and halogen, f is a number 0 or 1, R²⁷ and R²⁸ have the meaning of R¹⁸ and R¹⁹ given above and are identical to or different from this meaning or represent a radical of the formula —CO—NH₂, R²⁹ and R³⁰ have the meaning of R¹⁰ and R¹¹ given above and are identical to or different from this meaning, and/or cycloalkyl, aryl and/or the heterocycle are optionally substituted by straight-chain or branched alkyl having up to 6 carbon atoms which is optionally substituted by hydroxyl, carboxyl, by a 5- to 7-membered heterocycle having up to 3 heteroatoms from the group consisting of S, N and/or O or by groups of the formulae —SO₂—R³¹, P(O)(OR³²)(OR³³) or NR³⁴R³⁵, in which R³¹ is hydrogen or has the meaning of R⁹ given above and is identical to or different from this meaning, R³² and R³³ have the meaning of R¹⁰ and R¹¹ given above and are identical to or different from this meaning, R³⁴ and R³⁵ are identical or different and represent hydrogen or straight-chain or branched alkyl having up to 6 carbon atoms which is optionally substituted by hydroxyl or straight-chain or branched alkoxy having up to 4 carbon atoms, or R³⁴ and R³⁵ together with the nitrogen atom form a 5- to 6-membered saturated heterocycle which may contain a further heteroatom from rue group consisting of S and O or a radical of the formula —NR³⁶, in which R³⁶ has the meaning of R^(≠)given above and is identical to or different from this meaning, or R³ and R⁴ together with the nitrogen atom form a 5- to 7-membered unsaturated or saturated or partially unsaturated, optionally benzo-fused heterocycle which may optionally contain up to 3 heteroatoms from the group consisting of S, N, O or a radical of the formula —NR³⁷, in which R³⁷ represents hydrogen, hydroxyl, formyl, trifluoromethyl, straight-chain or branched acyl, alkoxy or alkoxycarbonyl having in each case up to 4 carbon atoms, or represents cycloalkyl having 3to 8 carbon atoms, or represents straight-chain or branched alkyl having up to 6 carbon atoms which is optionally mono- to trisubstituted by identical or different substituents from the group consisting of hydroxyl, trifluoromethyl, pyridyl, carboxyl, straight-chain or branched alkoxy and alkoxycarbonyl having in each case up to 6 carbon atoms, R³⁷ represents a radical of the formula —(CO)_(g)-G, in which g represents a number 0 or 1, G represents aryl having 6 to 10 carbon atoms or a 5- to 6-membered aromatic heterocycle having up to 4 heteroatoms from the group consisting of S, N and/or O, where the ring systems listed above are optionally mono- to unsubstituted by identical or different substituents from the group consisting of halogen, straight-chain or branched alkoxy, alkyl or alkylthio having in each case up to 6 carbon atoms, hydroxyl and trifluoromethyl, and the heterocycle mentioned under R³ and R⁴, formed via the nitrogen, is optionally mono- to trisubstituted optionally also geminally, by identical or different substituents from the group consisting of hydroxyl, formyl, carboxyl, straight-chain or branched acyl and alkoxycarbonyl having in each case up to 6 carbon atoms and groups of the formulae —P(O)(OR³⁸)(OR³⁹) and —(CO)_(g))—NR⁴⁰R⁴¹, in which R³⁸ and R³⁹ have the meaning of R¹⁰ and R¹¹ given above and are identical to or different from this meaning, g represents a number 0 or 1, and R⁴⁰ and R⁴¹ are identical or different and have the meaning of R¹⁸ and R¹⁹ given above, and/or the heterocycle mentioned under R³ and R⁴, formed via the nitrogen, is optionally substituted by straight-chain or branched alkyl having up to 6 carbon atoms which is optionally mono- to trisubstituted by identical or different substituents from the group consisting of hydroxyl, halogen, carboxyl, cycloalkyl or cycloalkyloxy having in each case 3 to 8 carbon atoms, straight-chain or branched alkoxy and alkoxycarbonyl having in each case up to 6 carbon atoms or by a radical of the formula —SO₃H, —NR⁴²R⁴³ or P(O)OR⁴⁴R⁴⁵, in which R⁴² and R⁴³ are identical or different and represent hydrogen, phenyl, carboxyl, benzyl or straight-chain or branched alkyl or alkoxy having in each case up to 6 carbon atoms, R⁴⁴ and R⁴⁵ are identical or different and have the meaning of R¹⁰ and R¹¹ given above, and/or the alkyl is optionally substituted by benzyloxy or aryl having 6 to 10 carbon atoms which for its part way be mono- to trisubstituted by identical or different substituents from the group consisting of halogen, hydroxyl, straight-chain or branched alkoxy or alkylthio having in cash case up to 6 carbon atoms, or by a group of the formula —NR^(42 ′)R^(43′), in which R^(42′) and R^(43′) have the meaning of R⁴² and R⁴³ given above and are identical to or different from this meaning, and/or the heterocycle mentioned under R³ and R⁴, formed via a nitrogen atom, is optionally substituted by aryl having 6 to 10 carbon atoms or by a 5- to 7-membered saturated, partially unsaturated or unsaturated heterocycle having up to 3 ring heteroatoms from the group consisting of S, N and/or O, optionally also attached via an N function, where the ring systems for their part may be substituted by halogen, hydroxyl or by straight-chain or branched alkyl, alkylthio or alkoxy having in each case up to 6 carbon atoms, or R³ and R⁴ together with the nitrogen atom form radicals of the formulae

 in which R⁴⁴ represents hydrogen or straight-chain or branched alkyl or alkoxycarbonyl having in each case up to 6 carbon atoms, R⁴⁵ and R^(45 ′)are identical or different and represent hydrogen or straight-chain or branched alkyl having up to 3 carbon atoms, R⁴⁶ represents hydroxyl or straight-chain or branched alkoxy having up to 6 carbon atoms, R⁵ and R⁶ are identical or different and represent hydrogen, straight-chain or branched alkyl having up to 6 carbon atoms, hydroxy or represents straight-chain or branched alkoxy having up to 6 carbon atoms, or stereoisomers thereof.
 2. A compound selected from the group consisting of:


3. A method for treating a disease or condition mediated by a cGMP-metabolizing phosphodiesterase, wherein said disease or condition is selected from the group consisting of erectile dysfunction, female sexual dysfunction, hypertension, neuronal hypertonia, stable and unstable angina, peripheral and cardial vasculopathies, arrhythmiae, thromboembolic disorders, myocardial infarction, angina pectoris, peripheral circulation obstruction, restenoses after thrombolysis therapy, percutaneous transluminal coronary angioplasties or bypass, stroke, hypertrophy of the prostate and incontinence, comprising administering parentally an effective amount of a compound of formula (I)

in which R¹ represents straight-chain or branched alkyl having up to 4 carbon atoms, R² represent straight-chain [lacuna] having at least 5 carbon atom or branched alkyl having at least 3 carbon atoms, or represents cycloalkyl having 3 to 10 carbon atoms, R³ and R⁴ are identical or different and represent hydrogen, or represent straight-chain or branched alkenyl having up to 8 carbon atoms, or represent a straight chain or branched alkyl chain having up to 10 carbon atoms which is optionally interrupted by an oxygen atom and which is optionally mono- to trisubstituted by identical or different substituents from the group consisting of trifluoromethyl, trifluoromethoxy, hydroxyl, halogen carboxyl, benzyloxycarbonyl, straight-chain or branched alkoxy, alkoxycarbonyl and alkylthio having in each case up to 6 carbon atoms and/or by radicals of the formulae —SO₃H, -(A)_(a)-NR⁷R⁸, —OC—NR^(7′)R^(8′), —S(O)_(b)—R⁹, HN═SO—R^(9′), —P(O)(OR¹⁰)(OR¹¹),

 in which a and b are identical or different and represent a number 0 or 1, A represents a radical CO or SO₂, R⁷, R^(7′), R⁸ and R^(8′)are identical or different and represent hydrogen, or represent cycloalkyl having 3 to 8 carbon atoms, aryl having 6 to 10 carbon atoms, a 5- to 6-membered unsaturated, partially unsaturated or saturated, optionally benzo-fused heterocycle having up to 3 heteroatoms from the group consisting of S, N and/or O, where the ring systems listed above are optionally mono- to trisubstituted by identical or different substituents from the group consisting of hydroxyl, nitro, trifluoromethyl, trifluoromethoxy, carboxyl, halogen, straight-chain or branched alkoxy and alkoxycarbonyl having in each case up to 6 carbon atoms or by a group of the formula —(SO₂)_(c)—NR¹²R¹³, in which c represents a number 0 or 1, R¹² and R¹³ are identical or different and represent hydrogen or straight-chain or branched alkyl having up to 5 carbon atoms, or R⁷, R^(7′), R⁸ and R^(8′) represent straight-chain or branched alkoxy having up to 6 carbon atoms, or represent straight-chain or branched alkyl having up to 8 carbon atoms which is optionally mono- or polysubstituted by identical or different substituents from the group consisting of hydroxyl, halogen, aryl having from 6 to 10 carbon atoms, straight-chain or branched alkoxy and alkoxycarbonyl having in each case up to 6 carbon atoms or by a group of the formula —(CO)_(d)—NR¹⁴R¹⁵, in which R¹⁴ and R¹⁵ are identical or different and represent hydrogen or straight-chain or branched alkyl having up to 4 carbon atoms, and d represents a number 0or 1, or R⁷ and R⁸ and/or R^(7′) and R^(8′) together with the nitrogen atom form a 5- to 7-membered saturated heterocycle which may optionally contain a further heteroatom from the group consisting of S and O or a radical of the formula —NR¹⁶, in which R¹⁶ represents hydrogen, aryl having 6 to 10 carbon atoms, or straight-chain or branched alkyl baying up to 6 carbon atoms, which is optionally substituted by hydroxyl, R⁹ and R^(9′) are identical or different and represent aryl having 6 to 10 carbon atoms or benzyl, or represent straight-chain or branched alkyl having up to 4 carbon atoms, R¹⁰ and R¹¹ are identical or different and represent hydrogen or straight-chain or branched alkyl having up to 4 carbon atoms, and/or the alkyl chain listed above under R³/R⁴ is optionally substituted by cycloalkyl having 3 to 8 carbon atoms, aryl having 6 to 10 carbon atoms or by a 5- to 7-membered partially unsaturated, saturated or unsaturated, optionally benzo-fused heterocycle which may contain up to 4 ring heteroatoms from the group consisting of S, N; O or a radical of the formula —NR¹⁷, where the alkyl chain may optionally also be attached via a ring nitrogen atom, in which R¹⁷ represents hydrogen, hydroxyl, formyl, trifluoromethyl, straight-chain or branched acyl or alkoxy having in each case up to 4 carbon atoms, or represents straight-chain or branched alkyl having up to 6 carbon atoms which is optionally mono- to polysubstituted by identical or different substituents from the group consisting of hydroxyl and straight-chain or branched alkoxy having up to 6 carbon atoms, and where aryl and the heterocycle are optionally mono- to trisubstituted by identical or different substituents from the group consisting of nitro, halogen, —SO₃H, straight-chain or branched monohydroxy-substituted alkyl, alkylthio or alkoxy having in each case up to 6 carbon atoms, hydroxyl, trifluoromethyl, trifluoromethoxy and/or by a radical of the formula —(SO₂)_(e)—R¹⁸R¹⁹, in which e represents a number 0 or 1, R¹⁸ and R¹⁹ are identical or different and represent hydrogen, phenyl, benzyl or straight-chain or branched alkyl or acyl having in each case up to 6 carbon atoms, and/or R³ or R⁴ represent radicals of the formulae —NR²⁰R²¹ or —(O)-E-NR²²R²³, in which R²⁰ and R²¹ have the meaning of R¹⁸ and R¹⁹ given above and are identical to or different from this meaning, or together with the nitrogen atom form a 5- or 6-membered saturated heterocycle having a further ring heterocycle from the group consisting of S and O or a radical —NR²⁴, in which R²⁴ has the meaning of R¹⁶ given above and is identical to or different from this meaning, E is a straight-chain alkylene group having up to 5 carbon atoms, R²² and R²³ have the meaning of R¹⁸ and R¹⁹ given above and are identical to or different from this meaning, and/or R³ or R⁴ represent radicals of the formulae

 or represent cycloalkyl having 3 to 8 carbon atoms, aryl having 6 to 10 carbon atoms or represent a 5- to 7-membered partially unsaturated, saturated and unsaturated, optionally benzo-fused heterocycle which may contain up to 4 heteroatoms from the group consisting of S, N; O or a radical of the formula —NR²⁵ which may optionally also be attached via a ring nitrogen atom, in which R²⁵ has the meaning of R¹⁶ given above and is identical to or different from this meaning, or represents carboxyl formyl or straight-chain or branched acyl having up to 5 carbon atoms, and where cycloalkyl, aryl and/or the heterocycle are optionally mono- to trisubstituted by identical or different substituents from the group consisting of halogen, trifluoromethyl, trifluoromethoxy, carboxyl, straight-chain or branched acyl or alkoxycarbonyl having in each case up to 6 carbon atoms, nitro and/or by groups of the formulae —SO₃H, —OR²⁶, (SO₂)_(f)NR²⁷R²⁸, —P(O)(OR²⁹ )(OR³⁰), in which R²⁶ represents a radical of the formula

 or  represents cycloalkyl having 3 to 7 carbon atoms, or hydrogen or straight-chain or branched alkyl having up to 5 carbon atoms which is optionally substituted by cycloalkyl having 3 to 7 carbon atoms, straight-chain or branched alkoxy or alkoxycarbonyl having in each case up to 6 carbon atoms, hydroxyl, carboxyl or phenyl, which for its part may be mono- to trisubstituted by identical or different substituents from the group consisting of straight-chain or branched alkoxy having up to 4 carbon atoms, hydroxyl and halogen, f is a number 0 or 1, R²⁷ and R²⁸ have the meaning of R¹⁸ and R¹⁹ given above and are identical to or different from this meaning or represent a radical of the formula —CO—NH₂, R²⁹ and R³⁰ have the meaning of R¹⁰ and R¹¹ given above and are identical to or different from this meaning, and/or cycloalkyl, aryl and/or the heterocycle are optionally substituted by straight-chain or branched alkyl having up to 6 carbon atoms which is optionally substituted by hydroxyl, carboxyl, by a 5- to 7-membered heterocycle having up to 3 heteroatoms from the group consisting of S, N and/or O or by groups of the formulae —SO₂—R³¹, P(O)(OR³²)(OR³³) or —NR³⁴R³⁵, in which R³¹ is hydrogen or has the meaning of R⁹ given above and is identical to or different from this meaning, R³² and R³³ have the meaning of R¹⁰ and R¹¹ given above and are identical to or different from this meaning, R³⁴ and R³⁵ are identical or different and represent hydrogen or straight-chain or branched alkyl having up to 6 carbon atoms which is optionally substituted by hydroxyl or straight-chain or branched alkoxy having up to 4 carbon atoms, or R³⁴ and R³⁵ together with the nitrogen atom form a 5- to 6-membered saturated heterocycle which may contain a further heteroatom from the group consisting of S and O or a radical of the formula —NR³⁶, in which R³⁶ has the meaning of R¹⁶ given above and is identical to or different from this meaning, or R¹ and R⁴ together with the nitrogen atom form a 5- to 7-membered unsaturated or saturated or partially unsaturated, optionally benzo-fused heterocycle which may optionally contain up to 3 heteroatoms from the group consisting of S, N, O or a radical of the formula —NR³⁷, in which R³⁷ represents hydrogen, hydroxyl, formyl, trifluoromethyl, straight-chain or branched acyl, alkoxy or alkoxycarbonyl having in each case up to 4 carbon atoms, or represents cycloalkyl having 3 to 8 carbon atoms, or represents straight-chain or branched alkyl having up to 6 carbon atoms which is optionally mono- to trisubstituted by identical or different substituents from the group consisting of hydroxyl, trifluoromethyl, pyridyl, carboxyl, straight-chain or branched alkoxy and alkoxycarbonyl having in each case up to 6 carbon atoms, or R³⁷ represents a radical of the formula —(CO)_(g)-G, in which g represents a number 0or 1, G represents aryl having 6 to 10 carbon atoms or a 5- to 6-membered aromatic heterocycle having up to 4 heteroatoms from the group consisting of S, N and/or O, where the ring systems listed above are optionally mono- to unsubstituted by identical or different substituents from the group consisting of halogen, straight-chain or branched alkoxy, alkyl or alkylthio having in each case up to 6 carbon atoms, hydroxyl and trifluoromethyl, and the heterocycle mentioned under R³ and R⁴, formed via the nitrogen, is optionally mono- to trisubstituted, optionally also geminally, by identical or different substituents from the group consisting of hydroxyl, formyl, carboxyl, straight-chain or branched acyl and alkoxycarbonyl having in each case up to 6 carbon atoms and groups of the formulae —P(O)(OR³⁸)(OR³⁹) and —(CO)_(g))—NR⁴⁰R⁴¹, in which R³⁸ and R³⁹ have the meaning of R¹⁰ and R¹¹ given above and are identical to or different from this meaning, g represents a number 0 or 1, and R⁴⁰ and R⁴¹ are identical or different and have the meaning of R¹⁸ and R¹⁹ given above, and/or the heterocycle mentioned under R³ and R⁴, formed via the nitrogen, is optionally substituted by straight-chain or branched alkyl having up to 6 carbon atoms which is optionally mono- to trisubstituted by identical or different substituents from the group consisting of hydroxyl, halogen, carboxyl, cycloalkyl or cycloalkyloxy having in each case 3 to 8 carbon atoms, straight-chain or branched alkoxy and alkoxycarbonyl having in each case up to 6 carbon atoms or by a radical of the formula —SO₃H, —NR⁴²R⁴³ or P(O)OR⁴⁴OR⁴⁵, in which R⁴² and R⁴³ are identical or different and represent hydrogen, phenyl, carboxyl benzyl or straight-chain or branched alkyl or alkoxy having in each case up to 6 carbon atoms, R⁴⁴ and R⁴⁵ are identical or different and have the meaning of R¹⁰ and R¹¹ given above, and/or the alkyl is optionally substituted by benzyloxy or aryl having 6 to 10 carbon atoms, which for its part may be mono- to trisubstituted by identical or different substituents from the group consisting of halogen, hydroxyl, straight-chain or branched alkoxy or alkylthio having in each case up to 6 carbon atoms, or by a group of the formula —NR^(42′)R^(43′), in which R^(42′) and R^(43′) have the meaning of R⁴² and R⁴³ given above and are identical to or different from this meaning, and/or the heterocycle mentioned under R³ and R⁴, formed via a nitrogen atom, is optionally substituted by aryl having 6 to 10 carbon atoms or by a 5- to 7-membered saturated, partially unsaturated or unsaturated heterocycle having up to 3 ring heteroatoms from the group consisting of S, N and/or O, optionally also attached via an N function, where the ring systems for their part may be substituted by halogen, hydroxyl or by straight-chain or branched alkyl, alkylthio or alkoxy having in each case up to 6 carbon atoms, or R³ and R⁴ together with the nitrogen atom form radicals of the formulae

 in which R⁴⁴ represents hydrogen or straight-chain or branched alkyl or alkoxycarbonyl having in each case up to 6 carbon atoms, R⁴⁵ and R^(45′) are identical or different and represent hydrogen or straight-chain or branched alkyl having up to 3 carbon atoms, R⁴⁶ represents hydroxyl or straight-chain or branched alkoxy having up to 6 carbon atoms, R⁵ and R⁶ are identical or different and represent hydrogen, straight-chain or branched alkyl having up to 6 carbon atoms, hydroxy or represents straight-chain or branched alkoxy having up to 6 carbon atoms, or stereoisomers thereof.
 4. The method of claim 3, wherein said compound is administered intra-nasally.
 5. The method of claim 3, wherein said cGMP-metabolizing phosphodiesterase is selected from the group consisting of PDE1, PDE2, and PDE5. 